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Abstract 
 Two Ru(III) complexes that have already entered clinical trials, [ImH]trans-
[RuCl4(dmso)(Im)] (NAMI-A, Im = imidazole) and [InH]trans-[RuCl4(Ind)2] (KP1019, Ind = 
indazole), are potential alternatives to Pt chemotherapeutic drugs since they are effective 
against cancers untreatable by cisplatin. These compounds have been proposed to operate 
by an “activation by reduction” process, with a reduction of Ru(III) to the more active Ru(II) 
species in vivo, which has thus generated an interest towards organometallic Ru(II) arene 
complexes.  
 The leading complexes of this field would be the RAPTA-C pioneered by Dyson and 
co-workers which showed anti-metastatic activity akin to NAMI-A and the [Ru(p-
cymene)(en)]Cl pioneered by Sadler and co-workers which displayed cytotoxicity in vitro. 
These compounds show great promise due to the versatility in systematically modifying 
them in order to exhibit desirable physical, chemical and biological properties, mainly by 
changing the nature of the arene ligand and introducing different chelating ligands that may 
enhance selectivity towards tumour cells. Traditional anticancer drugs were designed to 
target DNA but in recent years, serum proteins have been found to be more relevant for the 
field of Ru anticancer drugs. In order to improve drug efficacy, an understanding of the 
mechanisms and speciation of these complexes in biological medium is needed.  
 X-ray absorption spectroscopy (EXAFS, XANES) and X-ray fluorescence mapping (XFM) 
have been used according to previous methods to study the speciation in biological fluids, 
extracellular matrix and cells to provide insights into the biological activities of various Ru 
arene complexes. The compounds were first analysed using UV-Vis for their kinetics but this 
technique was not sensitive enough to differentiate the speciation products. A library of 
xiii 
 
Ru(II) arene model complexes containing biologically relevant ligands (N/O and S-donors) 
were synthesized and their structures confirmed using multiple scattering (MS). The Ru 
compounds reacted under various biological conditions were then analysed using multiple 
linear regression, and the speciation products formed either by aquation or ligand-exchange 
were able to be identified. In particular, the results of RAPTA-C in rat blood cells were 
interesting where large changes in the XAS spectra was observed when red blood cells were 
present in the samples, which indicates extensive metabolism of Ru in whole blood. XFM 
was useful in analysing the speciation of the Ru-bound proteins in electrophoresis gels and 
the preliminary results of NAMI-A, KP1019 and RAPTA-C provided good insights on the 
different serum protein binding affinity of these complexes, and how it might affect their 
anticancer properties.   
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1.1 Introduction  
1.1.1 An overview of cancer 
 Cancer is still a major cause of death worldwide and arises due to factors such as the 
effects of carcinogens, pathogens or genetic mutation that have damaged the DNA thereby 
causing normal cells to proliferate and spread out of control. For solid tumours,  
uncontrolled cell multiplication will eventually form a neoplasm, which can be benign (non-
cancerous), or in situ cancers, malignant (cancerous).1 
 Malignant tumours spread rapidly to other parts of the body in a process known as 
metastasis. The tumour cells will push and break through the surrounding cells and 
structures, with the aid of matrix metalloproteinases, which degrade the extracellular 
matrix. This enables the bloodstream and the lymphatic system to carry and lodge 
metastasising cells some distance away from the primary tumour, resulting in a secondary 
tumour or metastases. These tumours will interfere with the organs where they lodge, and 
are the main cause of cancer-related deaths.1 
 In 2012, more than 120,700 Australians were estimated to be diagnosed with cancer, 
with more than half being Australian males, the most common being prostate cancer (28% 
of the total diagnosed). For females, a total of 14,560 cases were diagnosed with breast 
cancer, accounting for 27% of the total diagnosed.1 Cancer accounted for 7.6 million deaths 
worldwide in 2008 and is estimated to increase to over 13.1 million in 2030, without 
improved medical interventions.2  
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1.1.2 Current treatments 
 Over the years, a variety of ways and means of treating cancer have been used. 
Treatment is undertaken in stages, such as surgery, followed by radiotherapy, often 
combined with chemotherapy, which is aimed primarily to remove as many cancer cells as 
possible and also to ensure the minimal possibility of recurrence.1 
 The main concern is the distant metastasis that may occur from primary tumours 
and are the major cause of death.3 Surgery and radiotherapy are more successful methods 
in removing the primary tumour but not metastatic ones due to their scattered locations.3, 4 
Since it is easy to overlook cancer symptoms in the early stages, metastases may have 
already occurred during the more advanced stages of the disease in which the use of 
chemotherapy treatments might be a more appropriate approach to reduce cancer 
progression and symptoms.3 However, different types of cancers at different sites in the 
body exhibit different biochemical properties; and the available treatments and drugs are 
not effective for some forms of metastases, which is why the discovery of novel active 
chemotherapeutic agents is important.4, 5 
 Chemotherapeutic drugs can also be designed to target selectively certain tumour 
cells. Thus, they are more suitable for treatments of tumours that have spread since they 
may be able to reach any location in the body.3 Most anti-cancer drugs are cytotoxic and 
induce cell death by interfering with vital mechanisms. Hence, they are required to be 
selective towards the tumour cells in order to minimise side-effects.4, 6 
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1.1.3 Platinum anti-cancer drugs and their development 
 The pharmaceutical industry was traditionally dominated by organic chemistry. As 
such, it overlooked metal-based drugs, which have served important roles in the treatments 
of various diseases dating back many centuries.7 These include arsenic and gold complexes 
for arthritis, bismuth for ulcer-treatment, magnesium and aluminium oxides for 
gastrointestinal problems and lithium for bipolar diseases.7-10 
 The serendipitous discovery of the platinum drug cisplatin (Figure 1.1), a square-
planar Pt(II) complex by Rosenberg in the 1960s opened the doors to the use of metal-based 
drugs for cancer treatment.4, 7 The proposed mechanism of action of cisplatin is that it binds 
to DNA and hinders replication by cross-linking with the adjacent guanine bases. This is 
because the changed shape of DNA is not recognized by enzymes that repair DNA and this 
induces cancer cell apoptosis.7 However, cisplatin has its limitations. It exhibits a high 
general toxicity, which causes severe side-effects. In addition, some patients develop 
tumour resistance to the drugs.7, 11 
 Cisplatin displays great efficacy against ovarian, bladder and, in particular testicular 
cancers, but has limited activity against breast and colon cancers, as well as being inactive 
against metastasis (secondary) tumours.3 However, the effective activity range has 
increased enormously by its use in combination therapy.7 
 These limitations have stimulated research for its less toxic Pt drugs; carboplatin and 
oxaliplatin; the only two other Pt drugs that have entered world-wide clinical use.4 As 
toxicity is associated with the rapid aquation rate of the chlorido ligands, preliminary studies 
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of the second-generation platinum drug, carboplatin displayed less side-effects and thus is 
more easily used in combination therapy.12 Carboplatin is used mainly for ovarian cancer 
treatment and oxaliplatin is now one of the most successful drugs for treating colon cancer 
in the market.13-15 
 These success stories have led to platinum drugs being regarded as one of the most 
effective classes of anti-cancer drugs which have so far played a major role in stimulating 
interest towards developing and designing other metal-based anti-cancer drugs. 
 
 
 
 
Figure 1.1: Platinum complexes currently used for anti-cancer chemotherapy. 
1.2 Ruthenium as anti-cancer alternatives 
1.2.1 Overview 
 Following the clinical success of platinum complexes, alternative anti-cancer 
complexes that satisfy the following criteria: (a) effective against Pt-resistant tumours,  
(b) void of cross resistance to cisplatin and (c) low side-effects; are constantly being  
sought.5, 6, 16 
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Ruthenium complexes are considered attractive due to several factors: 
a) the easily accessible oxidation states (from II to IV) via redox reactions in biological 
media, enabling them to be good redox-active agents;17 
b) the kinetic stabilities in various oxidation states for various ligand types, as well as 
the reversible nature of some redox couples;6 and  
c) the ease in preparing mixed-ligand complexes by controllable stepwise methods, 
which is crucial for drug design.3 
 Based on these traits, a wide range of complexes have been synthesized and tested. 
In general, they exhibit lower cytotoxicity at an active dose as compared to cisplatin, which 
resulted in the need for a higher therapeutic dose in vivo.18 Interactions with serum proteins 
are important in controlling both the activities and the bio-distribution of drugs within the 
body.19-21 Ruthenium-based anti-cancer drugs display a higher binding affinity to transferrin 
and albumin compared to platinum compounds under physiological conditions.19 This may 
allow Ru(III) complexes to be targeted to tumours since they have higher transferrin 
receptor densities than normal cells.3 The difference in ligand geometry leads to favourable 
Ru binding to DNA via inter-strand crosslinking, which is different to cisplatin where intra-
strand crosslinking is favoured.22, 23 
 Many ruthenium complexes are scavengers for nitric oxide (NO) molecules in cells.24 
NO is crucial for the growth and progression of tumour cells by regulating the blood flow for 
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tumour cells, as well as being active mediators for tumour angiogenesis.7, 24 As scavengers, 
Ru compounds undergo rapid reactions with NO to inhibit cell metastasis.24 
 
1.2.2 Development of ruthenium(III) complexes 
 
 Ru complexes were first tested successfully for anti-cancer activity by Dwyer and co-
workers in the 1950s.25, 26 In 1976, chloro-ammine Ru(III) complexes; e.g., fac-[Ru(NH3)3Cl3] 
were found to induce filamentous growth of Escherichia coli cells, with comparable activity 
to cisplatin.27 Subsequently, cis-[Ru(NH3)4Cl2] was observed by Clarke in 1980 to show 
anticancer properties.28 Unfortunately, these complexes turned out to be too insoluble for 
pharmaceutical use.29  
Later on, the Keppler group introduced Ru(III) complexes that displayed activity 
against several screening tumour lines, especially significant results against Pt-resistant 
colorectal tumours in mice.30-33 Sava focused on complexes bearing the DMSO-ligand, which 
were effective against solid metastasizing tumours in mice.34 
 After much extensive research, two ruthenium complexes, imidazolium trans-
tetrachlorido(dimethylsulfoxide)imidazoleruthenate(III) (NAMI-A) (developed by Sava et 
al.)35 and indazolium (trans-tetrachloridoruthenate(III)) (KP1019) (developed by Keppler et 
al.)36 (Figure 1.2) were found to display the highest potential as anti-cancer agents. 
Although they look similar, the properties displayed were found to be very different. Both of 
these compounds have successfully completed Phase I clinical trials.37 However, further 
progress with KP1019 was hindered due to its poor aqueous solubility and the fact that the 
Chapter 1 
 
8 
 
maximum tolerated dose and optimal dose could not be determined.38 This issue was solved 
by replacing the indazolium counter ion with sodium,38 and the new complex (called KP1339) 
is still undergoing clinical trials.39 
  
 
 
 
Figure 1.2 : Structures of a) NAMI-A and b) KP1019 
 
 The discovery of NAMI-A has been one of the most promising developments in 
metal-based anti-cancer drugs since cisplatin due to its strong anti-cancer properties and 
low toxicity.7 So far, it has shown encouraging results in Phase II clinical trials especially in 
liver, colon, head and neck and endometrial cancers.40 NAMI-A is known to be effective in 
reducing metastasis formation,41 but has a negligible effect on the primary tumour itself due 
to being mildly cytotoxic in vitro.42 It increased the life expectancy of the host (tumour 
bearing mice) regardless of the tumour types (tested against several tumour models Lewis 
lung carcinoma, TS/A mammary adeno-carcinoma, MCa mammary carcinoma and B16 
melanoma).43-45 Many of the properties of NAMI-A are postulated to be related to the 
dimethyl sulfoxide (DMSO) ligand3 which aids in the solubility of the complex, thus allowing 
it to diffuse through biological membranes readily. This is thought to improve the ease of 
a) b) 
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drug administration, which is also associated with the increased solubility of complexes in 
aqueous solutions.34  
In aqueous media, the chlorido ligands of the Ru complexes can exchange with water 
in an aqueous environment to form aqua complexes.46 An example is shown for the 
aquation of NAMI-A (Figure 1.3), in which the Cl ligand dissociates stepwise under 
physiological conditions (pH 7.4), while the dissociation is inhibited by decreases in pH.47 
The pH value was then thought to affect the overall treatment process of NAMI-A as at 
lower pH levels (e.g. pH < 6), only partial Cl hydrolysis was detected which may lead to 
selective activity in solid tumours.47, 48 This effect was observed in a study with tumour-
bearing mice in which 25% decrease in inhibiting metastasis formation resulted.46, 49- 51  
 
 
 
 
 
 
Figure 1.3: Proposed pathways of the aquation of NAMI-A in water at pH 7.4.47  
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 Because of this hypothesis regarding aquation and hydrolysis processes, Alessio et 
al.52 developed new NAMI-A type complexes, which had less basic ligands compared to 
imidazole, such as thiazole, pyrazole and pyrazine. These new complexes proved to be more 
stable in slightly acidic solutions due to a slower loss of DMSO. 
 KP1019 was the second Ru drug to pass Phase I clinical trials. Although its chemical 
properties largely resembled NAMI-A, it has the additional advantage of having the ability to 
induce cell apoptosis (programmed cell death). This is attributed to the different protein 
binding interactions of the two complexes.51, 53 
 Ru(III) complexes may be expected to remain in the same oxidation state until they 
reach the tumour site although partial reduction in biological media is still possible as 
revealed by XAS studies.51 The “activation-by-reduction” process , with the reduction of 
Ru(III) to the more reactive and labile Ru(II)-chlorido species in vivo is also expected to take 
place due to the lower oxygen content found in tumour cells. Thus Ru(III) complexes are 
considered as pro-drugs.54 Normally, Ru(III) complexes are relatively inert to ligand 
substitution. Consequently, the fairly rapid ligand exchange that is observed under 
biological conditions may depend on in vivo reduction to Ru(II) intermediates, the 
biologically active species which are reactive to chlorido loss.55 This is because the reduction 
of Ru(III) to Ru(II) fills the dπ orbitals, which causes the  π-donor ligands like Cl
 to dissociate 
since they do not bind strongly to Ru(II). As mentioned previously, selective reduction to 
Ru(II) is expected to take place in tumours where it is more hypoxic (low in O2) and acidic 
due to insufficient formation of new blood vessels.56 The lowering of the pH value is 
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because these cells tend to be more dependent on glycolysis for energy and produce an 
excess of lactic acid, thus affecting the pH value.57 Glutathione, a sulfur-containing 
tripeptide may act as a reducing agent for the pro-drugs and the formed adducts were 
shown to prevent Ru binding to DNA.58 As described in the previous section, activation by 
ligand substitution in Ru(III) are thought to be important for both NAMI-A and KP1019 
which has thus generated an interest towards compounds that have a stable Ru(II) oxidation 
state, such as the organometallic Ru(II) arene complexes.55, 59-61 
 
1.3 Ruthenium(II) arene complexes 
 
1.3.1 General structure 
 Ruthenium arene complexes were first tested for anti-cancer activity when the anti-
cancer agent metronidazole was coordinated to a Ru(II)-benzene complex to form [Ru(η6-
C6H6)Cl2(metronidazole)], and cytotoxic effects of the resulting compound were observed.
62, 
63 The amphiphilic behaviour of the metal-arene unit serves as a very useful and attractive 
scaffold for targeted drug design.64 The arene ligand provides a hydrophobic face with 
increasing hydrophobicity depending on the size of the arene ring system, which may assist 
in passive transport across cell membranes, as well as improving biomolecular recognition 
processes.46, 65 It also stabilizes ruthenium in its Ru(II) oxidation state, which is important in 
preventing the compound from oxidizing to Ru(III).66  
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Ru(II) arene compounds that are currently being actively investigated were originally 
developed by the Dyson and Sadler groups, and have the general formula  
[Ru(η6-arene)(X)(Y)(Z)], which resemble a half-sandwich “piano-stool” in structure (Figure 
1.4). The remaining three coordinating sites can be occupied in three different ways, 
tridentate (X-Y-Z), bidentate (X-Y) with monodentate (Z), or three monodentate ligands 
(X)(Y)(Z). “Z” is the “leaving group” ligand (usually a chlorido ligand) that is crucial for timing 
the activation process when undergoing hydrolysis. How these ligands are manipulated can 
give rise to reactive or labile complexes.16, 67 
 Overall these compounds show great promise due to the versatility in systematic 
modification of the ligands in order to exhibit desirable physical, chemical and biological 
properties. This is done mainly by changing the nature of the arene ligand and introducing 
different chelating ligands, which will enhance selectivity towards tumour cells.4, 60, 68, 69 
 
 
       Figure 1.4: General structures of Ru(II) “piano-stool” arene complexes  
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1.3.2 Ruthenium(II) arene complexes 
 The RAPTA series (Ruthenium Arene 1,3,5-triaza-7-phosphaadamantane) (Figure 1.5) 
pioneered by the Dyson group were found to exhibit similar properties to NAMI-A, being 
devoid of in vitro cytotoxicity, but capable of in vivo metastasis inhibition.61 These 
complexes exhibit pH-dependent damage towards DNA, and it was proposed that for the pH 
of hypoxic tumour cells, DNA was damaged; whereas little or none were detected at the pH 
of healthy cells.4, 68 This hypothesis, however, might not be valid since intracellular pH 
values are the same in tumour cells and normal cells, and only the extracellular pH values 
change.70, 71 
 The toluene derivative, RAPTA-T inhibits lung metastases in vivo, and also cell 
detachment from the primary tumour in vitro.68 The p-cymene analogue RAPTA-C also 
exhibits anti-metastatic activity, as observed in the increase of the survival rates of mice 
bearing Ehrlich ascites carcinoma (EAC).61, 72 These results were expected due to the 
similarity and relatively simple overall structures that might allow easier binding to many 
biomolecular targets.  
  
 
 
 
Figure 1.5: Examples of RAPTA complexes.73   
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 The RAPTA-C complex undergoes rapid aquation in pure water (over 20 minutes),61  
and would have to be administered together with saline (~100 mM) in order to suppress the 
rate of chloride substitution as this would greatly affect any further pharmocokinetic studies. 
Therefore, bidentate ligands were introduced to replace the labile chlorido ligands in order 
to stabilize the compound. These ligands also helped to increase solubility in aqueous 
environments and were more resistant to aquation and hydrolysis, as already shown from 
the development of cisplatin derivatives: carboplatin and oxaliplatin.17, 74 
The next group of arene compounds pioneered by the Sadler groups are of the Ru(II) 
piano-stool chelating ligand structure, (X-Y)(Z) (Figure 1.6). The linking of X and Y to form a 
chelating ligand helped to provide stability towards aquation by controlling the ligand-
exchange kinetics.75 It also has a major influence on the pKa of the products and selectivity 
of binding to the nucleobases. An example is [Ru(η6-arene)(en)(Cl]PF6 (en = 1,2-
ethanediamine) in which the replacement of ‘en’ with acetylacetonate (acac), resulted in an 
increase in the aquation and hydrolysis rate, which then changed the specificity of the 
nucleobase.75 A possible reason is thought to be the stronger electron-donating ability of 
the acac ligand.76 
 These compounds, unlike the RAPTA complexes, displayed high cytotoxic activity in 
vitro and in vivo.77 They bind strongly to G (guanosine bases) through N7 coordination 
together with arene-purine base stacking, to enable DNA intercalation, forming 
monofunctional adducts.69  Several derivatives of this complex were synthesized and tested 
against A2780 human ovarian cancer cells and the results showed an increase in activity 
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with the size of the coordinated arene: benzene < p-cymene < biphenyl < 
dihydroanthracene (DHA) < tetrahydroanthracene (THA).69, 77 In light of this information, 
further development by incorporating a biphenyl ligand allowed the arene ligands to have 
more flexibility through rotation around the arene-Ru π bonds, which enabled simultaneous 
arene-base stacking and N7 covalent binding in order to increase the DNA recognition 
behaviour of the compound.78 
 
 
 
 
 
Figure 1.6: Examples of Ru[(η6-arene)(en)(Cl]PF6 complexes.
67 
 
1.3.3 Speciation in blood and cells 
 
 Traditional anti-cancer drugs were mainly designed to target DNA due to the success 
of Pt drugs which formed the “DNA-paradigm”.7 However, it became increasingly obvious 
that other enzymes and serum proteins played a role in the anti-cancer activity.79 Therefore, 
drugs were later designed to target cellular signalling pathways that were specific to the 
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cancer cells instead. An emerging and fascinating new idea is to use proteomics and 
genomics as a base for designing novel agents and they have much potential.54 
 Many studies have focused on reactions within cells and not in the extracellular 
matrix or in the blood.5 Blood plasma is typically made up of around 90% water and other 
components including albumin (~4.5%), globulins (~2.5%), fibrinogen (~0.3%), sodium 
chloride, amino acids and many more.8 Blood serum can be differentiated from plasma by 
not containing fibrinogen and proteins that help with clotting.8 It is important to understand 
the interactions of ruthenium with plasma proteins and their speciation in biological media 
to optimize drug design.5  
 Albumin is the most abundant plasma protein comprising about 52% of the protein 
content in an average healthy individual.19, 80 It has been proven to have the ability to bind 
and transport a large variety of compounds; e.g. fatty acids, vitamins and metallodrugs.81, 82 
The binding affinity to albumin determines the amount of free drug concentrations in 
plasma, thus affecting the transfer to tissues. On average, pharmaceutical drugs are 
effective at a concentration way below the albumin drug site concentrations, so the protein 
itself is not yet saturated.83  
Albumin has also been observed to accumulate in malignant and inflamed tissues, 
and hence it can be used as a delivery vehicle as its clearance from tumour tissues is less 
efficient due to the defective lymphatic drainage system.83 With this in mind, passive 
tumour targeting by coordinating a complex with albumin has been proposed as an 
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alternative way to improve selectivity of therapeutic drugs,83, 84 In the case of NAMI-A, it 
was shown that the Ru-albumin complex was the active form of the drug.21 
 Human serum transferrin (hTf) is found in the blood plasma with a concentration of 
~2.5 g/L. It is the main protein that acts as an iron transporter through the body and is 
capable of binding two iron ions in the Fe(III) oxidation state.85 Ruthenium and iron were 
hypothesized to have similarities in the biochemistry, which would then result in the 
transport of ruthenium in the body via transferrin. Therefore, due to tumour cells having a 
higher demand for iron and increased number of transferrin receptors, the Ru(III) 
complexes were postulated to bind to transferrin, which can then serve as a natural route to 
deliver the Ru(III) complexes to the tumour cells to be released as active Ru(II) 
complexes.85,86, 87 Further investigations with XAS however, suggested passive diffusion into 
cells which is another possible route for cellular Ru uptake.51 Transferrin is only 30% 
saturated with iron. Therefore, it has potential binding sites for other metal ions at both the 
Fe binding site and surface protein residues.69, 88, 89  
The hydrolysis process as mentioned before, might be important for serum protein 
binding and thus determine the overall properties in vivo. Ruthenium compounds bind to 
both albumin and transferrin when incubated with each protein separately in buffers but 
there is a preference to albumin binding (~80-90%) in serum.85 Studies have also shown that 
the selectivity exhibited by some Ru complexes towards cancer cells have to do with their 
binding ability to hTf.90 The binding strengths of NAMI-A and KP1019 to these proteins have 
been extensively explored using a wide range of techniques.21, 85, 90-92 
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 When the Ru[(η6-arene)(en)(Cl]PF6 complex was incubated with albumin, binding to 
Cys34 was kinetically favoured and His128 binding was thermodynamically favoured.93 The 
nature of the arene ligand does, however, affect the binding process as the biphenyl 
complex was not observed to bind to Cys34 under similar conditions.93 RAPTA-T 
demonstrated binding to albumin with results comparable to cisplatin, which might mean 
that binding is possible under blood plasma conditions due to the abundance of this 
protein.20 This complex also exhibited more extensive binding to apo-transferrin compared 
to cisplatin, which indicated a greater selectivity in blood protein targeting.20 
A general summary of possible speciation pathways of Ru is shown in Figure 1.7.5 In 
the extracellular matrix (ECM), Ru complexes can form adducts with collagen or other ECM 
proteins40 or with cell surface proteins like actins, which might be the reason for anti-
metastatic properties.44 The complex can also diffuse into the cell cytoplasm, bind to 
enzymes5, 94 or be targeted to concentrate in this section after being coordinated to 
porphyrins, forming conjugates that are activated by photodynamic therapy (PDT).95, 96 In 
order to reach the nucleus, apart from the transferrin delivery pathway mentioned earlier, 
Ru complexes can passively diffuse and bind covalently or intercalate with DNA to form 
adducts.5 The reason for the cytotoxic nature of KP1019 was suggested to be due to the 
complex being readily taken up by cells because of its more aquation-resistant properties 
compared to NAMI-A.5 
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Figure 1.7 : Proposed metabolism pathways of Ru anti-cancer complexes.5 
 
Electron paramagnetic resonance (EPR) spectroscopy is a technique frequently used 
for the characterization of metal binding to serum components.  It is sensitive to changes in 
the coordination sphere and also selective to the particular metal. However, relatively high 
concentrations needed for this technique to observe speciation is a problem since 
biologically relevant concentrations are not used. Recently, KP1019 and KP418 have been 
characterized using EPR spectroscopy for their speciation in blood serum and shown to bind 
preferentially to albumin.97 Other useful methods for studying Ru speciation involve 
synchrotron-based techniques, such as XAS and XFM which can specifically detect the 
changes in the metal coordination environment in complex biological systems.21, 51, 98-102  
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1.4 Further developments in Ru anti-cancer drugs 
 
A study was done in which NAMI-A and cisplatin were co-administered on MCa 
mammary carcinoma cells, and the results showed superior activity compared to those 
observed for either drug individually.103 This further proved that the two drugs have their 
individual modes of action. Further development in combination therapy include the 
multitargeted Ru(II) arene complexes which incorporate flavonoids to the arene moiety.104 
These complexes inhibited topoisomerase IIα and binded covalently to DNA, demonstrating 
possibility for a double-strike approach in tumour therapy.105  
 Multinuclear compounds are another advance in chemotherapy, displaying a 
different mechanism of action and selectivity towards tumour cells.106-108 Dinuclear 
complexes coupled with pyridone linkers exhibited high activity comparable to cisplatin and 
oxaliplatin in A2780 and human colon cancer cell lines with the level of cytotoxicity 
dependant on the spacer length.109 A combination of multinuclear ruthenium arene 
complexes and dendritic polypyridyl scaffolds were developed based on the theory of 
targeting tumour cells with ‘enhanced permeability and retention’ effect.110 In this case, 
macromolecules accumulate at the tumour site due to increased blood vessel permeability 
within diseased tissues compared to healthy ones. They were then retained in the diseased 
tissues due to the absence of lymphatic drainage system.111 The compounds studied 
showed a correlation between size and cytotoxicity against human ovarian cancer cell lines, 
with the octanuclear systems being the most reactive.106 Encapsulating a RAPTA-pyrenyl 
compound in a water-soluble metalla-cage served as a good molecular carrier for targeted 
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drug delivery exploiting the EPR effect, thus producing ~10 times more cytotoxicity than 
RAPTA-C in several human cancer cell lines.112 
 
 
1.5 Aims 
 This thesis is centered on investigating the interactions of ruthenium arene anti-
cancer complexes with biological media, cells and extracellular proteins.  In order to predict 
the possible changes in the environment of the complex and gain further insights, an XAS 
library of model ruthenium(II) arene complexes containing mainly N-O, O-O, S ligands  were 
synthesized and characterized when their structures were unknown. 
 X-ray absorption spectroscopy (XAFS, XANES) has been employed as the main 
technique to study the biotransformation of various Ru arene complexes in biological media 
and with biomolecules in order to obtain a better understanding of the active forms of 
these drugs.5, 21, 113 The aim was to understand the biotransformation, speciation and 
biodistributions of Ru drugs in biological fluids and cells. This could be used to understand 
the important pathways of the activity of Ru drugs and the information might be useful for 
improved design of new drugs or improved methods of delivery.  
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2.1 Materials and Reagents 
 
 The following analytical and high purity grade reagents were used as received: 
diethyl ether, N,N-dimethylformamide (DMF), HPLC-grade methanol from Merck, 
dimethysulfoxide (DMSO) from Aldrich, dichloromethane (DCM) and toluene from Ajax, 
acetonitrile (CH3CN) from Lab-Scan, methanol (MeOH) (99.9% v/v), ethanol (EtOH) (99.7% 
v/v), acetone and hexane from Redox Chemicals. 
 The following starting materials were purchased and used without further 
purification [Ru(η6-p-cymene)Cl2]2, 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane (pta), 
1,2-ethanediamine (en), 2,4-pentanedione (acac), N-methylimidazole (mimid), sodium 
thiolphenolate (NaSPh), sodium methoxide (NaCH3O), Celite
®S filtration aid from Sigma-
Aldrich; tetrabutylammonium hexafluorophosphate (NH4PF6), sodium tetraphenylborate 
(NaBPh4), potassium hexafluorophosphate (KPF6) from Merck; sodium hydroxide (NaOH) 
and thiosalicylic acid from Fluka; sodium oxalate Na2(COO)2 from BDH chemicals, silver 
nitrate (AgNO3) from AGR Matthey; and triethylamine (Et3N) and magnesium sulfate 
(MgSO4) from Ajax. All solvents, methanol, ethanol and acetone were distilled over dry 
magnesium sulfate under argon prior to use. For NMR spectroscopy, the following 
deuterated solvents were used: CDCl3, D2O, MeOD-d4 and DMSO-d6 from Cambridge 
Isotope Laboratories Inc.  
 The following biochemicals were used as received: bovine serum albumin (BSA) 
fraction V (purity~99% Cat. No. A3059), bovine apo-transferrin (BTf, ≥98 %, Cat. No. 
T4382) and bovine type I collagen (≥98 %, Cat. No. C3511) from Sigma-Aldrich and 
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deoxyribonucleic acid sodium salt (DNA) from salmon testes from ICN Biomedicals. Cell 
culture materials were used as received: Dulbecco’s Modified Eagle’s Medium (DMEM 
with 2% v/v fetal calf serum), newborn calf serum, pre-sterilized solutions from 
Invitrogen and sterile disposable plasticware from Becton Dickinson. The HEPG2 human 
hepatoma cell line was received from the American Type Culture Collection (ATCC).1 
Stock solutions used for buffer preparation were HEPES-buffered saline (HBS: 20 mM 
HEPES and 140 mM NaCl, pH = 7.4) were stored at 4°C. Water was purified by the Milli-Q 
technique. 
 Blood samples were obtained from healthy male Sprague-Dawley rats handled in 
accordance with the policy of The University of Sydney (Animal Ethics Approval L07/1-
2004/3/3846). 
 
2.2 Analysis and Instrumentation 
 
2.2.1 NMR Spectroscopy 
 
 1H, 13C and 31P NMR spectroscopy were recorded on a Bruker AVANCE DRX-300 
MHz spectrometer equipped with an auto-switching quad-nucleus 5 mm QNP(HCPF) z-
gradient probe at 300 K. Chemical shifts (δ) are quoted at parts per million (ppm). δH and 
δC are referenced internally to tetramethylsilane (TMS) at 0 ppm, δP referenced 
externally to 85% H3PO4. The ruthenium complexes were dissolved in deuterated 
solvents just before analysis. Spectra was collected with Bruker TopSpin (ver. 3.0) 
software,2 and processed using Spinworks (ver. 3.13).3  
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2.2.2 Electrospray mass spectrometry (ESMS) 
 
 ESMS data were collected using a Finnigan LCQ ESI-APCI Triple Quadrupole Mass 
Spectrometer. Experimental settings were set as: capillary temperature = 200 °C; 
pressure of sheath gas (N2) = 50 psi; cap voltage = 15-45 V; spray voltage = 4.5 kV, tube 
lens offset = 25 V; m/z range = 150-1000 (positive- and negative-ion modes). Samples 
(1.0 mM) were dissolved in methanol or acetonitrile and injected with a flow rate of 0.3 
mL/min. 
2.2.3 UV-Vis spectroscopy 
 
 UV-Vis spectra were recorded on a Hewlett-Packard 8452A diode-array 
spectrophotometer fitted with a HP89090A Peltier temperature control, using a 1-cm 
path-length quartz cell. The stock solutions were prepared by dissolving the complexes in 
DMF or H2O/DMF and the spectra were monitored at 37 °C for the following spectra 
changes. Data were processed using the Origin 6.1 software4 and kinetics using the Pro-
Kineticist software.5 
 
2.2.4 Elemental analysis 
 
 Elemental analysis (C,H,N) were carried out by the Microanalytical Unit, Research 
School of Chemistry, Australian National University using a Carlo Erba 1106 automatic 
analyser. 
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2.2.5 Infrared (IR) Spectroscopy 
 
 Solid-state Fourier transform infrared (FTIR) spectra were recorded on a Varian 
FTS-800 Scimitar series spectrometer in a potassium bromide (KBr) matrix over the range 
4000-400 cm-1 at a wavenumber resolution of 4 cm-1. Samples were diluted ~1:10 with 
KBr and finely ground before use. A KBr background was collected and subtracted prior 
to the sample scan.  
 
2.2.6 X-Ray Absorption Spectroscopy (XAS) 
 
 Ru K-edge XAS data were recorded in the Australian National Beamline Facility 
(ANBF) at the Photon Factory, Tsukuba, Japan, or at the Australian Synchrotron (AS). The 
electron beam energy was 2.5 GeV (ANBF), or 3.0 GeV (AS), the electron beam current 
was 300-400 mA (ANBF), or 200 mA (AS). Measurements were carried out in the 
fluorescence mode, using a 36-pixel Ge detector (Canberra-Eurisys) at ANBF, or a 100-
element Ge detector (Canberra-Eurisys) at AS; and a water-cooled channel-cut double-
crystal Si(311) monochromator (ANBF), or a cryogenic double-crystal Si(311) 
monochromator (AS). Ionisation chambers contained an atmosphere of N2 (I0) or Ar (I1/I2). 
Data were recorded over the energy range of 21900-22900 eV (step size: 9 eV for pre-
edge, 21900-22080 eV; 0.25 eV for 22080-22180 eV XANES region; 0.05 Å-1 steps in k for 
22180-22900 eV EXAFS region). A Ru foil was used as the internal standard to calibrate 
the energy scale, the calibration energy = 22124 eV corresponded to y = 0 of the first 
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peak after the edge,6 instead of 22117 eV which corresponded to first peak of the first 
derivative of Ru(0) edge.7 Samples for the model Ru(II) complexes were mixed with 
boron nitride (1:10), ground to a fine powder and were used undiluted for the rest of the 
samples. These samples were pressed into four-slit 0.5 mm pellets supported within an 
Al spacer and secured on each side with 63.5-µm-thick Kapton tape. The temperature 
was maintained below 15 K, using a closed-cycle He CryoIndustries REF-1577-D22 
cryostat. 
 Data analysis of the results including averaging, background subtraction, 
modeling and calculations were carried out using the XFIT software package.8 Multiple 
scattering (MS) analysis of the EXAFS data was performed as reported previously9 using 
XFIT, which calculates ab-initio FEFF 6.01 algorithms for the fittings.10, 11 Multiple linear 
regression analysis was performed using the Origin software.4 For multiple scattering (MS) 
analysis, the scale factor S0
2 was constrained to be ~0.9, bond lengths and angles were 
restrained to within 0.02-0.05 Å and 2-10°, respectively, for model complexes. All arene 
rings were restrained to be planar, all C atoms in the ring restrained to ~1.41 Å from each 
other and constrained to be within a plane. The Debye-Waller factors were restrained 
between 0.0005 and 0.02 Å2 and equivalent atoms were constrained to be equal. 
Counter ions were not included in MS modeling. 
  Details of all constraints and restraints are presented in Appendix A2-A25. 
Conservative errors were estimated using a combination of systematic errors and Monte-
Carlo analysis as reported in previous work.12 More information was extracted from the 
EXAFS spectra by examining Fourier transforms (FT), which decomposed the k-space 
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𝜒filtered = ℑ
−1 Λ𝑅 ℑΛ𝑘𝑘
𝑛𝜒original    
signal into its constituent frequencies.13 This resulted in a series of peaks that 
corresponded to the shells of the atoms contributing to EXAFS, some which were caused 
by background noise.14 The FT spectra were useful to understand the shells present and 
the principal interatomic distances within the structures.14 However, peaks may overlap 
due to the spectrum consisting of both real and imaginary components thus causing 
destructive interference and loss of phase information.15 XFIT calculated this value by 
first filtering it to remove the noisy unwanted sections, producing equation 2.1:10  
 
  (2.1) 
 
where  is the FT, -1 is the inverse FT, Λk is the EXAFS window, ΛR is the FT window and 
n is the k-weighting. 
 Ru XFM experiments were performed at beamline 8-BM-B, Sector 8, Advanced 
Photon Source (APS), Lemont, IL, USA. The X-ray beam (12.8 keV) was monochromatized 
and passed through a pinhole (spot size on sample = 0.5 mm). Full X-ray spectra were 
collected in fluorescence mode and collected by a four-element silicon drift detector 
(Vortex EX, SII Nanotechnology) every 0.5 mm step over a 2 s dwell time. The spectra 
were fitted against NIST standards NBS1832 and NBS1833 using the MAPS software.16 
The experiments at the APS were carried out by Dr. Aviva Levina and Ms Hannah O'Riley. 
Maps and Ru content were processed and calculated by Dr. Jade Aitken. Some XFM 
measurements on Ru-protein complexes (separated by gel electrophoresis) were also 
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performed at the X-ray absorption spectroscopy (XAS) beamline, Australian Synchrotron 
(AS). The following beamline parameters were used: electron beam energy, 3.0 GeV; 
maximal electron beam current, 200 mA; monochromator, channel cut Si[111]; 
fluorescence detection mode (100-element Ge planar detector) and a Ru foil used for 
calibration. Settings for XANES spectra collection at Ru hotspots were as follows: (i) pre-
edge, 21917.0-22097.0 eV (step size, 10 eV); (ii) edge, 22097.0-22167.0 eV (step size, 
0.25 eV); and (iii) post-edge, linear range to kmax = 9 Å
-1 (step size, 0.05 Å-1). The dwell 
time per point was 2.0 s for the steps (i)-(iii).      
 
2.3 Synthesis and Characterisation of Ruthenium Arene Compounds 
 
Unless otherwise stated, these synthetic procedures were carried out under Ar 
using Schlenk methods to ensure an air and moisture-free atmosphere, despite most 
being reported to be air stable in literature.17,19,21 All solvents were freshly distilled prior 
to use and all reactions were conducted in a fume hood with the temperature constantly 
monitored. Literature characterization results are included if available. Numbers in 
brackets are the designated numbers for the compounds and will be referred to in later 
chapters. 
 
2.3.1 Synthesis of Ru (η6-p-cymene)(pta)Cl2  (RAPTA-C) (2) 
 
This synthetic procedure was modified from that in the literature.17 
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 A solution of [Ru(η6-p-cymene)Cl2]2 (55.1 mg, 0.09 mmol) and pta (28.3 mg, 0.18 
mmol) were suspended in freshly distilled MeOH (~22 mL) and the mixture was heated to 
reflux at 80 °C for 3 hr using an open-reflux system. The dark orange-red solution was 
then left to cool to room temperature, the small amount of black precipitate observed 
was filtered off and then the solution was rotary-evaporated (337 mBar, 60 °C) to 
remove the solvent. The product was then put under a vacuum pump for 2 hr to reveal 
an air-stable dark orange-red precipitate, which was then recrystallised from hot MeOH 
(yield: 52.5 mg, 63 %). 300-MHz 1H NMR (CDCl3): δ 5.43-5.51 (doublet of doublets, C6H4, J 
= 6 Hz), 4.54 (s, 6H), 4.34 (s, 6H), 2.80 (septet, CHCH3), 2.10 (s, 3H), 1.27 (d, 6H, J = 7 Hz). 
Literature 1H NMR (CDCl3): δ 5.46 (doublet of doublets), 4.53 (s), 4.32 (s), 2.78 (septet), 
2.08 (s), 1.22 (d). 31P-NMR (CDCl3): δ 36.51 (s). Literature 
31P NMR (CDCl3): δ 36.63 (s).
17 
ESI-MS (MeOH): m/z = 461 (M), 428 [Ru(η6-p-cymene)(pta)Cl]
+
 Literature ESI-MS (H2O): 
m/z = 464 (M+H
+
), 428 [Ru(η6-p-cymene)(pta)Cl]
+.17 Anal. found (calculated) for 
C16H26Cl2N3PRu: C, 41.14 (41.47); H, 5.64 (5.66). UV in MeOH λmax, nm (ε, M
-1 cm-1): 343 
(1.4 x 103). Literature UV in H2O λmax, nm: 342.
18  
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2.3.2 Synthesis of [Ru(η6-p-cymene)(en)Cl ]PF6 (3) 
 
This synthetic procedure was modified from that in the literature.19 The ligand, 1,2-
ethanediamine is hygroscopic and the reaction system needs to be degassed before 
adding it to the solution.  
 
 
 
 
 A solution of [Ru(η6-p-cymene)Cl2]2 (0.39 g, 0.64 mmol) was suspended in freshly 
distilled MeOH (150 mL) and an excess of 1,2-ethanediamine (0.12 g, 2.0 mmol) was 
added, which caused the solution to turn an intense yellow immediately. The solution 
was stirred at room temperature for 3 hr under Ar. The yellow solution was filtered to 
remove black precipitates, then a small amount was taken out for ESMS analysis. An 
excess of tetra-1-butylammonium hexaflourophosphate (0.52 g, 3.2 mmol) was added to 
the yellow filtrate, which was stirred for another hour then concentrated to 15 mL on a 
rotary evaporator (337 mBar, 60 °C). The flask was left standing in the refrigerator (~4 °C) 
to enable precipitation. The next day, the yellow precipitate was filtered and re-
crystallized with dry MeOH, concentrated again and left at 4°C until yellow-orange 
crystals formed. These crystals were washed with diethyl ether (4 x 2.5 mL) and dried 
under vacuum (yield: 0.26 g, 62 %). 300-MHz 1H-NMR (DMSO-d6): δ 6.10 (b, 2H), 5.50 (d, 
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2H, J = 6 Hz), 5.35 (d, 2H, J = 6 Hz), 4.17 (b, 2H), 2.73 (septet, CHCH3), 2.41 (m, 2H), 2.11 (s, 
3H), 1.22 (d, 6H, J = 7 Hz). Literature 1H-NMR (DMSO-d6): δ 6.13 (b), 5.48 (d), 5.32 (d), 
4.22 (b), 2.71 (septet), 2.43 (m), 2.11 (s), 1.25 (d).19  ESI-MS (MeOH): m/z = 295 (M), 331 
[Ru(η6-p-cymene)(en)Cl]
+
. Literature ESI-MS (H2O): m/z = 295 (M), 331  
[Ru(η6-p-cymene)(en)Cl]
+.19 UV in MeOH λmax, nm (ε, M
-1 cm-1): 313 (2.6 x 103).  
Literature UV in NaClO4 λmax, nm: 319.
20 Anal. Found (calculated) for C12H22ClN2PF6Ru: C, 
30.50(30.29); H, 4.75(4.66); N, 5.95(5.88). 
 
2.3.3 Synthesis of [Ru(η6-p-cymene)(acac)Cl] (4) 
 
This synthetic procedure was modified from literature.21 
 
 
 
 
Preparation of ligand Na(acac): 
 Bulk Na(acac) was prepared by first dissolving sodium hydroxide (4 g, 0.1 mol) in 
deionized water (5 mL), then the solution was added to freshly distilled MeOH (20 mL). 
The combined solution was then added to acetylacetone (10.26 mL, 0.1 mol) in a 100-mL 
conical flask. The mixture turned creamy light yellow with a white precipitate. The flask 
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was stoppered and left at 4°C for 7 hr. The salt was collected with vacuum filtration then 
washed with cold MeOH before use. 
Synthesis: 
 [Ru(η6-p-cymene)Cl2]2 (0.24 g, 0.40 mmol) and Na(acac) monohydrate (0.12 g, 
0.85 mmol) were stirred in acetone (27.3 mL) for 1 hr. The resulting orange liquid was 
concentrated on a rotary evaporator (337 mBar, 60 °C); the dark orange residue was then 
extracted with dichloromethane and filtered. The solvent was removed again and the 
residue was dissolved in acetone, then concentrated down and diluted with diethyl ether 
(5 mL). This was left to stand at 4°C until dark red crystals formed (yield: 0.09 g, 31 %). 
300 MHz 1H NMR (CDCl3): δ 5.45 (d, 2H, J = 6 Hz), 5.20 (d, 2H, J = 6 Hz), 5.14 (s, 1H), 2.86 
(septet, CHCH3), 2.26 (s, 3H), 1.98 (s, 6H), 1.32 (d, 6H, J = 7 Hz). Literature 
1H NMR (CDCl3): 
δ 5.46 (d), 5.21 (d), 5.16 (s), 2.88 (septet), 2.27 (s), 2.00 (s), 1.32 (d).21 ESI-MS (MeOH): 
m/z = 335 [Ru (η6-p-cymene)(acac)]+. UV in MeOH λmax, nm (ε, M
-1 cm-1): 312 (2.8 x 103) 
447 (3.7 x  102). Anal. Found (calculated) for C15H22ClO2Ru: C, 48.43 (48.57); H, 4.70 (4.66).  
 
2.3.4 Synthesis of [Ru(η6-p-cymene)(pta)(C2O4)] (OxaloRAPTA-C) (5) 
This synthetic procedure was modified from that in the literature.22 
 
 
 
1
. 
2
. 
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Preparation of ligand silver oxalate: 
 Silver oxalate was prepared by dissolving silver nitrate (1.86 g, 11 mmol) in 
deionised water, then the solution was added dropwise to sodium oxalate (0.67 g, 5 
mmol), in which a precipitate formed immediately. The solution was stirred for 10 min 
and the white precipitate was filtered, washed with water and dried over vacuum.      
Note: Silver oxalate had to be freshly prepared before each synthesis because its colour 
turned darker within 1 month, indicating decomposition.23 
Synthesis: 
 [Ru(η6-p-cymene)Cl2]2 (0.19 g, 0.32 mmol) and silver oxalate (0.24 g, 0.79 mmol) 
were stirred in deionized water (60 mL) for 12 hr at room temperature. The orange 
mixture was filtered through Celite to remove the AgCl precipitate. Then the solvent was 
removed under vacuum (80 mBar, 60 °C). The yellow residue was redissolved in MeOH 
(25 mL), then pta (0.12 g, 0.76 mmol) was added and the solution was stirred for a 
further 2 hr. The solvent was rotary evaporated down to ~10 mL and diethyl ether (25 mL) 
was added. The slurry was left in a refrigerator (~4 °C) for 12 hr to complete the 
precipitation. This was then filtered and recrystallised from MeOH/diethyl ether (1:1) to 
give a dark yellow precipitate, which was dried under vacuum (yield: 0.14 g, 45 %).       
300 MHz 1H NMR (D2O): δ 6.00, 5.93 (dd, 4H, J = 6 Hz), 4.60 (s, 6H), 4.19 (s, 6H), 2.65 
(septet, CHCH3), 2.09 (s, 3H), 1.27 (d, 6H, J = 7 Hz). 
31P NMR (D2O): δ -33.28. Literature 
1H-
NMR (D2O): δ 5.98, 5.89 (dd), 4.57 (s), 4.15 (s), 2.61 (septet), 2.05 (s), 1.22 (d). 
31P NMR 
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(D2O): δ -33.39.
22 ESI-MS (MeOH): m/z = 504 [M+Na]+; 984 [2M+Na]+. Literature ESI-MS 
(H2O): m/z = 504 [M+Na]
+; 984 [2M+Na]+.22 UV in MeOH λmax, nm (ε, M
-1 cm-1):  
305 (2.7 x 103). Literature UV in NaCl λmax, nm: 303.
22 Anal. Found (calculated) for 
C18H26N3O4PRu: C, 44.24 (44.17); H, 5.50 (5.45); N, 8.86 (8.75). 
 
2.3.5 Synthesis of [RuCl2(η
6-p-cymene)(mimid)] (6) 
This compound was synthesized according to literature procedures.24 N-methylimidazole 
is hygroscopic and has to be added into the air-free system with a syringe to prevent as 
much moisture as possible. 
 
 
 
 
 [Ru(η6-p-cymene)Cl2]2 (0.20 g, 0.33 mmol) was suspended in freshly distilled 
toluene (30 mL). N-methylimidazole (52 µL, 0.66 mmol) was added at room temperature. 
The resulting mixture was heated to reflux for 3 hr and a precipitate formed within an 
hour of vigorous stirring. After cooling down, the reddish brown precipitate formed was 
filtered, washed with diethyl ether (4 x 10 mL) and dried under vacuo (yield: 0.17g, 67 %). 
300 MHz 1H NMR (CDCl3): δ 7.87 (s, 1H), 7.30 (s, 1H), 5.45, 5.26 (dd, 4H, J = 6 Hz), 3.65 (s, 
3H), 2.99 (septet, CHCH3), 2.19 (s, 3H), 1.27 (d, 6H, J = 7 Hz). Literature 
1H NMR (CDCl3):        
δ 7.87 (s), 7.30 (s), 5.44, 5.25 (dd), 3.65 (s), 2.99 (septet), 2.19 (s), 1.28 (d).24 ESI-MS 
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(CH3CN): m/z = 353 [Ru(cymene)Cl(mimid)]
+, 312 [Ru(cymene)Cl(CH3CN)]
+, 271 
[Ru(cymene)Cl]+. Literature ESI-MS (CH3CN): m/z = 353 [Ru(cymene)Cl(mimid)]
+, 311.9 
[Ru(cymene)Cl(CH3CN)]
+.24  UV in MeOH λmax, nm (ε, M
-1 cm-1): 327 (1.25 x 103), 409 (8.6 
x 102). Literature UV in MeOH λmax, nm: 330, 407.
25 Anal. Found (calculated) for 
C14H20Cl2N2Ru: C, 43.35 (43.29); H, 5.17 (5.19); N, 7.50 (7.22). 
 
2.3.6 Synthesis of [Ru2(η
6-p-cymene)2(OH)3]BPh4.3H2O (7) 
This synthetic procedure was modified from that in the literature.26, 27 
 
 
 
 
 
 
 
 A solution of [Ru(η6-p-cymene)Cl2]2 (0.25 g, 0.4 mmol) was dissolved in deionised 
water (20 mL) with NaOH (0.15 g, 4.0 mmol). The solution was stirred and warmed up to 
60°C for 2 hr. The pale yellow solution was filtered to remove black impurities formed at 
the bottom of the flask then the filtrate was concentrated to 10 mL. NaBPh4 (0.20 g, 0.60 
mmol) in water (5 mL) was added, which resulted in a gummy precipitate. The solution 
was stirred vigorously for another 6 hr at 56 °C to give a chunky powdery yellow 
precipitate, which was filtered, washed with water and hexane and then dried under 
vacuo. The compound was recrystallised with acetone to yield the tri-hydroxido species 
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(yield: 0.27 g, 79 %). Selected IR: v(OH) 3560 cm-1. Literature: v(OH) 3550 cm-1.26 300 MHz 
13C{1H} NMR (CDCl3): δ 122-136 (BPh4
-), 96.7 (Ar), 93.3 (Ar), 77.4 (Ar), 74.9 (Ar), 31.1 (CH), 
22.6 (2CH3), 18.2 (CH3). Literature 
13C{1H} NMR (CDCl3): δ 121-136 (BPh4
-), 96.4 (Ar), 93.0 
(Ar), 77.4 (Ar), 74.8 (Ar), 31.1 (CH), 22.4 (2CH3), 17.9 (CH3).
26 ESI-MS (MeOH): m/z = 564 
[M+CMe2]
+
, 551 [M+CMe]
+
 520 [M]+. UV in MeOH λmax, nm (ε, M
-1 cm-1): 314 (8.3 x 102), 
400 (4.4 x 102). Anal. Found (calculated) for C47H57O4BRu2: C, 62.60 (62.79); H, 6.30 (6.39). 
 
2.3.7 Synthesis of [Ru(η6-p-cymene)(tsal)]2 (8) 
This compound was synthesized according to literature procedures.28 Note that the 
thiosalicylic acid is extremely pungent and the reaction has to be conducted in a fume 
hood. All used glassware has to be rinsed well in a base bath. 
 
 
 
 
 
 [Ru(η6-p-cymene)Cl2]2 (0.18 g, 0.20 mmol) and thiosalicylic acid (0.62 mg, 0.40 
mmol) were suspended in freshly distilled MeOH (10 mL), then triethylamine (Et3N) (0.11 
mL, 0.80 mmol) was added and the mixture was refluxed for 30 min. Deionised water (50 
mL) was added to the orange-red solution and the mixture was cooled to room 
temperature and an orange precipitate formed almost immediately. The flask was 
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purged with N2, sealed, and placed in the refrigerator (~4 °C) for more crystals to form. 
The orange powder formed was washed with water and 1-hexane then dried under 
vacuum (0.07 g, 45 %).  1H NMR (CDCl3): δ 8.10 (d, 1H, J = 7 Hz), 7.64 (d, 1H, J = 7 Hz), 
7.33 (t, 1H, J = 7 Hz), 7.25 (t, 1H, J = 7 Hz), 5.07 (d, 1H, J = 6 Hz), 4.75 (d, AB pattern, 1H, J 
= 6 Hz), 4.70 (d, 1H, J = 6 Hz), 2.54 (septet, CHCH3), 1.80 (s, 3H), 1.12 (d, 3H, J = 7 Hz), 0.82 
(d, 3H, J = 7 Hz). Literature 1H NMR (CDCl3): δ 8.08 (d), 7.62 (d), 7.31 (t), 7.23 (t), 5.04 (d), 
4.73 (d), 4.71 (d), 2.51 (septet), 1.79 (s), 1.10 (d), 0.81 (d).28 ESI-MS (MeOH): m/z = 777 
[2M+ H]
+. Literature ESI-MS (MeCN): m/z 777 [2M+H]+ .28  UV in MeOH λmax, nm (ε, M
-1 
cm-1): 277 (2.3 x 103), 362 (7.7 x 102). Anal. Found (calculated) for C34H36O4S2Ru2: C, 52.40 
(52.72); H, 4.65 (4.71). 
 
2.3.8 Synthesis of [Ru(η6-p-cymene)(en)(S-Ph)]PF6 (9) 
 
This new complex was synthesed by a procedure that was modified from a general 
method in literature.29 
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[Ru(η6-p-cymene)(en)Cl]PF6 (0.20 g, 0.43 mmol) was stirred with AgNO3 (0.07 g 
0.43 mmol) in 1:1 MeOH and H2O (40 mL) for 20 hr. Then AgCl was filtered off with celite, 
the solution was rotary-evaporated to dryness, then the solid was redissolved in MeOH. 
The solution was filtered then sodium thiophenolate (0.06 g, 0.48 mmol) was added and 
the mixture was stirred for a further 15 hr. After that, an excess of KPF6 (0.39 g, 2.14 
mmol) was added, the orange solution was stirred for 1 hr, purged with N2 then left in a 
refrigerator (~4 °C) for 8 hr. The first lot of pale yellow precipitate, which mainly 
consisted of KCl was discarded, then the solution was concentrated down to ~5 mL. It 
was cooled at 4 °C again to yield tiny yellow crystals (yield: 0.07 g, 21 %). 300 MHz 1H 
NMR (MeOD-d4): δ 7.49 (d, 2H, J = 7.5 Hz), 7.18 (t, 2H, J = 6.5 Hz), 7.13 (t, 1H, J = 6.7 Hz), 
5.68 (b, 2H), 5.28 (d, 2H, J = 6 Hz), 5.19 (d, 2H, J = 6 Hz), 3.75 (b, 2H), 2.75 (septet, 1H), 
2.51 (m, 2H), 2.19 (s, 3H), 1.22 (d, 6H, J = 6.9 Hz). ESI-MS (MeOH): m/z = 295 [(η6-
C10H14)Ru(en)]
+, 405 [(η6-C10H14)Ru(en)(S-Ph)]
+. UV in MeOH λmax, nm (ε, M
-1 cm-1): 269 
(8.6 x 102), 314 (4.5 x 102). Anal. found for C18H27N2SPF6Ru: C, 39.23 (39.34); H, 4.45 
(4.50); N, 5.27 (5.20). 
 
2.3.8.1 Other synthetic procedures for the benzenethiolato complex 
 
The benzenethiolato ligand was found to have a high affinity to Ru, and was more 
likely to form dimers and trimers; possibly replacing the en ligand either during the 
reaction or after recrystallization. Therefore, it had to be deprotonated and it was 
equally important to ensure complete removal of the Cl ligands in the starting 
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compound before continuing the reaction. Stirring 3 with AgNO3 for > 20 h was found to 
be the optimum time for chloride removal. As the thiol is hygroscopic, all water and 
moisture had to be removed from the reaction vessel after removal of AgCl. The addition 
of NH4PF6 for the counter anion as mentioned in the literature,
29 did not result in a pure 
compound, probably because NH4
+ reprotonated the thiophenolate. Thus, NaPF6 or KPF6 
were more appropriate for this synthesis.  
 
2.4 UV-Vis Kinetics Studies on Ru (II) complexes 
 
 UV-Vis electronic absorption spectroscopy was carried out for compounds 2-6 to 
investigate their aquation/decomposition rate in biological media (DMEM and HBS). 
Stock solutions (50 mM) were prepared by dissolving these complexes in a small amount 
of DMF or DMF/H2O before pipetting the solutions into the respective biological 
solutions (final concentration of 1.0 mM) prior to measurements. Measurements were 
performed in 1-cm path-length quartz cells. All reactions were performed at 37 °C. The 
background measurements were taken for solutions that contained all components 
accept Ru compounds. Global kinetic analysis of time-dependent UV-Vis spectra (range: 
300-800 nm; resolution: 2 nm) was performed with Pro-Kineticist software,5 as described 
previously.30 Application of singular value decomposition (SVD) procedure to the 
absorbance-wavelength-time data matrices led to separation of significant spectral 
changes from the noise and allowed a prediction of the numbers of independent 
absorbing species in the reaction mixture.30 On the basis of these observations, the 
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simplest kinetic models (typically one or two sequential pseudo-first reactions) were 
proposed.30  These models were then fitted to the matrices of experimental data using 
the Marquart-Levenberg non-linear least-squares fitting algorithm.5 This procedure 
provided the optimal values of rate constants, as well as the estimated spectra of the 
initial, intermediate and final absorbing species.5 This information was used to predict 
the nature of chemical changes in Ru(II) complexes during the interactions with biological 
media.30    
 
2.5 XAFS sample preparation 
 
2.5.1 Incubation in biological media 
 
 Stock solutions (60 mM) of each compound were prepared immediately before 
use according to previous published methods;31 5.0 μL was pipetted into 0.5 mL of 
biological media (HBS, DMEM or serum). All reaction mixtures were incubated at 37°C. 
For reactions with bovine serum albumin (BSA), 1.0 mL of each of the samples were 
prepared in HBS, after incubating for the respective times, a 100 μL aliquot of the sample 
was filtered through Bio-Gel P-30 spin columns (molecular mass cut-off at 30 kDa) and 
centrifuged for 2 min to remove unbound Ru. The purified samples were then freeze-
dried to stop the reaction, concentrate the Ru content, and to reduce photoreduction 
during XAS experiments.32  
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2.5.2 Reactions with HEPG2 cells 
 
 HEPG2 human liver carcinoma cells1 were grown for 1 week prior to their 
incubation with test compounds. The Ru compounds (0.60 mM) were used to treat the 
cells for 4 hr, using an incubation temperature of 37°C. The medium was then removed 
and the cell monolayers were washed three times with 0.5 mL of phosphate-buffered 
saline (PBS). The cells were then scraped off into PBS (~ 0.5 mL) on ice and centrifuged 
for 2 min. The pellets formed were suspended in fresh PBS. The solution (cells + buffer) 
was collected then freeze-dried. The cell medium was also kept for analysis to observe 
possible changes in the spectra.    
 
 
2.5.3 Reactions with DNA 
 
These samples were prepared by Dr. Aviva Levina. DNA sodium salt from salmon 
sperm (DNA-Na) was prepared in HBS (~pH 7.1) then RAPTA-C (0.60 mM) was added to 
different concentrations of DNA-Na; 10.0, 5.0 and 2.5 mg/mL. The samples were kept at 
room temperature in the dark for ~15 hr then freeze-dried.  
 
2.5.4 Reactions with Rat blood 
 
These samples were prepared by Dr. Aviva Levina and Dr. Tony Bonin. RAPTA-C 
(0.50 mM) was added into rat blood, centrifuged then separated into the red blood cell 
(RBC) and plasma fraction. These fractions were incubated for 1 or 6 hr at 37°C then 
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freeze-dried. For isolated reactions, the plasma fraction was first separated from the 
blood before reacting with Ru. 
 
2.5.5 Gel electrophoresis 
 
 The Ru samples and NuPAGE LDS sample buffer (4x) were loaded onto a NuPAGE 
12% Bis-Tris gel (1.0 x 15 well). The chamber was filled with MES running buffer (10x) (80 
mL) and deionized water (720 mL). Electrophoresis was then run at 200 V, 200 mA for 40 
min until completion. The membrane transfer buffer was the Bicine transfer buffer (100 
mL), MeOH (100 mL) and deionized water (800 mL), in which 600 mL of this buffer was 
used to soak blotting pads before use. The pads were properly squeezed and soaked to 
remove any air bubbles. The membrane, an Invitrolon PVDF Filter Paper Sandwich (0.45 
μm pore size) was soaked in MeOH for 30 s, then water and buffer before use. Filter 
paper was soaked in buffer then placed carefully on the gel, using the body of a glass 
pipette to gently roll over the surface. After that, the membrane was removed, rinsed 
with water, stained with Ponceau S solution for ~10 min to determine the molecular 
weights of the proteins, and left to dry for ~2 hr before inserting in sample bags for XAS.   
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3.1 Introduction and general theory 
 
 The XAS technique was used to characterise the structure of new complexes and 
to investigate the biological activities of ruthenium complexes.  Conventional X-ray 
crystallography is still mainly used for structure determination, but there are limitations 
as it is not always easy to obtain diffraction quality crystals and is not appropriate if the 
metal of interest is in solution. Using XAS, the local atomic environment of the metal can 
be determined by analysing the extended X-ray absorption fine structure (EXAFS) 
oscillations.1-4 
 XAS occurs when incoming X-rays are absorbed by core electrons, causing photo-
excitation thus ejecting the core electrons into a higher unoccupied orbital or the 
continuum (Figure 3.1). The promotion of core electrons generates an intense absorption 
that is known as an “edge”.  Relaxation can then happen by Auger electron emission 
and/or X-ray fluorescence, but the latter dominates at high energies, such as the Ru K-
edge.5 The energy of this absorption edge is specific for a specific element.6 The shape 
and position of the edge also gives information about the oxidation state, the geometry, 
the coordination number and the donor ligands.7 XAS can be divided into X-ray 
absorption near-edge structure (XANES), which is in the vicinity, ~50 eV from the edge 
and X-ray absorption fine structure (EXAFS), ~ 40-1000 eV above the edge (Figure 3.2).8 
The oscillatory pattern observed in EXAFS is due to constructive and destructive 
interferences with outgoing electron waves originating and propagating away from its 
absorber, and the backscattered wave from neighbouring atoms (scatterers).6 
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        Figure 3.1: Schematic illustration of the XAS theory.9 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Normalized XANES and EXAFS absorption spectrum of the Ru K-edge (~0.5 % 
solid mixtures of Ru w/w with BN). Constructive and destructive interference of the 
photoelectron waves are depicted within the spectrum in which A and S refer to the 
absorber and scatterer respectively.6, 10  
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3.1.1 XANES 
 
 X-ray absorption near-edge structure (XANES) is a type of X-ray spectroscopy in 
which the promotion of a core electron to an unoccupied orbital forms a steep edge due 
to intense absorption by allowed electronic transitions. These electrons are usually from 
the K shell (principal quantum number, n = 1) to unoccupied p-orbitals, or from the L (n = 
2) or M (n = 3) for heavier elements.10 The low photoelectron energy region has a large 
electron-scattering factor due to the long elastic mean free path, thus multiple scattering 
becomes an important aspect to consider.11  
 
3.1.2 EXAFS 
 
 Extended X-ray absorption fine structure (EXAFS) is the region after the edge in 
which the oscillations are extended for 1000 eV or more from the edge. It is used for 
quantitative analysis to determine the bond lengths and coordination environment of the 
absorbing atom and scatterers and the angular arrangement of ligands around the 
absorber when multiple- scattering is incorporated.5, 6, 12   
EXAFS, (k) is defined as the fractional modulation of the absorption coefficient, 
which includes both the total amplitude function and total phase function, thus giving 
rise to a general equation: 6 
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where k is the photoelectron wavevector, Ras is the absorber-scatterer distance, Ns is the 
number of scattering atoms, As is the backscattering amplitude, S0
2 is the amplitude 
reduction factor, λ(k) is the mean free path of the photoelectron, 2 is the mean-square 
deviation in Ras which the Debye-Waller factor depends on and as is the total phase shift 
that the photoelectron undergoes during the scattering process.6, 8, 11 
 The equation above (1) only assumes single scattering (the excited photoelectron 
travelling from the absorber to the scatterer and back) and breaks down at the low-k 
region (k < 3 Å-1), which is the low energy range of the photoelectron.6 This makes 
multiple-scattering theory important as shown, for instance, in Figure 3.3, which 
contributes to the observed EXAFS signal.6 
 
 
 
 
Figure 3.3: Illustration of possible scattering pathways for a three-body system with A 
being the absorber and S being the neighboring scatterers: a) Single-scattering, b) and c) 
being two of the possible multiple-scattering pathways.  
 
 
 Multiple-scattering is highly dependent on the scattering angle that determines 
the intensity.  Angles less than 150° generally have weak MS effects but angles between 
A S
 
S
 
A S
 
S
 
A S
 
S
 
(a) (b) (c) 
Chapter 3 
 
 
57 
 
150° and 180° have more significant MS, which may make major contributions to the 
measured EXAFS.12-14 For biological systems, linear arrangements such as in binding of 
C=O and rigid ligands such as porphyrins and imidazoles, have some of the most 
prominent MS effects.12,15-17 In general, this aspect is useful for finding out the bond 
angles and lengths as some of the coordinating groups demonstrate unique signals due 
to amplitude enhancement.6  
 
 
3.1.3 Sample preparation and experimentation 
 
 
 The field of XAS has blossomed ever since intense synchrotron radiation became 
readily accessible. For the research reported herein, electrons are accelerated by the 
bending magnets or wigglers in the storage ring producing broad energies of photons.10 
The experimental apparatus was set up as shown in Figure 3.4. The incident and 
transmitted beams are measured by ionization chambers (I0, I1, I2) in which I0 normalizes 
the output of the incident beam and I1 and I2 are used to measure the x-ray absorption 
spectrum of the standard in order to calibrate the incident beam, which varies over time 
due to change in the temperature of the monochromator and other factors.10 The 
sample holder was placed at an angle ~45° to I0 and a Ge fluorescence detector. This 
detector (that contained 34 live channels at ANBF) was moved as close as possible to the 
sample in order to capture the largest solid angle, which provided the highest signal-to-
noise for the fluorescent x-rays coming from the sample.10 However, care needed to be 
taken not to bring the detector too close to the sample as this would occlude detector 
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channels. A thin ruthenium foil with a known absorption edge (~22,100 eV) was placed 
between I1 and I2. The readings for each scan are then collected digitally.
5,10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4:  Illustration of the apparatus used for XAS experiments (not to scale). Arrows  
          shows the direction of the X-ray beam. 
 
 
 The fluorescent detection mode is much more sensitive than the absorption 
mode, which is why x-ray fluorescence is preferred for biological samples.12 Ruthenium 
samples were cooled in liquid nitrogen prior to experiments before moving the sample 
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into a cryostat, which was maintained at a temperature < 20 K by closed-cycle liquid He 
circulation for XAS measurements.5 This helped retain sample stability, reduced beam 
heating effects, minimized photoreduction and increased EXAFS intensities by minimizing 
Debye-Waller factors.10 Before running the experiments, traces of air were eliminated 
from the sample chamber with He/vacuum cycles and the sample was kept under 
vacuum in a He atmosphere to avoid water condensation problems.10  
 
3.2 Building the XAS Library for Linear Regression XAS Analysis 
 
 As mentioned above, the XANES spectra of the element of interest within 
biological samples can serve as a fingerprint to identify the possible products formed in 
reactions. Using a representative library of XAS of known model complexes containing 
the biologically relevant donor groups, spectral comparisons can thus be made using 
multiple linear regressions.5, 10, 18-20 
 The ruthenium arene complexes used in this study are illustrated in Figure 3.5: 
[Ru(η6-p-cymene)Cl2]2 (1), RAPTA-C (2), [Ru(η
6-p-cymene)(en)Cl]PF6 (3),  
[Ru(η6-p-cymene)(acac)Cl] (4), OxaloRAPTA-C (5), [Ru(η6-p-cymene)Cl2(mimid)] (6), 
[Ru2(η
6-p-cymene)2(µ-OH)3]BPh4 (7), [Ru(η
6-p-cymene)(tsal)]2 (8),  
[Ru(η6-p-cymene)(en)(S-Ph)]PF6 (9).  
 The choice of complexes, apart from the drugs being investigated, is dictated by 
the following. Imidazole is known to be a common binding site for serum proteins to Ru 
complexes,21, 22 the presence of tris-hydroxo ligands are thought to be the end product 
for compounds undergoing aquation and hydrolysis in aqueous media.23  Ru(II) 
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complexes also bind avidly and strongly to S-donor (thiol) ligands in biomolecules 
forming S-bound adducts which might then form S-bridged dimers.24, 25 In addition, Ru(II) 
may also bind to other N/O-donor ligands in other ligand-exchange reactions with 
biomolecules, as was observed with Ru(III) complexes.20, 26 A general comparison of the 
EXAFS and FT EXAFS spectra obtained for each compound is shown in Figure 3.6. 
 
 
Figure 3.5: Library of Ru(II) arene model complexes that were used for multiple linear  
regression and their structures determined by multiple-scattering analysis of EXAFS data. 
Synthesis procedures are described in detail in Chapter 2. 
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Figure 3.6: Comparison of: a) k3-weighted EXAFS; and b) FT EXAFS spectra of the nine 
model Ru(II) arene  compounds. All samples were prepared by mixing the solid 
compounds with BN (~1:10 ratio) and were ran at low temperature (10-15 K) in 
fluorescence detection mode to compare with biological samples. Spectra for models 2 
and 3 were only taken up to the k range of 13 Å due to the high noise levels.  
 
 
 
Chapter 3 
 
 
62 
 
3.3 Multiple-Scattering EXAFS Analysis of the Structures of Model Ru(II) 
Complexes 
 
 
First of all multiple-scattering analysis was performed on the EXAFS from 
crystallographically characterized complexes 2-8 to test the accuracy of the modeling to 
be applied to unknown structures. Complexes 7 and 9 were not characterized and other 
structurally similar complexes were used as references to build the models. The 
structures, atom-numberings, experimental and calculated EXAFS, FT spectra of the Ru(II) 
arene complexes are shown in Figures 3.7-3.22. Bond lengths are compared to published 
crystal structure data for previously characterized species and corresponded well; an R-
factor of around or less than 20% are considered satisfactory.27 Fitting parameters, which 
included the threshold energy, E0, scale factor, S0
2, and Debye-Waller factors, 2, are 
presented in Appendix Table A2-A25. 
The degree of determinacy of the system is quantified by a ratio of the number of 
independent observations, Ni and the number of refined parameters, p.
27 Taking both 
constrained and restrained refinements into consideration, the value of Ni is given by:  
   
 (  )(  )
 
 ∑[ (   )   ]    (2) 
 
where r and k are the ranges of the FT and EXAFS filtered spectra, D is the number of 
dimensions for refinement and N is the number of atoms in the unit.27 For an Ni/p ratio 
less than one, the fit is underdetermined and a unique answer is not possible. Values 
above one are required for overdeterminacy of the refinement.28 The ratio obtained for 
all models accessed were > 1.   
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3.4 Results 
 
3.4.1 RAPTA-C (2) 
 
The modeling conditions and fitting parameters for RAPTA-C are presented in 
Appendix Table A.2-A.3. The bond lengths and angles obtained from MS calculations 
(Table 3.1) were in good agreement and within error range with the literature crystal 
structure.29 The model (Figure 3.8) took into account all the non-hydrogen atoms within 
5 Å of the scattering atom that might contribute to the spectra;12 a fit of R = 18% was 
obtained over the k range 0-13 Å-1. Unfortunately, at k > 13 Å-1 the oscillations were 
weak and were mainly noise. As such a reduced k-range was used to collect the spectra.  
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Figure 3.7: k3-weighted EXAFS data and FT spectra for compound 2: Observed (black), 
calculated (red), residual (green) spectra, window function (dashed blue line). EXAFS cut 
at k = 13 Å-1 due to the noise levels at a higher k range. 
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The fit was overdetermined with an Ni/p value of 1.1. The EXAFS data and the 
corresponding FT are shown in Figure 3.7, together with the calculated data from the fit 
(red line). Appendix Table A.4 provides the significant paths for the calculated EXAFS 
spectra.  
 
 
 
 
 
 
 
Figure 3.8: The model used for the MS EXAFS fits based on the crystal structure of 
compound 2.29 Atom numbers correspond to Table 3.1. 
 
Table 3.1: Comparison of the bond lengths and angles of EXAFS analysis results to the 
published crystal structure of RAPTA-C. 
Atom-atom Crystal Structure29 EXAFS 
Bond lengths (Å)   
Ru0Cl1 2.412(3) 2.43(2) 
Ru0Cl2 2.429(2) 2.43(2) 
Ru0P3 2.296(2) 2.32(2) 
Ru0C13-18 2.194(10) 2.19(2) 
   
Bond angles ()   
P3Ru0Cl2  83.42(8) 82(3) 
P3Ru0Cl1  89.80(3) 89(2) 
Cl2Ru0Cl1  87.25(8) 88(1) 
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3.4.2 [(η6-p-cymene)Ru(en)Cl]PF6 (3) 
 
The model used for MS calculations was based on the published crystal 
structure,30 with a fit of R = 19% and an Ni/p value of 1.1. Experimental and calculated 
EXAFS and FT spectra are shown in Figure 3.9 and fitting parameters in Appendix Table 
A.5. A comparison is shown with the crystal structure bond angle and length data (Table 
3.2); best fits include the Ru-Cl bond (2.41 Å), the shorter Ru-N chelating bonds (average 
of 2.11 Å) and the Ru-arene carbon bonds (average 2.19 Å). Although the bonding 
parameters were consistent with literature values, the small k range used (~11 Å-1) would 
mean that some fitting parameters such as the Debye-Waller factors, are not optimal. 
MS analysis over a longer k range will be needed for more accurate results.    
 
 
 
 
 
 
 
 
 
 
Figure 3.9: k3-weighted EXAFS and FT spectra for compound 3: Observed (black), 
calculated (red), residual (green) spectra, window function (dashed blue line). EXAFS cut 
at k = 13 Å-1 due to the noise levels at a higher k range. 
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Conditions applied for MS modelling are similar to RAPTA-C but slightly loosened 
with bond lengths and angles within 0.03 Å and 2-5° respectively, according to the error 
range published.30  The model, based on the crystal structure, is given in Figure 3.10; 
further details of the significant path lengths, constraint and restraint parameters are 
presented in Appendix A.5-A.7. 
 
 
 
 
 
 
 
 
Figure 3.10: The model used in the MS EXAFS fits based on the crystal structure of 
compound 3.30 Atom numbers correspond to those in Table 3.2. 
 
Table 3.2: Comparison of the bond lengths and angles of EXAFS analysis results to the 
published crystal structure of [(η6-p-cymene)Ru(en)Cl]PF6. 
Atom-atom Crystal Structure30 EXAFS 
Bond lengths (Å)   
Ru0Cl1 2.442(5) 2.41(2) 
Ru0N12 2.130(2)  2.11(2) 
Ru0C3-8 2.195(3)  2.19(2) 
   
Bond angles ()   
N12Ru0N15  78.97(5)  77(6) 
N12Ru0Cl1  84.53(8)  84(7) 
Ru0N15C14  123.34(5)  128(6) 
N15C14C13 110.80(3) 112(6) 
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3.4.3 [(η6-p-cymene)Ru(acac)Cl]PF6 (4) 
 
The model used for MS EXAFS calculations was based on the published crystal 
structure,31 with a fit of R = 17% (Figure 3.11).   
 
 
 
 
 
 
 
Figure 3.11: Model used for the MS EXAFS analysis based on the crystal structure of 
compound 4.31 Atom numbers correspond to those in Table 3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: k3-weighted EXAFS and FT spectra for compound 4: Observed (black), 
calculated (red), residual (green) spectra, window function (dashed blue line). 
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Experimental and calculated EXAFS and FT spectra are shown in Figure 3.12; the 
resultant fitting parameters were within acceptable ranges (Table A.9, Appendix). A 
comparison of bond length and angle data is shown with the crystal structure data (Table 
3.3); best fits included the Ru-Cl bond (2.41 Å), the shorter Ru-O bond (2.05 Å) and the 
Ru-arene carbon bonds (average 2.16 Å). Restraints applied for MS modelling had bond 
lengths and angles within 0.03-0.05 Å and 2-5° respectively, according to the error range 
published.31  Further details of the significant path lengths, constraint and restraint 
parameters, are presented in A.8-A.11 Appendix.  
Table 3.3: Comparison of the bond lengths and angles of EXAFS analysis results to the 
published crystal structure of [(η6-p-cymene)Ru(acac)Cl]PF6. 
Atom-atom Crystal Structure31 EXAFS 
Bond lengths (Å)   
Ru0Cl1 2.406(2) 2.41(2) 
Ru0O3 2.061(4) 2.05(2) 
Ru0C10-15 2.169(2)) 2.16(2) 
   
Bond angles ()   
O3Ru0Cl1 87.26(7) 86(5) 
O7Ru0Cl1 83.34(7) 84(5) 
O7Ru0O3 85.24(8) 86(5) 
  
3.4.4 OxaloRAPTA-C (5) 
 
The model used for MS EXAFS calculations was based on the published crystal 
structure,32 with an excellent fit of R = 11% (Figure 3.13).  Experimental and calculated 
EXAFS and FT spectra are shown in Figure 3.14; fitting parameters were within 
acceptable values (Appendix Table A.12). A comparison is shown with the crystal 
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structure bond angle and length data (Table 3.4); best fits include the Ru-O bond (2.10 Å), 
O-C bonds (1.27 Å) and the Ru-arene carbon bonds (average 2.22 Å). Further details of 
the significant path lengths, constraint and restraint parameters are presented in 
Appendix A.11-A.13. 
 
 
 
 
 
 
 
 
Figure 3.13: Model used for the MS EXAFS analysis based on the crystal structure of 
compound 5.32 Atom numbers correspond to Table 3.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: k3-weighted EXAFS and FT spectra for compound 5: Observed (black), 
calculated (red), residual (green) spectra, window function (dashed blue line). 
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Table 3.4: Comparison of the bond lengths and angles of EXAFS analysis results to the 
published crystal structure of OxaloRAPTA-C. 
Atom-atom Crystal Structure32 EXAFS 
Bond lengths (Å)   
Ru0P1 2.310(1)  2.33(2) 
Ru0O3 2.093(2)  2.10(2) 
Ru0C9-14 2.224(2)  2.22(2) 
O3C26 1.288(3)  1.27(2) 
O5C26 1.232(3)  1.23(2) 
   
Bond angles ()   
O3Ru0O2  78.43(7)  74(5) 
P1Ru0O3  82.83(5)  82(5) 
P1Ru0O2  88.79(5)  86(5) 
 
 
3.4.5 [Ru(η6-p-cymene)Cl2(mimid)] (6) 
 
MS EXAFS calculations were based on the published crystal structure33 with a fit 
of R = 20% obtained (Figure 3.15).  Experimental and calculated EXAFS and FT spectra are 
shown in Figure 3.16; fitting parameters were within acceptable ranges (Appendix Table 
A.14). Comparisons with the bond length and angle data from the crystal structure are 
shown in Table 3.5; best fits include the Ru-Cl bond (2.44 Å), Ru-N, which was similar to 
compound 3 (2.12 Å) and the main N-C bonds in the imidazole ligand (average 1.37 Å). 
The results obtained were the same within experimental error.33 Further details of the 
significant path lengths, constraint and restraint parameters are presented in Appendix 
A.14-A.16.  
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Figure 3.15: Model used for the MS EXAFS analysis based on the crystal structure of 
compound 6.33 Atom numbers correspond to those in Table 3.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: k3-weighted EXAFS and FT spectra for compound 6: Observed (black), 
calculated (red), residual (green) spectra, window function (dashed blue line). 
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Table 3.5: Comparison of the bond lengths and angles of EXAFS analysis results to the 
published crystal structure of [Ru(η6-p-cymene)Cl2(mimid)]PF6. 
Atom-atom Crystal Structure33 EXAFS 
Bond lengths (Å)   
Ru0Cl1 2.422(1) 2.44(2)  
Ru0N3 2.122(2) 2.09(2) 
Ru0C5-10 2.181(2) 2.19(2) 
N3C16 1.352(15) 1.35(2) 
N3C15 1.380(4) 1.38(2) 
N4C15 1.355(3) 1.35(2) 
N4C18 1.374(7) 1.38(2) 
   
Bond angles ()   
Cl1N3Cl2  88.79(14)  87(5) 
Cl2Ru0N3  84.5(5)  84(3) 
N3Ru0Cl1  85.14(6)  84(3) 
 
3.4.6 [Ru2(η
6 -p-cymene)2(µ-OH)3]BPh4 (7) 
 
There was no crystal structure published, so the model for this compound was 
built with XFIT with reference to another structurally similar Ru(II) tris-hydroxido 
compound for the bond lengths and angles.34 A very good fit of R = 13% was obtained.  
Experimental and calculated EXAFS and FT spectra are shown in Figure 3.18; fitting 
parameters were within acceptable ranges and are given in Appendix Table A.18. 
Comparisons with bond lengths and angles from reported structures with similar bonding 
are shown in Table 3.6. The Ru-Ru distance (3.04 Å) fell within the range reported for the 
tri-hydroxido benzene complexes and the di-hydroxido p-cymene complex,34 the bond 
angles for the bridging hydroxide groups compared with those in the structures of the 
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benzene complex.34 The Ru-O3 bond length did not agree with the crystal structure value 
within error. This might be due to the poor refinement results at k > 10 Å-1 which would 
also affect the Debye-Waller factors. Further details of the significant path lengths, 
constraint and restraint parameters are presented in Appendix A.17-A.19.  
 
Figure 3.17: Model used for the MS EXAFS analysis based on a reference crystal structure 
for compound 7.34 Atom numbers correspond to those in Table 3.6. 
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Figure 3.18: k3-weighted EXAFS and FT spectra for compound 7: Observed (black), 
calculated (red), residual (green) spectra, window function (dashed blue line). 
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Table 3.6: Comparison of the bond lengths and angles of the EXAFS analysis results to the 
reference crystal structure of [Ru2(η
6 -p-cymene)2(µ-OH)3]BPh4. 
 
Atom-atom EXAFSa Reference Complex34 
Bond lengths (Å)   
Ru0Ru1 2.98(2) 2.989(3) 
Ru0O2 2.07(2) 2.090(3) 
Ru0O3 2.13(2)
b 2.085(3) 
Ru0C10 2.18(2) 2.181(4) 
Ru1C20 2.18(2) 2.188(5) 
   
Bond angles ()   
O3Ru0O2  77(5) 76.0(1) 
Ru1O3Ru0  88(5) 90.3(3) 
Ru1O2Ru0  91(5) 91.5(1) 
aModel built and compared with structurally similar Ru(II) tris-hydroxido compound, 
[Ru2(η
6-arene)2(µ-OH)3]BF4 for bond lengths and angles.
34 bBond length did not 
correspond to crystal structure value due to data quality. 
 
3.4.7 [Ru(η6-p-cymene)(tsal)]2 (8) 
 
MS EXAFS calculations used for the model in Figure 3.19 were based on the 
published crystal structure35 and resulted in an excellent fit of R = 12%.  Experimental 
and calculated EXAFS and FT spectra are shown in Figure 3.20; fitting parameters were 
within acceptable value ranges (Appendix Table A.20). Comparisons with the crystal 
structure are shown in Table 3.7; Ru-S (average 2.40 Å), Ru-O (average 2.09 Å) and all 
other bonds and angles obtained were in very good agreement. Details of the significant 
path lengths, constraint and restraint parameters are presented in Appendix A.20-A.22.  
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Figure 3.19: Model used for the MS EXAFS analysis based on the crystal structure of 
compound 8.35  Atom numbers correspond to Table 3.7. 
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Figure 3.20: k3-weighted EXAFS and FT spectra for compound 8: Observed (black), 
calculated (red), residual (green) spectra, window function (dashed blue line). 
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Table 3.7: Comparison of the bond lengths and angles of the published crystal structure 
and EXAFS analysis results of [Ru(η6-p-cymene)(tsal)]2. 
Atom-atom Crystal Structure35 EXAFS 
Bond lengths (Å)   
Ru0S1 2.3848(4) 2.38(2) 
Ru0O2 2.0930(12) 2.09(2) 
Ru0C13 2.2274(17) 2.21(2) 
Ru0S22 2.4177(4) 2.41(2) 
O3C4 1.230(2) 1.25(2) 
S1C6 1.7831(18) 1.78(2) 
O2C4 1.288(2) 1.26(2) 
   
Bond angles ()   
O2Ru0S1 87.80(4) 88(5) 
O2Ru0S22 77.80(4) 78(5) 
S1Ru0S22 80.714(15) 82(5) 
Ru0S1Ru21 99.286(15) 98(5) 
 
 
3.4.8 [Ru(η6-p-cymene)(en)(S-Ph)]PF6 (9) 
 
The crystal structure for this compound has not been reported. From the 
modelling of the structures for compounds 2-6, 8 a model for MS EXAFS analysis was 
built (Figure 3.21). The Ru-arene bond lengths and angles were assigned the same 
starting values, as in all the previous compounds, en and S-Ph were referred to published 
data with similar ligands.36, 37 A good fit of R = 19% was obtained.  Experimental and 
calculated EXAFS and FT spectra are shown in Figure 3.22. Fitting parameters including 
acceptable ranges are given in Appendix Table A.24.  
Chapter 3 
 
 
77 
 
 
 
Figure 3.21: Model used for the MS EXAFS analysis based on a reference crystal structure 
for compound 9.36 Atom numbers correspond to those in Table 3.8. 
5 10 15
-10
-5
0
5
0 1 2 3 4
0
5
10
k (Å
-1
)
k3
(
k)
 (
Å
-3
) 
R (Å)
|
(R
)|
 (
Å
-4
) 
 
Figure 3.22: k3-weighted EXAFS and FT spectra for compound 9: Observed (black), 
calculated (red), residual (green) spectra, window function (dashed blue line). 
 
Comparisons with the literature bond length and angle values on a structurally similar 
complex is shown in Table 3.8, notable fits were Ru-S (2.38 Å) and Ru-N (average 2.13 Å). 
Chapter 3 
 
 
78 
 
The Ru-en angle (73(5) Å) was not significantly different to the literature value (79 Å) for 
a similar complex,37 and was the same value as that obtained for compound 3 (73 Å). 
Further details of the significant path lengths, constraint and restraint parameters are 
presented in Appendix A.23-A.25.  
 
Table 3.8: Comparison of the bond lengths and angles of the EXAFS analysis results to the 
reference crystal structure of [Ru(η6-p-cymene)(en)(S-Ph)]PF6. 
 
Atom-atom EXAFS Reference Complex36 
Bond lengths (Å)   
Ru0 S3 2.38(2) 2.3936(6) 
Ru0N1 2.13(2) 2.134(2) 
S3C21 1.75(2) 1.768(2) 
Ru0C6-11 2.16(2) 2.175(2) 
   
Bond angles ()   
N1Ru0N2 73(5) 79.16(8) 
S3Ru0N2 82(5) 82.76(6) 
S3Ru0N1 83(5) 83.75(6) 
aModel built and compared with a structurally similar compound,[Ru(η6-arene)(en)(S-Ph)]+ for 
bond lengths and angles.36 
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4.1     UV-Vis results in biological media 
 
Many studies concerning the aquation and hydrolysis process of 
metallocomplexes in aqueous media have been conducted, which have been crucial for 
predicting the in vivo mode of action and interactions with biomolecular targets.1-6 As 
discussed in Chapter 1 (Section 1.3.2), the nature of the coordinated ligands affect the 
aquation rate constants of the compound, as does the size of the arene ligand,3 which 
has not been investigated in the current studies. A general understanding of the kinetics 
of reactions of these compounds under different biologically relevant conditions is a 
precursor for the subsequent XANES studies. 
UV-Vis kinetic experiments were undertaken to investigate the stability of 
compounds 2-6 in cell culture medium (DMEM), with proteins in buffer solutions at 
physiological pH values. Studies in calf serum could not be conducted due to the 
cloudiness of the solutions. Sample preparation procedures and experimental conditions 
are described in Chapter 2.    
 
4.1.1 RAPTA-C (2) 
4.1.1.1 Reaction of complex 2 in HBS (pH 7.4) 
As already noted in the literature,3, 7 due to the presence of the two chlorido- 
ligands, which can potentially undergo ligand-exchange reactions in solution, RAPTA-C 
(compound 2) undergoes rapid substitution chemistry that goes to completion within  
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1 hr (Figure 4.1a). The substitution reactivity of compound 2 in HEPES-buffered saline 
(HBS: 20 mM HEPES, 140 mM NaCl, pH 7.4) and pure HEPES (a weakly coordinating 
buffer, 20 mM, pH 7.4)8 are shown in Figure 4.1 a,c.  In HBS, the strong absorption band 
at 343 nm, corresponding to the parent complex,3 decreased with time to produce 
another species that absorbed at 297 nm and this peak continued to grow up to 24 hr 
incubation. This process was characterized with three isosbestic points at 322, 375 and 
440 nm. Similar reactivity was observed in an NMR spectroscopic study carried out in 
aqueous solutions (pH 7)3 and a UV-Vis spectral study in phosphate buffer (pH 7).7 The 
results were compared to previous DFT calculations performed for the aquation of 
RAPTA-B.9 These observations indicated that the newly formed species might be a 
mixture of aquation and hydrolysis products ([Ru(η6-p-cymene)Cl(OH2)(PTA)]
+) and 
hydroxido-aqua ([Ru(η6-p-cymene)(OH)(OH2)(PTA)]
+) complexes (Scheme 4.1).3  
 
 
   
 
 Scheme 4.1: Aquation and hydrolysis of RAPTA-C in aqueous media.3 
The presence of sodium chloride in the HBS (~140 mM Cl ions) suppressed the 
rate of aquation as compared to that in HEPES (no Cl), where the rapid substitution 
chemistry went to completion within 5 min (Figure 4.1a,b)3. However, the Cl 
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concentration of 140 mM was not enough to inhibit aquation entirely, which was in 
contrast to reports in the literature that 100 mM NaCl was enough to prevent any 
aquation.3 Therefore, compound 2 would undergo partial ligand exchange in the 
bloodstream, which has the Cl concentration of ~150 mM before entering the cells.3 
Previous studies of the hydrolysis of RAPTA-B showed that the side product; 
dihydroxido complex, was unlikely to form at biologically relevant pH values (~pH 6.5-7.4) 
for tumours whereas hydroxido-aqua complexes (Scheme 4.1), which were stable over a 
wide pH range might be the dominant species.9 This is a more desirable outcome as the 
tendency to form inert dihydroxido-species might lower the compound’s reactivity 
towards biological targets as was observed with the Os(II) arene complexes.1 Therefore, 
the aquation product at 60 min was compared to the spectra for the tris-hydroxido- 
compound 7 (Figure 4.1c), but was found to be very different. This may be partly due to 
significant binding of the chlorido ligands at equilibrium. 
The pseudo-first order rate constant k and concentration profiles were 
determined using global kinetic analysis (refer to Chapter 2, Section 2.4), in which the 
kinetic data were fitted with the model reactions with initial concentrations fixed as: A 
(initial compound) 0.001 M; B(intermediate) 0.0 M; C (final product) 0.0 M. Results are 
listed in Table 4.1. Not all values could be determined due to the lack in spectral changes 
for some of the compounds within the analyzed timeframe and the reversible reactions 
were not modelled.  
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Figure 4.1: UV-Vis electronic absorption spectra for compound 2 (1.0 mM): (a) time 
evolution in HBS (1 h, 20 mM HEPES, 140 mM NaCl, pH 7.4); (b) time evolution in HEPES 
(5 min, 20 mM, pH 7.4) at 37 °C; and (c) comparison with the spectrum of compound 7 at 
60 min. The arrows indicate the direction of changes within the spectra. 
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Figure 4.2: Global kinetic analysis results for the extinction coefficients and time 
dependent concentration profiles upon aquation of 1.0 mM compound 2 in a) HBS (20 
mM HEPES, 140 mM NaCl, pH 7.4) and b) HEPES (20 mM, pH 7.4) at 37 °C. Product refers 
to the final state of the reaction after the specified reaction time. 
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Table 4.1: Selected first order rate constants obtained from global analysis kinetic data 
for Ru compounds (1.0 mM) in aqueous buffers and DMEM at pH 7.4, 37 °C. Literature 
values provided if available. 
 Experimental Results 
Conditions 2 (x10-2) (s-1) 3 (x10-2) (s-1) 
HBS (140 mM NaCl, 
pH = 7.4) 
k1 = 0.21 ± 0.01  
 
 
( 
k1 = 0.12 ± 0.01 
k2 = 0.08 ± 0.01  
HEPES (20 mM,        
pH = 7.4) 
 
k1 = 2.81 ± 0.02 NA 
k2 = 0.94 ± 0.01  
HEPES (20 mM, 4.0 
mM NaCl, pH = 7.4) 
k1 = 4.03 ± 0.02 k1 = 1.47 ± 0.05 
k2 = 1.98 ± 0.01  
DMEM (pH = 7.4) k1 = 0.44 ± 0.01 k1 = 0.13 ± 0.01 
k2 = 1.28 ± 0.02  
 Literature Values 
Aqueous  
 
0.33 ± 0.01a 0.12 ± 0.01b 
Conditions described in literature which might contribute to the difference in 
experimental values: a1 mM Ru in 150 mM NaClO4 at 25 °C, pH 7.0; 
b100 mM NaCl at 
25 °C, pH 6.27.  The missing data is due to minimal changes in the spectrum. 
 
4.1.1.2 Reaction of complex 2 in HEPES buffer 
 
In the HEPES solution (20 mM, pH 7.4) under the same conditions, the initial peak 
at 343 nm shifted rapidly to 392 nm with two peaks arising at 297 and 390 nm 
characterized with three isosbestic points at 321, 383 and 425 nm; displaying a similar 
behaviour to the reactivity in HBS (Figure 4.1b). This reaction had to be monitored every 
10 s due to the rapid aquation rate. The same absorption maximum indicated the same 
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decomposition product forming as was the case in HBS.  Concentration profiles revealed 
that equilibrium was reached after 60 min in HBS and 6 min in HEPES, which confirmed 
that aquation in HEPES occurred at a rate that was an order of a magnitude faster than in 
HBS (Table 4.1 and Figure 4.2). 
 
4.1.1.3 Reaction of complex 2 in DMEM 
 
The initial absorption band at 348 nm, which corresponded to compound 2 
shifted to 385 nm and decreased with time, whereas another species that absorbed at 
300 nm gradually formed (Figure 4.3a). This reactivity was characterized by three 
isosbestic points at 320, 384 and 421 nm in the spectrum, which were slightly different 
from those observed in HBS and showed some differences in products. The rate 
constants differed from the values observed in HBS, with the reaction rate of the second 
chlorido exchange faster than the first one, indicating other ligand-exchange processes 
occurred in the medium. Only detailed UV-Vis studies in aqueous buffer have been 
reported and the more complex spectrum in DMEM is to be explored further in Chapter 
5.  
The spectrum at 60 min was compared to the spectrum of the tris-hydroxido 
compound 7 (Figure 4.3b) and was, surprisingly, found to have a similar absorption peak 
at 385 nm but deviated in λmax value for the new peak by ~4 nm. This observation 
suggested that compound 2 might have undergone aquation in DMEM to form 
hydroxido-bridges before interacting with other components. 
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Figure 4.3: UV-Vis electronic absorption spectra for compound 2 (1.0 mM) in DMEM (pH 
7.4) at 37 °C: (a) time evolution taken within a timeframe of 60 min, recorded at 30 s 
intervals; and (b) comparison with compound 7 at 60 min. The arrows indicate the 
direction of changes within the spectra.  
 
 
  
 
 
 
 
 
Figure 4.4: Global kinetic analysis results for the (a) molar extinction coefficients and  
(b) time dependent concentration profiles upon the aquation of compound 2 (1.0 mM) in 
DMEM (pH 7.4) at 37 °C. Product refers to the state of the solution after the reaction 
time. 
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The rate constants were then determined using global kinetic analysis (Table 4.1) 
and the concentration profiles revealed that an equilibrium was reached in ~15 min, 
which is at a slightly faster rate compared to the reactivity in HBS and the literature value 
in aqueous media.3 Since those buffer solutions have a similar chloride concentration to 
that in DMEM, which is representative of the blood concentration (~150 mM Cl), the 
hydrolysis of 2 should be suppressed. The results indicated that there was competition 
for Cl rebinding and biomolecule binding, such that less Cl is bound in the final product 
mixture.  
4.1.1.4 Reactions of complex 2 with BSA 
 
To observe reactivity with proteins, the kinetics in pure HBS was compared to 
those in a solution of 5.0 mg/mL bovine serum albumin (BSA) in HBS with 1.0 mM 
compound 2.  
 
 
 
 
 
Figure 4.5: UV-Vis electronic absorption spectra for compound 2 (1.0 mM) incubated with 5.0 
mg/mL BSA in HBS, pH 7.4 at 37 °C (a) comparison with HBS-only sample; and (b) time evolution 
for a timeframe up to 2 hr at pH 7.4. The arrows indicate the direction of changes within the 
spectra.              
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The spectra observed showed that the presence of BSA had no major effect above 
300 nm (Figure 4.5a). Kinetic studies showed that the intensity of the initial peak at 341 
nm decreased over time, eventually flattening out at around 2 hr (Figure 4.5b). Although 
an isosbestic point was observed at ~388 nm for the first 110 min, the last spectrum at 
170 min did not pass through this isosbestic point, which shows another slower reaction 
occurred. This showed a more complicated set of reactions and the rate constants could 
only be determined if the reaction was followed for a longer period of time. 
 
4.1.2 [(η6-p-cymene)Ru(en)Cl]PF6 (3) 
 
4.1.2.1 Reaction of complex 3 in HBS 
 
Arene complexes with p-cym as the coordinated arene and 1,2-ethanediamine 
(en) as a co-ligand have been reported to undergo slower aquation in comparison to 
compound 2,10 due to less pπ donation to the electron rich Ru(II) when one Cl ligand is 
lost.11 Compound 3 showed little evidence of reactivity for at least 24 hr in HBS at pH 7.4 
(Figure 4.6a). There was no peak shift at 311 nm and 400 nm but a slight increase in 
absorbance, which might just be a slow formation of precipitate. However, the similarity 
of the spectrum to the final products of the reaction of 2 with BSA indicates a rapid initial 
loss of the Cl ligand, with a slow subsequent exchange reaction of the new donor group 
with a similar donor group.  
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Figure 4.6: UV-Vis electronic absorption spectra for compound 3 (1.0 mM) at 37 °C a) in 
HBS (20 mM HEPES, 140 mM NaCl, pH 7.4) up to 24 hr, b) with BSA (5.0 mg/mL) up to 50 
min, c) in DMEM (pH 7.4) up to 50 min, d) comparison with compound 7 at 50 min in 
DMEM. The arrows indicate the direction of the changes within the spectra. 
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reasonably stable in extracellular chloride concentrations (~150 mM)12 before becoming 
activated in cells (~4 mM), but the experiments were not performed in the presence of 
BSA. Hence, further research needs to be performed in this area in the future. 
 
4.1.2.2 Reaction of complex 3 in DMEM 
 
Compared to its reaction in HBS, 3 displayed a more interesting reactivity in 
DMEM (Figure 4.6c), an overall change over this timeframe resulted in a ~2 nm peak shift 
to lower wavelengths and a slight decrease in absorbance over time. The isosbestic point 
at 351 nm suggested a single-step reaction with loss of the chlorido ligand and 
conversion to the more reactive aqua complex [Ru(η6-p-cymene)(H2O)(en)]
2+, which then 
undergoes rapid substitution in DMEM or in the presence of BSA. This aqua intermediate 
is supposed to be the dominant species at biological pH values in the absence of other 
ligands compared to the less active hydroxido complex, [Ru(η6-p-cymene)(OH)(en)]+.13, 14 
A comparison to compound 7 (Figure 4.6d) showed a difference in positions with a 
deviation of ~12 nm. Since the en ligand has not been reported to dissociate under these 
conditions, 3 would have reacted with the other components in DMEM to form a 
different species, as also observed for 2. 
The pseudo-first-order rate constant for the reaction obtained (k = 1.29 x 10-3 s-1) 
(Table 4.1) was consistent with results for the biphenyl en complex reported in literature 
(range: 1.23-2.26 x 10-3 s-1), 13 Albeit this was much slower compared to that of 
compound 2, which was consistent with observations that the presence of the en ligand 
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slowed down the rate of loss of the chlorido leaving group.3, 13 Another possibility for 
slower reactions may involve further binding of protein residues. The process reached 
equilibrium at about 50 min (Figure 4.7b).  
 
 
 
 
 
 
 
 
 
Figure 4.7: Global kinetic analysis results for: a) the molar extinction coefficients; and  
b) time-dependent concentration profiles upon the aquation of 1.0 mM compound 3 in 
DMEM (pH 7.4) at 37 °C. Product refers to the state of the solution after the reaction 
time (50 min) 
 
4.1.2.3 Reaction of complex 3 with BSA 
 
The reactivity with BSA (Figure 4.6b) was quite similar to that in HBS with no 
shifts for the peaks at 311 and 400 nm for at least 50 min. Compound 3 has been shown 
to bind to the histidine, methionine and the thiolate of cysteine residues on serum 
albumin under similar conditions (pH 7.4, 37 °C)15 using LC-ESI-MS. Although UV-Vis 
spectroscopy shows how stable the compound is in aqueous buffer, the kinetics were 
generally too complex to follow and thus XAS studies were undertaken. 
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4.1.2.4 Reaction of complexes 2 and 3 in a low chloride buffer (4.0 mM NaCl) 
 
Kinetic studies were carried out for compounds 2 and 3 in an environment that 
simulated the low intracellular chloride concentration (20 mM HEPES with 4.0 mM NaCl, 
pH 7.4). 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Global kinetic analysis results for the molar extinction coefficients and time 
dependent concentration profiles of the aquation of 1.0 mM; a) compound 2, and b) 
compound 3 (20 mM HEPES, 4.0 mM NaCl, pH 7.4) at 37 °C. Product refers to the state of 
the solution after the reaction time. 
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The reactivity was about an order of a magnitude faster compared to that in the 
high saline environment (Table 4.1) and went to completion within 5 min; similar to that 
observed in HEPES (Figure 4.8). Despite some aquation at low chloride concentrations, 
the reactivity of these complexes are still highly suppressed which, as postulated in 
literature,16 would later form reactive aquated species once the complexes enter the 
cells; a behaviour that was also observed for cisplatin.16 
 
4.1.3 [(η6-p-cymene)Ru(acac)Cl]PF6 (4) 
4.1.3.1 Reaction of complex 4 in HBS 
 
Apart from the en N,N-chelating ligand, O,O-chelating donor sets have been 
actively investigated to change the stabilities of the complexes and, hence, their 
anticancer activities.1, 17, 18  
The peaks in the UV-Vis spectra for compound 4 (acac chelating ligand) decreased 
in intensity within 1 hr (Figure 4.9a); at 24 hr the band at 443 nm was almost flat 
whereas the peak at 311 nm had shifted and decreased in wavelength to 300 nm. The 
dissolution of complexes with a chelating O,O donor set with a halido ligand in aqueous 
media has resulted in rapid aquation to form the more reactive aqua complex (dominant 
species),19 though in some cases hydroxido-bridged dimers might form as a side-product, 
which was thought to render the complex inactive.18 The peak at 300 nm for 4 is not 
solely due to the tris-hydroxido-bridged complex 7, since the spectrum overall does not 
match that of 7 but it may be a component of a mixture of products. 
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Figure 4.9: UV-Vis electronic absorption spectra for compound 4 (1.0 mM) at 37 °C a) in HBS (20 
mM HEPES, 140 mM NaCl, pH 7.4) up to 24 hr; b) in DMEM (pH 7.4) up to 24 hr; and c) with BSA 
(5.0 mg/mL) up to 24 hr. The arrows indicate the direction of the changes within the spectra. 
Saturation occurs at absorbance values above 2.8. 
 
4.1.3.2 Reaction of complex 4 in DMEM 
 
The aquation in DMEM (Figure 4.9b) was not as straightforward as in HBS. The 
intensity at ~311 nm increased steadily for 1 hr, however, a totally different spectrum 
was observed at 24 hr which, as postulated for 2; might be indicative of another slower 
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reaction happening in solution. This again points to the compound undergoing a range of 
reactions within 24 hr, thus leading to a mixture of adducts present in solution.  
 
4.1.3.3 Reaction of complex 4 with BSA 
 
The spectrum for BSA binding showed similar behaviour to its activity in HBS 
within 1 hr (Figure 4.9c). At 24 hr, there was a change in the band at ~350 nm, which was 
attributed to BSA binding. These results seem to indicate that 4 is reasonably stable to 
aquation in biological media, as compared to 3, but the change observed in the spectra 
at 24 hr is indicative of another process happening.  
 
4.1.4 OxaloRAPTA-C (5) 
4.1.4.1 Reaction of complex 5 in HBS 
 
The aquation of an O,O-chelating ligand in compound 5 was also studied using 
both UV-Vis and NMR spectroscopies and it was reported to be more kinetically stable to 
aquation and hydrolysis compared to 2,20 with a maximum absorbance at ~302 nm. 
These results were comparable to the results observed for compound 5 in HBS (Figure 
4.10a) where the initial absorbance did not change much within 1 hr, signifying a 
considerable amount of stability at pH levels of ~7.4.20  
 
4.1.4.2 Reaction of complex 5 in DMEM 
 
In DMEM, the compound exhibited a decrease in absorbance in the region of 300 
to 330 nm in a very similar way as was observed in the spectral changes for 3, once again 
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showing the reactivity of chelated complexes in the medium (Figure 4.10b). There was, 
however, no significant change for the peak at 381 nm, which might mean that ligand-
exchange reaction was happening for similar donor groups. The substitution of oxalato 
ligands for chlorido ligands was observed for relatively high Cl concentrations (150 
mM).21 From the results, it is clear that 5 was reacting with the components in DMEM 
due to the different changes occurring in the spectrum compared to that in HBS. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: UV-Vis electronic absorption spectra for compound 5 (1.0 mM) at 37 °C; a) in HBS 
(20 mM HEPES, 140 mM NaCl, pH 7.4) up to 24 hr; b) in DMEM (pH 7.4) up to 60 min; and c) with 
BSA (5.0 mg/mL) up to 24 hr.  
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4.1.4.3 Reaction of complex 5 with BSA 
 
The similarity of the spectrum to that of 4 was a rough indication of how the O,O-
donors bind to proteins in aqueous media (Figure 4.10c). Compound 5 remained stable 
for at least 1 hr before binding to BSA which is evidenced by the change in the 24 hr 
spectrum. The peak at 309 nm shifted and decreased to 302 nm and since this resembled 
its activity in DMEM, the resulting species might be the same.  
 
4.1.5 [Ru(η6-p-cymene)Cl2(mimid)] (6) 
4.1.5.1 Reaction complex of 6 in HBS 
 
The UV-Vis spectral results indicated that compound 6 displayed ligand exchange 
in HBS (pH 7.4)within 1 hr but subsequent changes resulted in a shift to 387 nm within 24 
hr (Figure 4.11a) without an isosbestic point. This showed that several reactions occurred 
on different timescales. The peak at 312 nm had a steady increase in absorbance 
throughout, which shows the formation of a new species after 24 hr. A comparison to the 
spectra of the product with that of compound 7 (Figure 4.11b) suggested that compound 
6 might have formed some dihydroxido-bridged species due to the similarity in peak 
positions. This observation also indicated that despite being a dichlorido complex, like 2, 
6 exhibited a somewhat slower substitution rate in aqueous solutions, which might be 
due to the electronic effects induced at the metal centre by the imidazole ligand.18, 21 
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Figure 4.11: UV-Vis electronic absorption spectra for compound 6 (1.0 mM) at 37 °C; a) in HBS 
(20 mM HEPES, 140 mM NaCl, pH 7.4) up to 24 hr; b) comparison of the spectra in HBS with that 
of compound 7 at 24 hr; c) in DMEM (pH 7.4) up to 60 min; and d) with BSA (5.0 mg/mL) up to 24 
hr. The arrows indicate the direction of changes within the spectra. 
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4.1.5.2 Reaction of complex 6 in DMEM 
 
In contrast to HBS, the changes in the spectra of compound 6 in DMEM were 
quite different and were characterized by an isosbestic point at 360 nm (Figure 4.12c). 
After 1 hr, the peak at 389 nm had shifted to 384 nm and decreased in intensity whereas 
another species that absorbed at 300 nm gradually formed. This was very similar to the 
spectral observation for compound 2 under the same conditions, which is indicative of 
binding to similar proteins in solution. The calculated rate constants (4.15 x 10-4 s-1) were 
an order of a magnitude lower than 2 (4.35 x 10-3 s-1) and 3 (1.29 x 10-3 s-1) in the same 
medium, which can be attributed to the ability of the imidazole ligand to stabilize the 
complex.18, 22 
 
 
 
 
 
  
  
 
Figure 4.12: Global kinetic analysis results for: a) the molar extinction coefficients; and  
b) time-dependent concentration profiles upon the aquation of 1.0 mM compound 6 in 
DMEM at 37 °C. Product refers to the state of the solution after the reaction time. 
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4.1.5.3 Reaction of complex 6 with BSA 
 
Despite the peaks being more prominent, the kinetics generally resembled the 
reactivity in HBS (Figure 4.12d), thus the interaction with BSA did not exhibit any special 
characteristic features.  
 
4.2    Discussion 
  
 Overall the Ru(II) arene compound, 2 showed the most reactivity in both cell 
culture medium and buffer at psychological pH values, which is likely to contribute to its 
anti-metastatic properties that resemble those of NAMI-A.23 In contrast, compound 3 
being more stable for longer hours in biological media then exhibits cytotoxic properties 
comparable to cisplatin.24  The results reported herein show clear competition for the 
binding of proteins compared to the re-coordination of Cl ligands according to Scheme 
4.2: 
 
 
 
 
Scheme 4.2: Aquation and protein binding pathways of Ru(II) arene complexes in         
                    biological media. 
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 In the absence of added Cl, the aquation goes almost to completion, but in its 
presence equilibrium is obtained that shifts dependent on [Cl]. To determine the values 
of k1 and k-1 and the second aquation for the dichlorido species k-2, detailed Cl
 
dependent studies will be required. However, these have not been pursued here because 
Cl is always present in biological media and the reactions have been examined under 
those conditions which are biologically relevant. When proteins are present in the media 
(e.g. BSA or proteins in DMEM), the imidazole, carboxylato and S-donors can effectively 
compete with the back-reaction to rebind chlorido ligands. Therefore, studies carried out 
in HBS alone can give misleading results as to the reactivity in blood and the extra- , and 
intracellular environments of tumours. All of the studies here show that the reactions 
with biomolecules are fairly rapid and, hence, the nature of these reactions has been 
investigated in Chapter 5 using X-ray absorption spectroscopy. 
 
4.3    References 
 
1. Peacock, A. F. A.; Melchart, M.; Deeth, R. J.; Habtemariam, A.; Parsons, S.; Sadler, P. J., 
Chem. Eur. J. 2007, 13, 2601-2613. 
 
2. Zhang, Y.; Guo, Z.; You, X.-Z., J. Am. Chem. Soc. 2001, 123, 9378-9387. 
 
3. Scolaro, C.; Hartinger, C. G.; Allardyce, C. S.; Keppler, B. K.; Dyson, P. J., J. Inorg. Biochem. 
2008, 102, 1743-1748. 
 
4. Vargiu, A. V.; Robertazzi, A.; Magistrato, A.; Ruggerone, P.; Carloni, P., J. Phys. Chem. B 
2008, 112, 4401-4409. 
 
5. Kung, A.; Pieper, T.; Wissiack, R.; Rosenberg, E.; Keppler, B. K., JBIC, J. Biol. Inorg. Chem. 
2001, 6, 292-299. 
 
Chapter 4 
 
105 
 
6. Futera, Z.; Klenko, J.; Sponer, J. E.; Sponer, J.; Burda, J. V., J. Comput. Chem. 2009, 30, 
1758-1770. 
 
7. Scolaro, C.; Bergamo, A.; Brescacin, L.; Delfino, R.; Cocchietto, M.; Laurenczy, G.; 
Geldbach, T. J.; Sava, G.; Dyson, P. J., J Med Chem 2005, 48, 4161-4171. 
 
8. Sokolowska, M.; Bal, W., J. Inorg. Biochem. 2005, 99, 1653-1660. 
 
9. Gossens, C.; Dorcier, A.; Dyson, P. J.; Rothlisberger, U., Organometallics 2007, 26, 3969-
3975. 
 
10. Morris, R. E.; Aird, R. E.; Murdoch, P. d. S.; Chen, H.; Cummings, J.; Hughes, N. D.; Parsons,  
S.; Parkin, A.; Boyd, G.; Jodrell, D. I.; Sadler, P. J., J. Med. Chem. 2001, 44, 3616-3621. 
 
11. Peacock, A. F. A.; Habtemariam, A.; Fernandez, R.; Walland, V.; Fabbiani, F. P. A.; Parsons, 
S.; Aird, R. E.; Jodrell, D. I.; Sadler, P. J., J. Am. Chem. Soc. 2006, 128, 1739-1748. 
 
12. Jennerwein, M.; Andrews, P. A., Drug Metab. Dispos. 1995, 23, 178-184. 
 
13. Wang, F.; Chen, H.; Parsons, S.; Oswald, I. D. H.; Davidson, J. E.; Sadler, P. J., Chem. Eur. J. 
2003, 9, 5810-5820. 
 
14. Chen, H.; Parkinson, J. A.; Morris, R. E.; Sadler, P. J., J. Am. Chem. Soc. 2003, 125, 173-186. 
 
15. Hu, W.; Luo, Q.; Ma, X.; Wu, K.; Liu, J.; Chen, Y.; Xiong, S.; Wang, J.; Sadler, P. J.; Wang, F., 
Chem. Eur. J. 2009, 15, 6586-6594. 
 
16. Ang, W.-H.; Casini, A.; Sava, G.; Dyson, P. J., J. Organomet. Chem. 2011, 696, 989-998. 
 
17. Kurzwernhart, A.; Kandioller, W.; Baechler, S.; Bartel, C.; Martic, S.; Buczkowska, M.; 
Muehlgassner, G.; Jakupec, M. A.; Kraatz, H.-B.; Bednarski, P. J.; Arion, V. B.; Marko, D.; 
Keppler, B. K.; Hartinger, C. G., J. Med. Chem. 2012, 55, 10512-10522. 
 
18. Kandioller, W.; Hartinger, C. G.; Nazarov, A. A.; Bartel, C.; Skocic, M.; Jakupec, M. A.; 
Arion, V. B.; Keppler, B. K., Chem. Eur. J. 2009, 15, 12283-12291. 
 
19. Kurzwernhart, A.; Kandioller, W.; Bartel, C.; Baechler, S.; Trondl, R.; Muehlgassner, G.; 
Jakupec, M. A.; Arion, V. B.; Marko, D.; Keppler, B. K.; Hartinger, C. G., Chem. Commun. 
2012, 48, 4839-4841. 
 
20. Ang , W. H.; Daldini, E.; Scolaro, C.; Scopelliti, R.; Juillerat-Jeannerat, L.; Dyson , P. J., Inorg. 
Chem. 2006, 45, 9006-9013. 
 
21. Kilpin, K. J.; Cammack, S. M.; Clavel, C. M.; Dyson, P. J., Dalton Trans. 2013, 42, 2008-2014. 
 
22. Clarke, M. J.; Bailey, V.; Doan, P.; Hiller, C.; LaChance-Galang, K. J.; Daghlian, H.; Mandal, S.; 
Bastos, C. M.; Lang, D., Inorg. Chem. 1996, 35, 4896-4903. 
  
Chapter 4 
 
106 
 
23. Bergamo, A.; Gaiddon, C.; Schellens, J. H. M.; Beijnen, J. H.; Sava, G., J. Inorg. Biochem. 
2012, 106, 90-99. 
 
24. Aird, R. E.; Cummings, J.; Ritchie, A. A.; Muir, M.; Morris, R. E.; Chen, H.; Sadler, P. J.; 
Jodrell, D. I., Br. J. Cancer 2002, 86, 1652-1657. 
 
 
107 
Chapter Five 
  
 
 
 
 
 
 
Speciation Studies  
using  
XAS and XFM 
 
Chapter 5 
 
 
108 
 
5.1  Introduction 
 
 The chemical speciation of biologically active metals in living systems has always 
sparked considerable interest. Complexes often undergo ligand-exchange, hydrolysis 
(mentioned in Chapter 1), and redox reactions in biological systems, which changes the 
properties of the pro-drugs before reaching the targeted cells or tissue. XANES has thus 
emerged as a tool for obtaining important information, such as changes of the metal 
oxidation states and the spin-state, which might not be achievable using crystallographic 
experiments.1 Spectra obtained using XANES can be used as a fingerprint for identifying 
speciation of metallodrugs with the help of a library of model complexes with known 
structures.2 However, if an important model compound is absent from this library, the 
fitting obtained might be distorted from the actual speciation, which could result in some 
additional uncertainty in the biotransformations of the pro-drugs.1 The studies reported 
here only concentrate on EXAFS values up to k = 9 Å-1 for linear regression analysis. Detailed 
EXAFS analysis at k > 9 Å-1 was not pursued due to noise and/or mixtures of products making 
MS analysis inappropriate.  
 
5.1.1 X-ray Fluorescence Mapping 
 Due to the rising interest in the detection and quantification of elemental content in 
samples, this technique has been used in combination with XAS to determine species-
specific maps.3, 4 This enables the determination of spatial distribution of different elements 
by mapping the X-ray fluorescence intensity for different X-ray emission peaks.3 Finney et. 
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al.5, 6 have demonstrated the use of XFM in combination with 2D-gel electrophoresis to 
identify metalloproteins in complex biological mixtures. A typical setup of this technique is 
shown in Figure 5.1. The beam passes through a double crystal monochromator and is 
focused onto the sample with the help of a pinhole.5 The sample is then raster-scanned 
through the focal spot and at each scan position, 10 or more elements are mapped pixel-by-
pixel and quantified.5 The emitted beam is collected at 90°. 
 
Figure 5.1: Schematic illustration of the principal components of an X-ray  
                    fluorescence microprobe beamline (not to scale).5  
 
5.2 XANES results 
 
5.2.1 Comparison of model compounds 
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A general comparison of the XAS spectra for the Ru(II) model compounds 1-9 (listed 
in Chapter 3, Figure 3.5) is displayed in Figure 5.2.  While all EXAFS had similar general 
features, upon closer examination they have significantly different white-line absorbance 
intensities (Figure 5.2b) and energies as listed in Table 5.1. The post-edge regions were also 
quite different (Chapter 3 Fig 3.6), which serves as a good reference for predicting the 
coordination environment.  
 
 
 
 
 
 
 
Figure 5.2.: Ru K-edge spectra of model Ru(II) compounds 1-9 (15 K, fluorescence detection 
mode): a) General XAS spectra comparison, b) overlay of the edge regions. Compounds 
were mixed at a 1:10 BN ratio. 
 
The XANES spectral parameters of Ru(II) model complexes used in this study are 
listed in Table 5.1. For further observations of the changes in edge energy, spectra for a 
Ru(III) complex, [RuIII(NH3)6]Cl3 (which was found to have the closest edge compared with 
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the Ru(II) models) and a Ru(IV) complex, RuIVO2 were obtained for oxidation state 
comparisons. A detailed comparison of the edge regions is shown in Figure 5.3, in which 
compound 2 was used as a reference. As already noted in literature,7 the edge energy 
increased when the Ru oxidation state increased; a difference of 2.6 eV was observed 
between Ru(II) (2) and Ru(III) and a further 3.2 eV difference between Ru(III) and Ru(IV) 
(Figure 5.3a). The position of the edge energy for this Ru(III) complex was used to determine 
if there was a loss of the arene ligand after reaction. The edge energies of both compounds 
4 and 5 differed to that of 2 by a ~0.4 eV increase in energy, which served as a good 
indication for the presence of O-donor ligands. The XANES of the two thiol models 8 and 9, 
which are representative of complexes with S-bound ligands, showed a significant decrease 
in the edge energy of 1-1.3 eV (Figure 5.3c). Compound 7 with OH bridges showed a slight 
decrease in XANES edge energy by 0.4 eV, whereas the XANES of compound 3, with N-donor 
ligands, only differed to that of 2 in intensity (Figure 5.3d), as has been observed for Cr(III) 
complexes.8  
XAS from three additional model complexes were obtained and introduced into the 
library for further references. Reactions of 2 in buffer solutions at pH 2 and pH 7 produced 
the aqua/chlorido and a hydroxido/aqua species, respectively after 1 hour.9 Therefore, 
additional model compounds derived from 2 were obtained from reactions under these pH 
values, and the products were characterized by UV-Vis spectroscopy. The XAS of the 
resultant products 10a (pH 2) and 10b (pH 7) were introduced into the model library (Figure 
5.3e). Differences between the XANES of 2 and 10b were very small, whereas that from the 
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aqua compound, 10a, showed a ~0.8 eV decrease in the edge energy. The XAS from 
Na[RuIII(edta)(SG)] (11) was used as an extra XAS reference for a Ru(III) model complex with 
S-bound ligands.10 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
Figure 5.3: Comparison of the Ru K-edge XAS edge regions for the model Ru complexes 
(Table 5.1): changes dependent on the a) oxidation state and b-e) different donor ligands at 
15 K, fluorescence detection mode. X-axis of graphs are scaled to 22100 - 22130 eV. 
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Table 5.1: White line and edge energies for model compounds 1-11 (Refer to Chapter 3,  
                   Figure 3.5). 
 Model Compounds[a] 
White-
line 
Height 
White-
line 
Energy 
Edge 
Energy 
(eV) 
Donor 
ligands[b] 
1 [Ru(η6-p-cymene)Cl2]2 1.12 22129.3 22113.2 2Cl 
2 RAPTA-C 1.13 22127.6 22113.4 P, 2Cl 
3 [Ru(η6-p-cymene)(en)Cl]PF6 1.19 22127.8 22113.3 2N, Cl 
4 [Ru(η6-p-cymene)(acac)Cl] 1.22 22129.5 22113.8 2O, Cl 
5 OxaloRAPTA-C 1.19 22126.1 22113.7 2O, P 
6 [Ru(η6-p-cymene)Cl2(mimid)] 1.15 22127.6 22113.5 N, 2Cl 
7 [Ru2(η
6 -p-cymene)(OH)3]BPh4 1.16 22126.9 22112.9 3OH
- 
8 [Ru(η6-p-cymene)(tsal)]2 1.14 22126.8 22112.4 1S, 2O 
9 [Ru(η6-p-cymene)(en)(S-Ph)]PF6 1.18 22126.8 22112.6 2N, S 
10a [Ru(η6-p-cymene)Cl(H2O)(PTA)]
+ 1.12 22127.5 22112.6 H2O,Cl
-,P 
10b [Ru(η6-p-cymene)(OH)(H2O)(PTA)]
+ 1.12 22127.6 22113.2 OH-,H2O,P 
11 Na[RuIII(edta)(SG)] 1.17 22134.5 22112.4 N, O, S 
[a] Designations of the ligands: PTA = 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane;  en = 1,2-
ethanediamine; acac = 2,3-pentanedionato; mimid = N-methylimidazole; tsal = thiosalicylato acid; S-
Ph = deprotonated benzenethiolato; SG = deprotonated S-bound glutathione (GSH); edta = N,N,N’N’-
ethanediaminetetraacetate(4). [b] Other than the arene carbons. 
 
5.2.2 List of Samples 
Sample preparation procedures and experimental conditions are described in 
Chapter 2 together with the syntheses of the model compounds 2-9. The XAS obtained from 
the decomposition of compounds 2-6 in biological media, cells and blood samples were 
Chapter 5 
 
 
114 
 
studied under biologically relevant conditions; detailed designations are listed in Table 5.2. 
All samples were freeze-dried prior to XAS measurements to stop reactions, maximize Ru 
concentration and minimize Ru photoreduction in the X-ray beam.1, 11 
Table 5.2: Sample preparation conditions for Ru(II) pro-drug interactions in biological media.  
[a] The letters indicate the treatment conditions and numbers indicate the model compounds. 
 
Sample[a]  Description Incubation (h) 
Reactions with Bovine Serum Albumin (A-D) 
A 0.60 mM Ru + 0.15 mM BSA in HBS, pH 7.4 1 
B 0.60 mM Ru + 0.15 mM BSA in HBS, pH 7.4  24 
C2a,b,c 1 mM Ru + 0.60, 0.30, 0.15 BSA in HBS, pH 7.4 15 
D3-6 0.60 mM Ru + 0.30 mM BSA in HBS, pH 7.4 24 
 Buffer Samples at Physiological pH – E (Ru – 0.60 mM) 
E Ru in HBS (pH 7.4) 24 
Cell Culture Medium (DMEM,  2% v/v fetal calf serum) Samples - F (Ru – 0.60 mM) 
Fa,b Ru in DMEM, pH 7.4 1,4 
Serum Samples - G (Ru – 0.60 mM) 
Ga,b Ru in bovine serum 1,4 
HEPG2 Samples – H 
Ha, b Ru + HEPG2 cells or cell culture medium 4 
DNA Samples – I 
I2a,b,c Ru with 10, 5, 2.5 mg/mL DNA in HBS, pH 7.4 15 
Rat Blood Samples – J-K 
J2a,b Ru in red blood cell (RBC) fraction (whole blood) 1,6 
K2a,b Ru in plasma fraction (isolated) 1,6 
K2c Ru in plasma fraction (whole blood)  1 
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Figure 5.4: Comparison of edge energies and white-line intensities for model compounds 1-10b and the biological samples, 
designations correspond to Table 5.1 and 5.2. Ru(III) is [RuIII(NH3)6]Cl3 shown in Figure 5.3a for edge energy comparisons. 
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The 2D and 3D plots of white-line intensities and energy comparisons for the model 
and biological complexes are displayed in Figure 5.4 and 5.5, in which the plot of the white-
line intensity against the edge energy provided the best separation (Figure 5.4). The XAS 
data from the biological samples fell at edge energy ranges below that of  [RuIII(NH3)6]Cl3, 
which does not contain arene ligands and thus serves as an indication that the samples 
retained their arene ligands and were not oxidized to Ru(III). The cluster of XANES in the Ru-
O and Ru-N regions indicated a mixture of Ru(II) arene species with O and/or N donors in the 
remaining three positions from the ligand-exchange process. A 3-D plot of white-line 
intensity vs. white-line energy plot that also included edge-energy (Figure 5.5b) did not 
improve the separation. 
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Figure 5.5: a) a 2D plot of the Ru K-edge white-line intensities vs white-line energies and b) a 
3D plot for model compounds 1-10b and the biological samples. These plots did not provide 
good enough separation for all the compounds, compared with Figure 5.4. 
 
 
5.2.3 Reactions with Bovine Serum Albumin (BSA) 
 
A comparison of XANES data for the reaction products of the Ru(II) compounds with 
BSA  (4:1 Ru to BSA molar ratio) for 1 hr in HBS (pH 7.4) are shown in Figure 5.6 and multiple 
linear regression results are given in Table 5.3.  The spectra for compound 2 and 6 adducts 
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(A2 and A6) were significantly different to those of their parent compounds, which indicated 
considerable reactivity within less than an hour. In contrast, the XANES of compounds 3, 4 
(A3, A4) barely differed from those of the parent complexes perhaps due to the chelating 
ligand providing more stability. This was consistent with UV-Vis spectroscopic results 
(Chapter 4). Compound 5 (A5) showed a slight shift of ~0.5 eV to lower energy (Figure 5.5). 
When all adducts were compared (Figure 5.6f), A4 and A6 converged indicating they had 
similar products, in which A6 might contain O-donor ligands; A2 and A3 were very similar 
perhaps signifying an N-donor exchange for A2. 
Next, the XANES of the Ru(II)-BSA adducts at 24 hr were compared to those from 
samples at 1 hr (Figure 5.7) and the only difference observed was a significant decrease in 
the edge energy by ~0.7 eV for compound 2 (B2). The presence of XANES from 11 (32 %) in 
the best fits indicated S-donor binding (Table 5.3). Unlike that of compound 2, the spectra 
for compounds 3-6 remained similar to those at 1 hr after 24 hr. A general comparison of the 
XANES of all adducts obtained after 24 hr of reaction (Figure 5.7f) showed that B4 and B6 
still converged with linear regression results showing O-donor ligands as the majority 
contributions to the three non-arene sites (Figure 5.8b).  The linear regression fits to the 
XANES of B3-B6 pointed to these Ru compounds having a higher affinity for O-donor ligand 
substitution and any Ru-S binding was probably too small to be detected. However, the fits 
for B3, which pointed to a complete change in coordination environment, were inconsistent 
with the XANES results and would have to be reanalysed to obtain a better fit.  
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Figure 5.6.: Ru K-edge XANES (15 K, fluorescence mode) of compounds 2-6 (0.60 mM) and 
their reaction products with BSA (0.15 mM) in HBS (1 hr, 37 °C); and f) is the overlay. 
Designations are given in Table 5.2. All difference spectra are those of the parent compound 
minus those of the decomposition samples. 
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Figure 5.7.: Ru K-edge XANES (15 K, fluorescence mode) of compounds 2-6 (0.60 mM) and 
their reaction products with BSA (0.15 mM) in HBS for 1 h (conditions A) and 24 hr 
(conditions B) at 37 °C; f) is the overlay of the spectra of Ru-BSA adducts after 24 hr 
incubation. Designations are given in Table 5.2. 
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Figure 5.8.: Multiple linear regression results for the best fits of the Ru K-edge XANES for a) 
conditions A and b) B (designations given in Table 5.2). Details of the fits are shown in Table 5.3. 
 
 
Table 5.3: Multiple linear regression analyses fits to the Ru K-edge XANES for conditions A 
and B.a 
 
Sample Parent (%) 3 (%) 4 (%) 5 (%) 7 (%) 10b (%) 11 (%) R2 
A2 - 21(1) 33(4) 46(3) - - - 0.99921 
A3 68(3) - 32(3) - - - - 0.99977 
A4 100(1) - - - - - - 0.99967 
A5 58(3) - - - 42(7) - - 0.99844 
A6 - 3(1) 97(3) - - - - 0.99948 
B2 - - - - - 68(1) 32(1) 0.99962 
B3 - - 60(3) - 40(3) - - 0.99845 
B4 93(2) -  7(2) - - - 0.99952 
B5 47(2) - 20(2) - 33(1) - - 0.99971 
B6 - 9(2) 91(4) - - - - 0.99926 
aThis table shows the calculated molar percentages (%) of the XANES from the contributing model 
complexes with errors to the last significant figures and correlation coefficients (R2) included. 
Multiple linear regression analyses were performed within the range 22100 – 22430 eV. Designations 
of the models and biological samples correspond to those given in Table 5.2.  
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Further experiments were conducted for compound 2 (1.0 mM), which was 
incubated with different concentrations of BSA (0.15 – 0.60 mM) for 15 hr at 37 °C, Figure 
5.9 (conditions C in Table 5.1). Post-edge regions are not shown since they were unchanged 
within experimental error. The XANES of all adducts differed significantly from those of the 
parent complex and had higher white-line intensities. For BSA concentrations lower than 
0.60 mM, the edge shifted to the higher (C2b), or lower energy regions (C2c), depending on 
the conditions. The XANES of all three adducts displayed similar shapes (Figure 5.9d), which 
indicated common reaction products were formed, mainly O-donor ligands (Table 5.4), This 
also showed that 1.0 mM of 2 underwent ligand-exchange reactions with BSA regardless of 
the concentration within 0.15 – 0.60 mM of BSA.  
A comparison of XAS for Ru(II):BSA adducts (2:1) for the pre-edge and post-edge 
regions for compounds 3-6 is shown in Figure 5.11 (conditions D in Table 5.1). Significant 
differences were observed in the XANES for D6, which had a more prominent shift to higher 
energy compared to that of B6 (Figure 5.7e) in both the pre-edge (~1.2 eV) and post-edge 
regions. The spectral shapes for both samples were still the same, which might mean that 
the same decomposition products were forming. Linear regression results of the best fits to 
the XANES consisted of those from model 4 (70%) and the parent complex (30%), which 
points to a mixture of N/O ligands (Table 5.4). Reactions of compounds 3, 4 and 5 with BSA 
resulted in slight XANES spectral changes that were most apparent in the post-edge region 
but were overall similar to those of  B3, B4 and B5 (Figure 5.7b-d).  
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Figure 5.9: Ru K-edge XANES (15 K, fluorescence mode) comparison of compound 2 (1.0 mM) 
with different concentrations of BSA (conditions C): a) 0.60 mM, b) 0.30 mM, c) 0.15 mM in 
H2O  for 15 hr at 37 °C; d) is the overlay of the spectra of Ru-BSA adducts after 15 h 
incubation. Designations are given in Table 5.2. 
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Figure 5.10.: Multiple linear regression results for the best fits of the XANES for a) conditions C and b) 
D (designations given in Table 5.2). Details of the fits are shown in Table 5.4. 
 
 
 
       Table 5.4: Multiple linear regression analyses Ru K-edge XAS fits for conditions C and D.a 
 
Sample Parent (%) 4 (%) 5 (%) 7 (%) 9 (%) 10b (%) R2 
C2a - - 58(1) - - 42(3) 0.99972 
C2b - 51(2) - - - 49(2) 0.99964 
C2c - - 42(2) - 58(2) - 0.99977 
D3 - 49(1) - 51(2) - - 0.99972 
D4 83(2) - - 17(1) - - 0.99972 
D5 61(3) 12(2) - 27(3) - - 0.99972 
D6 30(2) 70(3) - - - - 0.99923 
aThis table shows the calculated molar percentages (%) of the XANES from contributing 
model complexes with errors to the last significant figures and correlation coefficients (R2) 
included. Multiple linear regression analyses were performed within the range 22100 – 
22430 eV. Designations of the models and biological samples correspond to those given in 
Table 5.2. 
 
a) b) 
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Figure 5.11.: Ru K-edge XAS (15 K, fluorescence mode) comparison of compounds 3-6 (0.60 
mM) with BSA (0.30 mM) in HBS (pH 7.4) for 24 hr at 37 °C (conditions D).  Designations are 
given in Table 5.2. 
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5.2.4 Reactions in aqueous buffer  
The XANES spectra for all compounds incubated in HBS (pH 7.4) were compared in 
Figure 5.13 (conditions E, Table 5.2). After 24 hr, the XANES edge of compound 5 (E5) 
showed the biggest difference with a shift of 1.1 eV to a lower energy, which on linear 
regression fitting was indicative of complete changes in the coordination environment of the 
non-arene ligand sites. The best linear regression fits consisted of XAS from Model 1 (23%) 
and Model 7 (77%) (Table 5.5), indicating that the decomposition product E5 had undergone 
complete ligand exchange in the non-arene positions and probably lost its PTA ligand. In 
contrast to compound 2 (E2), which only showed slight changes in the XANES over 24 hr, the 
changes observed for compound 5 were not consistent with the literature claims that this 
compound was kinetically more stable than 2 in aqueous media.12 
Over 24 hr, the XANES from the reactions of compounds 2, 4 and 6 exhibited slight 
changes in their intensities compared to the parent complexes, whereas the XANES of 
compound 3 remained largely unchanged, retaining 85% of the parent complex over 24 hr in 
the best fit to the XANES (Table 5.5). This suggests that the N-N chelating ligand is 
comparatively more tightly bound in an aqueous buffer environment at pH 7.4. An overlay of 
the spectra showed that the XANES of the decomposition products of compounds 3 (E6) and 
6 (E6) converged with linear regression results pointing to a mixture of N/O-donor ligands, 
possibly forming common products.  
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Figure 5.12.: Multiple linear regression results for fits to the Ru K-edge XAS under 
conditions E (designations are given in Table 5.2). Details of the fits are shown in 
Table 5.4. 
 
 
 
      Table 5.5: Multiple linear regression analyses fits to the Ru K-edge XAS for conditions E.a 
 
Sample Parent (%) 1 (%) 3 (%) 4 (%) 7 (%) 10b (%) R2 
E2 17(2) 46(3) - - - 37(2) 0.99990 
E3 85(2) - - 15(2) - - 0.99987 
E4 55(2) - 45(2) - - - 0.99983 
E5 - 23(3) - - 77(3) - 0.99952 
E6 41(2) - - 59(2) - - 0.99961 
aThis table shows the calculated molar percentages (%) of the XANES from the contributing 
model complexes with errors to the last significant figures and correlation coefficients (R2) 
included. Multiple linear regression analyses were performed within the range 22100 – 
22430 eV. Designations of the models and biological samples correspond to those given in 
Table 5.2. 
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Figure 5.13: Ru K-edge XANES (15 K, fluorescence mode) from the decomposition products of 
compounds 2-6 (0.60 mM) in HBS (pH 7.4) for 24 hr at 37 °C (conditions E), f) overlay of the 
compounds at 24 h. Designations are given in Table 5.2. All difference spectra are those of 
E2 minus E3 – E5. 
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5.2.5 Reactions of Ru complexes in cell culture medium and serum 
Compounds 2-6 were incubated in cell culture medium (DMEM, containing 2% v/v 
fetal calf serum) (Figure 5.15) (conditions F, Table 5.2) or newborn calf serum (Figure 5.17) 
(conditions G, Table 5.2) for 1 or 4 hr at 37 °C, and the resultant spectra were compared 
(Figures 5.14 – 5.17).  The XAS spectra for the decomposition products of compound 4 in 
DMEM were the same for both the 1- and 4-hr treatments (Figure 5.15c). There was a 
decrease in white-line intensity but negligible changes in edge energy compared to those of 
the parent complex and linear regression results suggested partial aquation and N-donor 
ligand exchange (Table 5.5). There were subtle differences between the 1 and 4 hr XAS for 
the reaction of compound 3, which indicated slow ligand-exchange reactions (Figure 5.15b). 
The XANES edge energy of compound 3 showed a gradual shift to higher energy, which 
might be due to an increase in the average number of O-donors (Table 5.5).  
The XANES edge energy for compound 5 slightly shifted to the lower values, which 
may indicate partial binding to S-donor ligands (Figure 5.15d). This is supported by the 
results for the best fit in linear regression of the XANES: ~22-25% fit to model 11. Larger 
changes in the XAS were observed for both compounds 2 and 6, which had edge shifts to 
lower and higher energies, respectively. Compound 6 displayed similar spectral changes to 3, 
in which the edge shifted ~0.35 eV to a higher energy with a concomitant increase in white-
line peak intensity, which once again suggested an exchange to O-donor ligands (Figure 
5.15e).   
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Figure 5.14.: Multiple linear regression results for the best fits to the XANES from conditions F 
(designations given in Table 5.2). Details of the fits are shown in Table 5.5. 
 
 
Table 5.5: Multiple linear regression analyses fits to the Ru K-edge XANES for conditions F.a 
Sample Parent (%) 4 (%) 6 (%) 7 (%) 10b (%) 11 (%) R2 
F2a 15(3) - - - 85(3) - 0.99973 
F3a 53(3) 21(3) 26(3) - - - 0.99974 
F4a 27(2) - 39(1) 34(2) - - 0.99982 
F5a 21(3) - - - 57(3) 22(1) 0.99970 
F6a 35(2) 65(2) - - - - 0.99962 
F2b - 11(2) - - 89(2) - 0.99962 
F3b - 51(2) 49(2) - - - 0.99970 
F4b 21(2) - 47(1) 32(2) - - 0.99980 
F5b 24(2) - - - 51(3) 25(1) 0.99976 
F6b 34(3) 47(2) - 19(3) - - 0.99974 
aThis table shows the calculated molar percentages (%) of the XANES from contributing model 
complexes with errors to the last significant figures and correlation coefficients (R2) included. 
Multiple linear regression analyses were performed within the range 22100 – 22430 eV. Designations 
of the models and biological samples correspond to those given in Table 5.2. 
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Figure 5.15:  Ru K-edge XAS (15 K, fluorescence mode) XAS comparison of the decomposition 
of compounds 2-6 (0.60 mM) in DMEM  for 1 and 4 hr at 37 °C (conditions F); f) is the overlay 
of the compounds in DMEM after 4 hr. Descriptions and designations are listed in Table 5.2. 
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Figure 5.15 (cont.) 
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From the overlay of all spectra at 4 hr, the XAS of compounds 4 and 6 converged in 
both the edge and post-edge regions, implying a common mixture of N/O-ligands in the 
decomposition products (Figure 5.15f). The XAS of 3 showed a similar XANES region to both 
4 and 6 but a significantly different post-edge region, which may be due to retaining around 
~50% of its parent compound after 4 hr, as indicated from the best fits from the linear 
regression results; thus, a different coordination environment. The XAS of compounds 2 and 
5 were similar and showed good fits to O/H2O ligands. It is also worth noting that the XAS of 
F2b was similar to the reaction with BSA (B2) (Figure 5.7a), which supports the evidence that 
2 has a high binding affinity to serum proteins (BSA) during decomposition in serum-
containing media due to the abundance of albumin.10, 13  
The Ru K-edge XAS results for the decomposition in undiluted serum are shown in 
Figure 5.17 (conditions G, Table 5.2), and the results of multiple linear regression analyses 
are given in Table 5.6. The edge for compounds 3 and 6 shifted to higher energies, which 
indicated substitution of some of the ligands with O-donors (Table 5.6) though the changes 
seemed to occur faster for compound 6 (G6b) with only ~30% of the parent XANES 
contributing to the best fit after 4 hr. The XAS of compounds 2, 4 and 5 had slight decrease 
in their intensities compared to their parent complexes, but overall, their XAS did not show 
changes as significant as in DMEM; especially for the post-edge part of the spectra. This 
indicated that the compounds were either reasonably stable in serum up to 4 hr, or, more 
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likely, underwent ligand exchange with similar donor groups that were different in the 
presence of serum proteins.   
An increase in the white-line intensity of the XANES was observed for compound 2 
between the 1 (G2a) and 4 hr (G2b) reactions (Figure 5.17a). Linear regression gave good fits 
to the XANES using models 1 (53%), 4 (17%) and 5 (30%), which pointed to O-donor 
exchanges over time. Comparatively, differences between the XAS of the samples at 1 and 4 
hr for the other compounds were not prominent, which showed that most decomposition 
had happened within 1 hr. Compound 4 even appeared to be relatively inert throughout this 
time period (Figure 5.17c, Table 5.6). The overlay of all spectra showed that compounds 3 
and 6, compounds 2 and 5 shared similar decomposition products (Table 5.6, Figure 5.17f). 
Since BSA is the most abundant serum protein,14 not surprisingly the XAS spectra of the 
decomposition products had similar shapes to the Ru-BSA adducts (Figure 5.6, Conditions A 
and B).  
 
 
   
 
 
Figure 5.16.: Multiple linear regression results for fits to the Ru K-edge XAS for conditions G 
(designations given in Table 5.2). Details of the fits are shown in Table 5.6. 
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Figure 5.17: Ru K-edge XAS (15 K, fluorescence mode) from the decomposition of compounds 
2-6 (0.60 mM) in serum for 1 and 4 hr at 37 °C (conditions G); f) is the overlay in serum after 
4 h. Designations are given in Table 5.2. 
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Figure 5.17 (cont.) 
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Table 5.6: Multiple linear regression analyses of Ru K-edge XANES fits for conditions G.a 
 
Sample Parent (%) 1 (%) 4 (%) 5 (%) 11 (%) R2 
G2a - - 35(2) 65(2) - 0.99981 
G3a 63(4) - 37(4) - - 0.99929 
G4a 100(1) - - - - 0.99953 
G5a 55(2) 37(2) - - 8(1) 0.99970 
G6a 28(2) - 72(2) - - 0.99950 
G2b - 53(4) 17(1) 30(2) - 0.99967 
G3b 72(2) - 28(2) - - 0.99982 
G4b 100(1) - - - - 0.99972 
G5b 50(2) 47(2) - - 3(1) 0.99979 
G6b 33(2) - 67(2) - - 0.99963 
aThis table shows the calculated molar percentages (%) of the XANES from contributing 
model complexes with errors to the last significant figures and correlation coefficients (R2) 
included. Multiple linear regression analyses were performed within the range 22100 – 
22430 eV. Designations of the models and biological samples correspond to those given in 
Table 5.2. 
 
 
5.2.6 Reactions with HEPG2 cells 
 Compounds 2 and 3 (0.60 mM) were incubated with HepG2 liver carcinoma cells for 
4 hr, the medium was then separated to enable analysis of both the freeze-dried cells and 
medium. All results are shown in Figure 5.19 (conditions H, Table 5.2) and the results of 
multiple linear regression analyses are given in Table 5.7. Significant changes in the Ru K-
Chapter 5 
 
 
138 
 
edge XAS were observed for compound 2 in both the cells and the cell medium, the edge 
shift for 2 in cells (H2a) was larger than in the medium (H2b), which showed that it 
underwent a higher degree of substitution in the cells, or at the cell surface, compared to 
reactions in the medium. The decrease in the white-line intensity (~0.04 units) in the XANES 
for H2b (Figure 5.19b) and the large changes in the period and intensities of the EXAFS 
oscillations showed that 2 was already undergoing substitution in the extracellular media 
before cellular uptake. The linear regression fits to the XAS for both H2a and H2b pointed to 
similar reaction products; represented by the models 10b and 11. The noisy spectra for H2a 
resulted in a relatively poor fit (R2 = 0.99703) compared to other fits, however the spectra 
for both reaction products look the same within the experimental error of the noise.  
The spectral difference between the reaction products of 3 in HEPG2 cells (H3a) and 
in medium (H3b) were minimal (Figure 5.19c,d); however, shifts in the oscillations to higher 
energies were observed in the EXAFS region though not as much as in 2. The shape of the 
spectra was very similar to the XAS of 3 in DMEM (F3b, Figure 5.14b), which indicated 
similar reactivity in cell culture media. The best regression fits to the XANES pointed to large 
proportions of O (52%) and S-donor (~48%) ligands in the product (Table 5.7).  
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Figure 5.18.: Multiple linear regression results for fits to the Ru K-edge XAS 
for conditions H (designations given in Table 5.2). Details of the fits are shown 
in Table 5.7. 
          
 
 
       Table 5.7: Multiple linear regression analyses for Ru K-edge XANES fits for conditions H.a 
 
Sample 4 (%) 9 (%) 10b (%) 11 (%) R2 
H2a  - -  66(5) 34(4) 0.99703 
H2b - - 60(2) 40(2) 0.99917 
H3a 52(2) 36(2) -  12(1) 0.99955 
H3b 52(1) 40(1) - 8(1) 0.99976 
aThis table shows the calculated molar percentages (%) of the XANES from the contributing 
model complexes with errors to the last significant figures and correlation coefficients (R2) 
included. Multiple linear regression analyses were performed within the range 22100 – 
22430 eV. Designations of the models and biological samples correspond to those given in 
Table 5.2. 
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Figure 5.19: Ru K-edge XAS (15 K, fluorescence mode) spectra for compounds 2 and 3 (0.60 mM) 
incubated with a, c) HEPG2 cells and b, d) the separated medium for 4 hr at 37 ⁰C (conditions H). 
Designations are given in Table 5.2. 
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5.2.7 Reactions with DNA 
 Additional experiments were conducted to examine the reactivity of compound 2 
(1.0 mM) with different concentrations of DNA-Na at 10, 5 and 2.5 mg/mL for up to 15 hr 
(Figure 5.21) (conditions I, Table 5.2). The resulting XAS for all adducts were significantly 
different from those of the parent compounds, which was consistent with previous studies, 
which showed that this compound lost its chlorido ligands before binding to DNA.15, 16 The 
XANES from the lowest DNA concentration at 2.5 mg/mL (I2c); however, showed a different 
edge energy from the others with a 0.5 eV shift to lower energy (Figure 5.21d). This 
indicated the presence of different adducts at different Ru:DNA ratios, thus showing the 
versatility of 2 to bind to different sites.  
Multiple linear regression results for I2a and I2b displayed good fits to models 4 (11-
17%), 5 (19%) and 10b (65-70%), which pointed to aqua/hydroxido and other O-donor ligand 
substitution reactions (Table 5.8). The results for I2c differed to the others with a significant 
proportion of the best fit to the XANES being attributed to model 7 (Figure 5.20), which may 
point to the formation of OH bridges at lower DNA concentrations and, thus, another 
possible mode of DNA interaction. The presence of model 10b in all fits is a sign that 
aquation may be a pre-requisite for DNA-binding, which is consistent with literature 
results.17 
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Figure 5.20.: Multiple linear regression results for fits to the Ru K-edge XANES for conditions 
I (designations given in Table 5.2). Details of the fits are shown in Table 5.7. 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
Figure 5.21: Ru K-edge XANES (15 K, fluorescence mode) spectra for compound 2 (1.0 mM) 
reacted with different concentrations of DNA: a) 10 mg/mL, b) 5 mg/mL, c) 2.5 mg/mL in 
HBS for 15 hr; (pH 7.1, 22 °C, conditions I); d) is the overlay of XANES from all reactions after 
15 hr. Designations are given in Table 5.2. 
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Table 5.8: Multiple linear regression analyses of Ru K-edge XANES fits for conditions I.a 
 
Sample 4 (%) 5 (%) 7 (%) 10b (%) R2 
I2a 17(2) 18(4) - 65(3) 0.99975 
I2b 11(2) 19(3) - 70(2) 0.99981 
I2c - - 27(1) 73(1) 0.99987 
aThis table shows the calculated molar percentages (%) of the XANES from the contributing 
model complexes with errors to the last significant figures and correlation coefficients (R2) 
included. Multiple linear regression analyses were performed within the range 22100 – 
22430 eV. Designations of the models and biological samples correspond to those given in 
Table 5.2. 
 
5.2.8 Reactions with Rat Blood 
 
 The K-edge Ru XANES of compound 2 showed profound changes in both cell culture 
medium and serum (Figures 5.15a and 5.17a). Further studies were carried out to examine 
its decomposition in rat blood; red blood cells (RBC), and plasma after 1 or 6 hr (Figure 5.23 
conditions J and K, Table 5.2). Two types of plasma samples were prepared for comparisons: 
the plasma fraction isolated from the whole blood sample before the addition of Ru (K2a, 
K2b), and the plasma fraction isolated after Ru had reacted with the whole blood sample 
(K2c). Prominent shifts in the edges (-0.7 eV) for the RBC fractions (J2) compared with the 
parent compound were observed, the XANES for 1 hr (J2a) had a lower edge energy (~0.4 eV) 
than the XANES for 6 hr (J2b) indicating different decomposition products.  
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 The reaction of 2 in isolated plasma (K2a) displayed a slight increase (~0.4 eV) in the 
XANES edge energies (Figure 5.23b). The whole blood plasma, K2c had a slightly lower edge 
energy value compared to the isolated plasma, K2a (Figure 5.23c), and was similar to that of 
the RBC fraction (J2a) (Figure 5.23d and Table 5.9). This observation showed that RBC 
played a crucial role in Ru metabolism in the whole blood, which has not been discussed in 
literature and would be interesting to conduct further studies. Multiple linear regression fits 
to the XAS for J2a and J2b (Table 5.10) suggested that the products in RBC mainly consisted 
of S-donor ligands; models 8 (70-77%) and 11 (23-30%); although these results were not 
definitive for J2a due to the somewhat poorer fit obtained (R2 = 0.99748) compared to the 
other fits. XAS of the isolated plasma samples displayed good fits to model 10b, which 
indicated that 2 was prone to aquation in blood plasma. 
 
Table 5.9: XANES edge energy values for conditions J and K 
 
Sample Edge Energy (eV) 
Parent 22113.40 
J2a 22112.60 
J2b 22113.02 
K2a 22113.43 
K2b 22113.03 
K2c 22112.90 
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Table 5.10: Multiple linear regression analyses of Ru K-edge XANES fits for conditions J and 
Ka. 
 
Sample 8 (%) 10b (%) 11 (%) R2 
J2a 77(4) - 23(4) 0.99748 
J2b 70(2) - 30(2) 0.99942 
K2a - 100(1) - 0.99962 
K2b 21(2) 66(2) 13(1) 0.99977 
K2c 87(2) - 13(2) 0.99940 
aThis table shows the calculated molar percentages (%)of the XANES from the contributing 
model complexes with errors to the last significant figures and correlation coefficients (R2) 
included. Designations of the models and biological samples correspond to those given in 
Table 5.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.22.: Multiple linear regression results from the best fits to the Ru K-edge XAS for 
conditions J and K (designations given in Table 5.2). Details of the fits are shown in Table 5.9. 
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Figure 5.23: Ru K-edge XANES (15 K, fluorescence mode) from compound 2 (0.60 mM) in rat 
blood incubated for 1 or 6 hr at 37 °C, (conditions J and K). Designations are given in Table 
5.2. 
 
 
5.3 Speciation of Ru-Protein Reactions with Protein Gels 
 
 
5.3.1 Reactions with Albumin and Transferrin 
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Initial studies combining XFM with gel-electrophoresis were carried out for the Ru 
compounds NAMI-A (1), KP1019 (2) and RAPTA-C (3) with BSA (1.0 mg/mL) and bovine apo-
transferrin (BTf) (1.0 mg/mL) (For the XFM experiments, compounds were renumbered once 
again for convenience). The compounds were reacted with these proteins in HBS for 4 hr at 
37 °C. The upper section of the SDS-PAGE gel that contained high-MW proteins were not 
scanned in XFM and only the lower section which contained the monomers for BSA (~65 kDa) 
and BTf (~80 kDa) (Figure 5.24a) was focused on. It was possible to view the strong binding 
interactions between these Ru compounds and the proteins through XFM (Figure 5.24b, c). 
The strong signals at more than 80 kDa in the raw scan were evidence for the extensive 
cross-linking interactions between KP1019 and the serum proteins; in agreement with the 
literature.18, 19 Both NAMI-A and RAPTA-C showed comparatively weaker binding, which 
might be a factor for their anti-metastatic properties. 
XANES scans were conducted for the Ru-BTf monomers (labelled A, B, C in Figure 
5.24c) and the noisy spectra obtained made it hard for accurate linear regression analysis. 
However, the Tf adducts of these three compounds had significantly different edge energies 
(NAMI-A being the lowest at 22112.5 eV and RAPTA-C the highest at 22113.3 eV) to each 
other, which shows a different coordination environment. This showed that some of the 
original ligands from each of the parent complexes were bound in the adduct, at least for 
RAPTA-C (Figure 5.24d).10  
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Figure 5.24: a) Protein stain of gels b) Raw XFM scan and c) enhanced XFM scan for the reaction 
products of Ru compounds NAMI-A (1), KP1019 (2), RAPTA-C (3) (0.20 mM each) with BSA (1.0 
mg/mL) and BTf (1.0 mg/mL) in HBS (4 hr, 37 °C), separated by gel electrophoresis. Protein bands at 
65 and 80 kDa correspond to monomeric forms of BSA and BTf, respectively; d) XANES for the 
compounds with monomeric BTf, scanned at spots A, B, C in c). The lane that is not investigated here 
corresponds to the [RuII((CH2)6S3)(dmso)Cl2] studied separately by Ms. Hannah O’Riley. Graph for the 
XANES spectra prepared by Dr. Aviva Levina. Maps displayed are quantified with threshold values in 
µg/cm2. Experiment performed at the Australian Synchrotron. 
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Figure 5.25: The calculated Ru content for the reactions of Ru compounds NAMI-A (1), KP1019 (2), 
RAPTA-C (3) with BSA and BTf. Total expected amount in each lane was ~200 ng per rectangular area, 
which was close to most of the values obtained except for 2 with BTf. Maps displayed are quantified 
with threshold values in µg/cm2. 
 
The calculated Ru content for each lane showed that there was protein content in 
the samples with values close to the expected amount (~200 ng) (Figure 5.25) for complete 
Ru binding to proteins. The results for KP1019 (2) to BTf displayed a huge deviation from the 
other compounds with a total of 590 ng, which could be due to the small volumes of Ru (1.0 
µL stock) used in the sample preparation process, thus causing an error. This needs to be 
investigated further. NAMI-A (1) appeared to have weaker signals, showing a lower degree 
of binding compared to KP1019. This was consistent with the reports from phase I clinical 
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trials that KP1019 was bound to serum proteins to a higher extent.20 It could be observed 
that RAPTA-C (3) also displayed lots of BSA crosslinking interactions, comparable to KP1019. 
Figure 5.26 shows maps of the interactions of NAMI-A (black box) and RAPTA-C (red 
box) with various proteins, or with albumin-depleted bovine serum. The interactions of 
NAMI-A with actin21 and hemoglobin (Hb)22 have been reported and thus served as a good 
comparison. The monomeric and dimeric Hb (~16 kDa and 32 kDa respectively) could be 
easily observed for both complexes; RAPTA-C however, showed more crosslinking with Hb. 
In collagen, RAPTA-C showed stronger binding at 24 hr (red spot) compared to NAMI-A, 
which seemed to contradict the results in lung metastases in which RAPTA-C was found to 
exit the lung faster than NAMI-A with an assumption that it was due to weaker collagen 
binding.15  
Blood serum differs from plasma by having no blood-clotting proteins.20 The 
commercial bovine serum and fresh rat plasma, used in this experiment, were albumin-
depleted, to allow for the studies of Ru binding to less abundant protein. Binding was still 
observed for both NAMI-A and RAPTA-C, but it was much weaker although it still resembled 
the binding patterns with BSA (Figure 5.26 lower left).  
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Figure 5.26: XFM maps of the interactions of the reaction products of 0.50 mM Ru compounds: 
NAMI-A (Black box) and RAPTA-C (Red box) with various proteins in HBS at 37 °C. separated by gel 
electrophoresis. (Upper left) Actin and Hemoglobin (1 mg/mL) at 8 hr. (Upper right) Collagen (1 
mg/mL) at 4 and 24 hr. (Lower left) Albumin-depleted bovine serum and rat plasma at 8 hr. (Lower 
right) BSA and BTf (2 mg/mL) at 8 hr. Maps displayed are quantified with threshold values in µg/cm2. 
Additional lanes observed here that are not mentioned in this study correspond to the 
[RuIICl2([9]aneS3)dmso], [Ru
IIBr2([9]aneS3)dmso], [Ru
IICl(S2COC(CH3)2)(dmso)3], and 
[Ru3Br6(Me2tacn)2]Br that will be reported by Ms Hannah O’Riley. Experiment was performed at the 
APS. 
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For reactions in rat plasma, more interactions were found in the higher MW fraction, 
which might be representative of the blood-clotting proteins. The yellow spots observed for 
RAPTA-C indicated much stronger binding with the blood proteins. The binding of NAMI-A to 
BTf was also observed to be stronger than RAPTA-C with higher intensity spots for Ru-BTf 
monomers and dimers (Figure 5.26 lower right). 
 
 
     
 
 
 
 
 
 
 
 
 
Figure 5.27: XFM maps of NAMI-A (1), KP1019 (2) and RAPTA-C (3) (1.0 mM) reaction 
products with BSA (1.0 mg/mL) at 4 hr, 37 °C, separated by gel electrophoresis. (Upper left) 
Photograph of blot. Maps displayed are quantified with threshold values in µg/cm2. Results 
obtained from the Australian Synchrotron. 
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Figure 5.27 shows the mapping for the BSA interactions (obtained from the 
Australian Synchrotron) with NAMI-A (1), KP1019 (2) and RAPTA-C (3) in HBS at 4 hr. The 
map here, however, displayed less resolution but clearly showed protein-bound Ru. The 
intense band for 1 showed strong BSA monomer bindings whereas 2 concentrated on the 
high MW region. A good resolution for the iron content was not achieved to determine its 
distribution, although the green and yellow spots did indicate its presence. The Zn map 
showed similar densities to the Ru map, which is due to albumin being a major zinc carrier in 
the bloodstream (~80%  of plasma zinc bound)23 
The results for the interactions in a BSA collagen mixture are illustrated in Figure 5.28 
with increased clarity, which resemble the previous observations for BSA studies (Figure 
5.27). Once again, the results emphasize bindings to the BSA monomers. A large amount of 
Ru and Zn were observed to be concentrated on the monomeric region for 1-BSA whereas 2 
showed a stronger interaction with collagen in the high MW region, which has an implication 
for their different anticancer properties. Data could not be extracted for the Fe content 
beyond the noise level. 
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Figure 5.28: XFM maps of the reaction products NAMI-A (1), KP1019 (2), RAPTA-C (3) 
(1.0 mM) with a mixture of BSA and collagen (1.0 mg/mL each) in HBS (pH 7.4) for 4 
hr at 37 °C, separated by gel electrophoresis. (Upper left) Photograph of blot. Maps 
displayed are quantified with threshold values in µg/cm2. Results obtained from the 
Australian Synchrotron. 
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6.1 Summary of Results 
  
In the rapidly expanding field of Ru anti-cancer drugs, Ru(II) arene complexes are 
among the most prominent classes of compounds, due to their structural versatility and the 
ability to combine cytotoxic and anti-metastatic properties (Chapter 1). In this work, a 
library of model Ru(II) arene complexes with biologically relevant donor groups has been 
synthesized (Chapter 2) and characterized using a range of experimental techniques, 
including multiple-scattering EXAFS analysis (Chapter 3). Preliminary studies of the 
reactivities of Ru(II) arene complexes under biologically relevant conditions were performed 
by UV-Vis spectroscopy (Chapter 4), and more detailed studies were performed by empirical 
analysis of XANES spectra (Chapter 5) to identify the speciation products formed during 
ligand exchange reactions in biological media.  
The reaction pathways of Ru complexes with biomolecules (discussed in detail in 
Chapter 1) are shown in Scheme 6.1. In general, both UV-Vis and XAS results showed that 
compounds which were prone to ligand substitution (RAPTA-C, 2) exhibited anti-metastatic 
properties,1, 2 whereas compounds that remained stable for longer periods in biological 
media ([Ru(η6-arene)(en)(Cl]PF6, 3) were cytotoxic.
3, 4 All of the Ru(II) complexes studied 
formed Ru-BSA adducts in which halido and some other ligands exchanged to bind N-, O-
donor ligands of the protein within 24 hr. The linear regression fits for 2 indicated a 
stepwise exchange of chlorido-ligands with N/O-donors, proceeding on to form reaction 
products with S-donor ligands after 1 hr, which can be attributed to BSA-binding.5, 6 The 
crystal structure of a Ru-protein adduct obtained by soaking a model protein (human 
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carbonic anhydrase) in an aqueous buffer of NAMI-A showed binding to the His64 residue, 
thus supporting the observation of N-binding.7  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 6.1: General reaction pathways of Ru anti-cancer complexes where L are the   
bound ligands and X is the leaving group. The biomolecules are indicated in blue  
boxes, specific binding locations in red boxes and the proposed mode of  
action in white boxes.8 
 
It was surprising to find that the XAS results for OxaloRAPTA-C (5) showed more 
prominent ligand-exchange reactions in HBS (pH 7.4) compared to 2, especially since the 
chelating ligand was supposed to provide more stability to aquation (also observed for the 
UV-Vis results in Chapter 4). This might be due to the lack of other components in the buffer 
solution to compete with the reversed of re-coordination of chlorido ligands, unlike in 
biological media and cells where other donors can compete with this back-reaction. Also, 
although aquation is generally thought to be suppressed under the high saline environment 
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([Cl] ~150 mM) of the blood,2 the change in the edges from the XANES results and peak 
shifts in the UV-Vis spectra clearly show that this suppression is not complete. Even in the 
absence of competing ligands, the equilibrium of the products shows some chloride loss. 
It was obvious from the linear regression fits that the speciation of the Ru(II) 
compounds in cell culture media were complicated and the kinetics could not be resolved 
easily using UV-Vis spectroscopy alone. On the other hand, in undiluted bovine serum, the 
XAS spectra for Ru(II) complexes displayed less prominent changes, although another 
possibility would be ligand-exchange reactions occurring within similar donor groups. The 
fits for the complexes in undiluted serum (Chapter 5, Table 5.6) showed different speciation 
products from their reactions in cell culture media (Chapter 5, Table 5.5) and, therefore, 
indicated other binding processes taking place in the presence of serum proteins.  
Studies of 2 in cell culture media (with 2% v/v fetal calf serum) and undiluted serum 
revealed similar XAS spectra to those of the Ru-BSA adducts, which pointed to preferential 
binding to albumin due to its abundance in the bloodstream. This has contributed to passive 
tumour targeting by tethering albumin to Ru in an attempt to improve drug efficacy,9 and 
suggests that in protein-rich systems, serum albumin acts as a suitable carrier for 
transporting the complexes to the tumour cells.10 The presence of model 10b in the spectral 
fit for the reaction products of 2 in cell culture media (F2) indicated the replacement of the 
chlorido ligand by a hydroxido or aqua ligand, which subsequently led to the binding of O-
donor groups (model 4) of the protein sites. This was consistent with the similarity of the 
UV-Vis spectra for 2 in cell culture media after 1 hr and the hydroxido-bridged model 7 
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(Chapter 4, Figure 4.3). Furthermore, the absence of model 5 in the fit pointed to the 
dissociation of the PTA ligand upon aquation before adduct formation; consistent with the 
ESI-MS results reported in the literature.10 The loss of the PTA ligand however, might lower 
the solubility of the complex and thus hinder diffusion through biological membranes. In 
contrast to 2, compound  3 had slower ligand-exchange reactions with 53% of the parent 
drug being retained after 1 hr, only to bind to O,N-donors over 24 hr. This is in agreement 
with the observations from the UV-Vis spectroscopic studies of the kinetics in cell culture 
media (Chapter 4, Figure 4.6). The higher stability of this complex to aquation would then 
allow its diffusion into the cytoplasm, thus exhibiting cytotoxicity (Scheme 1).3  
The coordination environments for 2 and 3 in the HEPG2 cells were observed to be 
similar to those in the HEPG2 cell medium within experimental error (Chapter 5, Figure 
5.19), yielding similar reaction products (Chapter 5, Table 5.7). However, the noisy XANES 
spectra might give inaccurate regression fits, especially for the cell samples in which poor R2 
values were obtained. Compound 2 showed large changes in the EXAFS region for the 
HEPG2 cell medium (H2b), implying reactivity in the extracellular medium before cellular 
uptake. This might be the reason why 2 is only weakly cytotoxic compared to the platinum 
anticancer complexes. Unlike its activity in cell culture media (F2), the presence of model 11 
in the linear regression fits indicated the formation of an S-bound adduct, possibly from the 
binding of 2 to cathepsin B or other thiol-containing enzymes.11 The large proportion of 
model 10b, present in the spectral fits for both 2 in HEPG2 cell medium and in cell medium 
(2% v/v serum) (F2) suggests similar coordination environments, and that the reaction 
products for 2 in DMEM may be responsible for cell interactions.2 Compound 3 displayed 
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minimal reactivity in the XANES region for the HEPG2 cell samples (H3), although the 
presence of S-donors in the spectral fits might indicate binding to Cys residues of 
cytoplasmic proteins.6, 12 Apart from the presence of model 4, the reaction products for 3 in 
HEPG2 cell medium were found to be different to the fits for cell culture medium (F3), 
indicating that the cellular decomposition occurred through different pathways.  
Although initial interest to DNA-binding for compound 2 has waned due to 2 
favouring serum protein binding over DNA interactions (postulated to be due to the 
hydrophobic arene moiety),13 XAS studies were still carried out for different DNA 
concentrations and found to have different regression fits (Chapter 5, Table 5.8). The 
aqua/hydroxido (model 10b) present in all fits is evidence for chlorido loss before DNA-
binding.14 For higher concentrations of DNA (5-10 mg/mL), N/O-donor substitutions (model 
4,5) were observed that is indicative of purine site binding right after losing its chlorido 
ligand.15 At lower concentrations (2.5 mg/mL), the presence of OH bridges (model 7) might 
be attributed to preferential binding to the adenine site.14, 16 These results show that there 
is a lack of specific adduct formation at the DNA sites for 2, which may not desirable for 
targeted drug delivery; as opposed to the selectivity shown with proteins.11, 17-19 
For reactions in rat blood, the XANES of 2 in whole blood plasma (K2c) showed 
similar spectral  fits to that of the RBC fractions (J2a) (Chapter 5, Figure 5.23d), and largely 
differed to the isolated plasma and serum samples. Therefore, RBC can be postulated to 
play an important part for the metabolism of Ru in whole blood and may potentially serve 
as a transport mechanism for tumour targeted drug delivery.20 The linear regression fits for 
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the RBC samples pointed to a large proportion of S-donor ligands in the product (modelled 
by 8 and 11). The isolated plasma samples demonstrated different speciation, with the 
exchange of the chlorido ligand for aqua/hydroxo species (modelled by 10b) being 
dominant. To my knowledge, these results have not yet been discussed in detail in literature, 
and together, they suggest the various possible binding modes of compound 2 to the 
components in the bloodstream which can account for its anti-metastatic properties. This 
has been described for NAMI-A, KP1019,2 and for anti-diabetic Vanadium complexes (Levina, 
A., “to be submitted”). It is also important to mention that the arene ligands for all the Ru(II) 
complexes studied remained bound and under biologically relevant conditions, there was 
no oxidation to Ru(III) as a consequence of the ligand-exchange processes (Chapter 5, Figure 
5.4), which then should not affect the hydrophobic properties of the complexes.  
Preliminary results for the XFM elemental studies of Ru-protein adduct speciation 
using protein gels showed the power of this technique to understand interactions of Ru with 
various proteins. We attempted to ascertain the extent of transferrin binding in mixtures by 
a co-localization of Ru and Fe but we were not able to obtain sufficient sensitivity for the Fe 
maps using excitation at the Ru K-edge to examine the resolution. KP1019 showed extensive 
cross-linking interactions with BSA and BTf, whereas both 2 and NAMI-A showed 
comparatively weaker binding, thus, a possible factor for their anti-metastatic properties as 
discussed in previous studies.2, 17 The difference in edge energy for the three Ru-BTf adducts 
suggested that some of the original ligands from the parent complexes were still bound in 
the adduct. Another reason would be the difference in ligand-exchange mechanisms for the 
Ru complexes with BTf, as reported for NAMI-A and KP1019.6  
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The XFM maps for the interactions of 2 and NAMI-A with various proteins (Chapter 5, 
Figure 5.26), clearly displayed their different binding abilities. The strong signals observed 
for 2-Hb (~15 kDa) might be evidence for the binding of Hb contributing to the large spectral 
changes in the XAS of red blood cells (Chapter 5, Figure 5.23). The signals in the high MW 
fraction of plasma suggested binding to blood-clotting proteins; once again supporting the 
XAS results of the different speciation products between plasma and RBC. The signals in 
collagen increased between 4 and 24 hr reactions, showing that 2 binds more strongly to 
collagen compared to NAMI-A; contradicting the literature results.1 To summarize with 
reference to the XAS results, 2 had been observed to display a large amount of reactivity in 
the blood plasma and the extracellular matrix, which largely contributes to its anti-
metastatic properties (Scheme 1). With such knowledge, Ru drugs can be designed to target 
specific cellular signalling pathways to improve selectivity.   
 
6.2 Future Work 
The reactions of Ru(II) complexes with isolated proteins and in biological media led 
to changes in the coordination environment, as shown by the spectral differences in UV-Vis 
spectroscopic studies of reactive bonds and verified by multiple linear regression analysis of 
the time-dependent XAS. This was achievable using an XAS database of Ru(II) arene model 
compounds although the uncertainty of some of the results (especially for cell and blood 
samples), indicated a larger variety of ligand coordinations for Ru would be needed to 
improve the fits. Some samples produced weak XAS spectra with moderate noise levels and 
future analysis would benefit by the use of more intense beamlines and/or more scans. As 
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of now, the current library synthesized would serve as a good starting point for future Ru(II) 
arene studies.  
More research is required to cor-relate the UV-Vis spectroscopic studies of the 
reactions in biological media with the XAS results for the serum and blood samples. As the 
field of the binding of serum proteins to RAPTA is still being explored, the preliminary XFM 
results shown here, although not yet conclusive, are useful in identifying the speciation with 
reference to KP1019 and NAMI-A.2 These interactions will most likely provide further 
explanation for their different anticancer activities and it will be worthy carrying out 
detailed studies for their reactivity with serum proteins and the activities of the Ru-arene 
adducts with proteins on the cytotoxicities and anti-metastatic properties of Ru-arene 
pathways. Future studies will also include obtaining Fe maps with higher sensitivity before 
drawing anymore conclusions of their overall distribution. 
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Appendix A.1  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1: Main peaks for 300 MHz 1H NMR spectra of a) compound 2 in CDCl3 and b) 
compound 3 in DMSO-d6, huge peak at 3.3 ppm is attributed to the water peak in the 
solvent. All peak assignments are listed in Chapter 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
b) 
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Figure S2: Experimental (lines) and simulated isotope distributions (columns) for major 
ESMS spectra for a) compound 2 and b) compound 3 in MeOH. Simulation was performed 
using the IsoPro 3.01 software (M.Senko, Sunnyvale, CA, 1998).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3: Main spectra for Complex 9: a) 1H NMR spectra in MeOD-d4, detailed peak 
assignments are listed in Chapter 2 and b) ESMS spectra in MeOH, experimental (lines) and 
simulated isotope distributions (columns) are shown. 
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Table A.2 Conditions, restraints, and constraints used in MS XAFS fitting for RAPTA-Ca 
 
 
 
Continued on the next page 
Conditions  
K range, Å1 : 0-13 b 
FT range, Å  : 1-5b  
Determinancy (Ni/p):
c 2.1 
Maximal effective path length of a photoelectron: 5.0 Å 
Maximum number of legs: 4 
Plane-wave path filter threshold: 0% 
Curved-wave path filter threshold: 0% 
Scale factor: 0.9  0.1 
  
Bond length restraints (Å):d  
Ru0-Cl1  2.42 {0.02} Ru0-C13  Ru0-C14  Ru0-C15 {0.02} 
Ru0-Cl2  2.42 {0.02} 
Ru0-P3  2.42 {0.02} 
Ru
0
-C
16
  Ru0-C17  Ru0-C18 {0.02} 
P
3
-C
7
  P3-C8 P3-C9 {0.01} 
Ru0-C13  2.18 {0.02} 
Ru0-C16  2.18 {0.02} 
P3-C7  1.83 {0.01} 
N
5
-C
8
  N5-C10  N5-C12 {0.02} 
N
4
-C
7
  N4-C10  N4-C11 {0.02} 
N
6
-C
9
  N6-C11  N6-C12 {0.02} 
N4-C7  1.47 {0.01} 
N5-C8  1.47 {0.01} 
N6-C9  1.47 {0.01} 
C13-C14  1.41 {0.02} 
C16-C17  1.41 {0.02} 
C20-C21  1.53 {0.02} 
C15-C19  1.51 {0.02} 
C
14
-C
15 C15-C16  C16-C17 {0.02} 
C
16
-C
17
  C17-C18 {0.02} 
C
15
-C
19
  C18-C20 {0.02} 
C
20
-C
21
  C20-C22 {0.02} 
 
Bond angle restraints (°):d 
 
C18-C13-C14 = 120 {2} C18-C13-C14 = C17-C16-C15 {2} 
C18-C20-C21 = 110 {2} C18-C20-C21 = C20-C21-C22 = C22-C20-C18 {2} 
Cl2-Ru0-Cl1 = 88 {5}  
Cl2-Ru0-P3 = 82 {5}  
Cl1-Ru0-P3 = 89 {5}  
C13-C12-C11 = 120 {3}  
C12-C11-C10 = 120 {3}  
C11-C10-N7 = 119 {3}  
  
Debye-Waller factor restraints (Å2):d  
0.001{0.0005} < i
2 < 0.02 {0.001}, i= 1-22  
i
2 (Ru0) > (i
2 (C13) + 0.001) {0.0005}  
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Debye-Waller factor constraints:d  
i
2 (Cl1) = i
2 (Cl2)   
i
2 (C7) = i
2 (C8) = i
2 (C9)  
i
2 (N5) = i
2 (N5) = i
2 (N6)  
i
2 (C10) = i
2 (C11) = i
2 (C12)  
i
2 (C13) = i
2 (C14) = i
2 (C15)  
i
2 (C16) = i
2 (C17) = i
2 (C18)  
i
2 (C21) = i
2 (C22)  
  
Atoms restrained to be approximately coplanar  
(C18 – C17) x (C16 – C17)^ . (C14 - C17)  0 {0.1}  
(C13 – C14) x (C15 – C14)^ . (C17 - C14)  0 {0.1}  
  
 
aExperimental and calculated spectra are shown in Figure 3.7 (Chapter 3).. bThe applied 
window functions are shown in Figure 3.7. cThe number of independent observations (Ni) 
and the number of varied parameters (p) were calculated taking into account the applied 
restraints and constraints [ref. 27 in Chapter 3]. d The atom numbering used in the MS XAFS 
calculation are shown in Figure 3.8 (Chapter 3). 
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Table A.3 Results of MS XAFS Analysis Fitting for RAPTA-Ca 
 
Parameterb  
-E0  15.38 
S0
2 0.92 
2 (Cl1), Å2 c 0.0065(1) 
2 (P3), Å2 c 0.0005(1) 
2 (N4), Å2 c 0.0005(1) 
2 (C10), Å2 c 0.0070(5) 
2 (C13), Å2 c 0.0011(3) 
2 (C16), Å2 c 0.0029(1) 
2 (C19), Å2 c 0.0005(1) 
2 (C20), Å2 c 0.0043(2) 
2 (C21), Å2 c 0.0010(2) 
      
aExperimental and calculated spectra are shown in Figure 3.9 (Chapter 3). 
bDesignations of parameters: -E0 is the threshold energy; S0
2 is the scale factor; 2 
(Å2) is the Debye-Waller factor; and N is the number of scatterers in a shell. cAtom 
numbering corresponds to Figure 3.8  with the resulting fit parameters listed in Table 
3.1 (Chapter 3). 
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Most significant Photoelectron Scattering Paths in the Calculated XAFS spectrum of 
RAPTA-C   
Path Legs Dege-
neracy 
i
2, Å2 Length
, Å 
Contribution, 
% 
Ru(0)Cl(7) 2 1 0.00286 2.189 100.00 
Ru(0)C(14) 3 1 0.00116 2.191 100.00 
Ru(0)C(13) 1 1 0.00116 2.184 53.90 
Ru(0)P(3) 1 1 0.00050 2.425 37.59 
Ru(0)Cl(1) 1 1 0.00651 2.427 24.85 
Ru(0)Cl(2) 1 1 0.00651 2.427 24.85 
Ru(0)C(16) C(15) 4 1 0.00266 2.887 12.99 
Ru(0)C(18)C(17) 4 1 0.00379 2.891 12.36 
Ru(0)C(19) 1 1 0.00050 3.201 11.82 
Ru(0)C(7) 1 1 0.00050 3.592 7.89 
Ru(0)C(8) 1 1 0.00050 3.625 7.89 
Ru(0)C(13)Ru(0) 2 1 0.00166 4.609 7.79 
Ru(0)C(20)-C(18) 2 1 0.00461 3.524 7.54 
Ru(0)C(9) 1 1 0.00050 3.426 7.26 
Ru(0)C(20) 1 1 0.00439 3.354 7.24 
Ru(0)C(14)C(13) 2 1 0.00153 2.893 6.59 
Ru(0)N(6)C(9) 2 1 0.00051 4.867 6.39 
Ru(0)C(19)C(15) 2 1 0.00075 3.446 6.26 
Ru(0)C(18)C(13) 2 1 0.00268 2.912 5.72 
Ru(0)N(5)P(3) 2 1 0.00052 4.862 5.52 
Ru(0)C(9)P(3) 2 1 0.00061 3.841 4.92 
Ru(0)N(4)P(3) 2 1 0.00053 4.883 4.89 
Ru(0)C(22)C(18) 2 1 0.00114 4.630 4.79 
Ru(0)C(15)-Ru(0) 2 1 0.00767 4.608 4.77 
Ru(0)C(14)-Ru(0) 2 1 0.00166 4.616 4.47 
Ru(0)C(18)-Ru(0) 2 1 0.00938 4.610 4.34 
Ru(0)C(21) 1 1 0.00104 4.001 4.32 
Ru(0)C(16)-Ru(0) 2 1 0.00938 4.610 4.29 
Ru(0)C(17)-Ru(0) 2 1 0.00938 4.616 4.26 
Ru(0)C(13)-P(3) 2 1 0.00165 4.598 3.53 
Ru(0)N(4)-C(7) 2 1 0.00053 4.927 3.46 
Ru(0)C(7)-P(3) 2 1 0.00059 3.924 3.44 
Ru(0)-C(22) 2 1 0.00059 3.940 3.19 
Ru(0)-N(5) 1 1 0.00050 4.785 3.11 
Continued on the next page 
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Path Legs Dege-
neracy 
i
2, Å2 Length
, Å 
Contri-bution, 
% 
Ru(0)-C(5)-C(8) 2 1 0.00053 4.940 3.08 
Ru(0)-N(4) 1 1 0.00050 4.792 3.07 
Ru(0)-C(14)-P(3) 2 1 0.00163 4.549 2.99 
Ru(0)-N(6) 1 1 0.00050 4.838 2.79 
Ru(0)-C(18)-Ru(0) 3 1 0.01146 4.366 2.78 
Ru(0)-C(8)-Cl(1) 2 1 0.00355 4.319 2.70 
Ru(0)C(20)C(22) 2 1 0.00165 4.779 2.68 
Ru(0)C(22)C(20) 2 1 0.00157 4.736 2.48 
Ru(18)C(22)C(18) 1 1 0.00146 4.673 2.46 
Ru(0)C(9)N(6)-C(9) 1 1 0.00056 4.896 2.45 
Ru(0)C(15)C(16)-C(15) 3 1 0.00592 3.591 2.44 
Ru(0)P(3)C(18) 2 1 0.00320 4.402 2.16 
Ru(0)C(13)C(15) 2 1 0.00180 3.399 2.13 
Ru(0)C(15)Cl(1) 2 1 0.00762 4.579 2.09 
Ru(0)C(17)C(15) 2 1 0.00314 3.407 1.97 
Ru(0)C(16)Cl(1) 2 1 0.00931 4.576 1.94 
Ru(0)C(18)Cl(2) 2 1 0.00931 4.577 1.94 
Ru(0)C(17)Cl(2) 2 1 0.00931 4.581 1.93 
Ru(0)C(18)C(16) 2 1 0.00447 3.405 1.92 
Ru(0)C(18)C(20)-C(18) 1 1 0.00646 3.693 1.91 
Ru(0)C(16)C(14) 2 1 0.00314 3.417 1.88 
Ru(0)C(17)C(13) 2 1 0.00315 3.425 1.79 
Ru(0)C(17)Ru(0)-C(17) 2 1 0.01146 4.378 1.79 
Ru(0)C(18)C(14) 2 1 0.00315 3.428 1.76 
Ru(0)C(16)C(15)-C(17) 4 1 0.00521 4.114 1.71 
Ru(0)C(15)C(16)-C(14) 4 1 0.00435 4.121 1.71 
Ru(0)C(16)C(15)-C(16) 2 1 0.00875 3.594 1.51 
Ru(0)C(18)C(17)-C(18) 2 1 0.01042 3.593 1.41 
Ru(0)C(21)C(18) 2 1 0.00174 4.337 1.40 
Ru(0)C(14)C(15)-C(14)-C(15) 4 1 0.00690 4.301 1.17 
Ru(0)C1(1)C(14) 2 1 0.00730 4.378 1.05 
Ru(0)C(16)C(17)-C(16)-C(17) 4 1 0.01709 4.301 0.92 
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Table A.5 Conditions, restraints, and constraints used in MS XAFS fitting for  
[(η6-p-cymene)Ru(en)Cl] a 
 
Condition  
K range: 2-13 Å-1 b 
FT range : 1-4.5 Å b  
Determinancy (Ni/p):
c 1.1  
Maximal effective path length of a photoelectron: 5.0 Å 
Maximum number of legs: 2  
Plane-wave path filter threshold: 0%  
Curved-wave path filter threshold: 0%  
Scale factor: 0.9  0.1  
  
Bond length restraints (Å)  
Ru0Cl1  2.42 {0.04} Ru0-C3  Ru0-C4  Ru0-C5 {0.03} 
Ru0N12  2.12 {0.04} Ru0-C6  Ru0-C7  Ru0-C8 {0.03} 
Ru0C3  2.19 {0.03} Ru0N12  Ru0N15 {0.04} 
Ru0C6  2.19 {0.03} C6C9  C2C3 {0.03} 
C6C9  1.52 {0.03} C9C10  C9C11 {0.03} 
C9C10  1.52 {0.03}  
N12C13  1.30 {0.05} N12C13  N15C14 {0.05} 
C13C14  1.49 {0.05} C3C4  C4C5  C5C6 {0.03} 
C3C4  1.41 {0.03} C6C7  C7C8  C8C3 {0.03} 
C6C7  1.41 {0.03}  
  
Bond angle restraints (⁰):  
C5C4C3  120 {10} C
5-C4-C3 = C8-C3-C4= C7-C8-C3 {10} 
C7C6C5  120 {10} C7C6C5 = C6C5C4= C8C7C6 {10} 
C13C14N15  110 {10} Ru0N15C14 = Ru0N12C13 {10}  
N12Ru0N15  78{10}  
Cl1Ru0N15  83 {10}  
Cl1Ru0N12  84 {10} 
Ru0N15C14  123 {10} 
 
  
 Debye-Waller factor restraints (Å2):  
 0.001{0.0005} < i
2 < 0.02 {0.001}, i= 1-15  
 i
2 (Ru0) > (i
2 (C11) + 0.001) {0.0005}  
 
 
 
 
 
 
 
Continued on the next page 
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Debye-Waller factor constraints:  
i
2 (C2) = i
2 (C9)  
i
2 (C10) = i
2 (C11)   
i
2 (C3) = i
2 (C4) = i
2 (C5) = i
2 (C6)  
i
2 (N12) = i
2 (N15) 
 
 
Atoms restrained to be approximately coplanar  
(C3 – C4) x (C5 – C4)^.(C7 – C4)  0 {0.2}  
(C8 – C7) x (C6 – C7)^.(C4 – C7)  0 {0.2}  
  
 
aExperimental and calculated spectra are shown in Figure 3.9 (Chapter 3).  
bThe applied window functions are shown in Figure 3.9. cThe number of independent 
observations (Ni) and the number of varied parameters (p) were calculated taking into 
account the applied restraints and constraints [ref. 27 in Chapter 3]. d The atom numbering 
used in the MS XAFS calculation are shown in Figure 3.10 (Chapter 3). 
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Table A.6 Results of MS XAFS Analysis Fitting for [(η6-p-cymene)Ru(en)Cl]a 
 
Parameterb  
-E0 20.34 
S0
2 0.95 
i
2 (Cl1), Å2 c 0.0004(1) 
i
2 (C2), Å2 c 0.0005(1) 
i
2 (C8), Å2 c 0.0008(1) 
i
2 (C9), Å2 c 0.0005(1) 
i
2 (C10), Å2 c 0.0005(1) 
i
2 (N12), Å2 c 0.0005(1) 
i
2 (C13), Å2 c 0.0005(1) 
i
2 (N15), Å2 c 0.0005(1) 
      
aExperimental and calculated spectra are shown in Figure 3.9 (Chapter 3). bDesignations of 
parameters: -E0 is the threshold energy; S0
2 is the scale factor; 2 (Å2) is the Debye-Waller 
factor; and N is the number of scatterers in a shell. The values in the parentheses are the 
errors in the last significant figures, obtained from the Monte-Carlo analysis. cAtom 
numbering corresponds to Figure 3.10 with the resulting fit parameters listed in Table 3.2 
(Chapter 3). 
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Most significant Photoelectron Scattering Paths in the Calculated XAFS spectrum of  
[(η6-p-cymene)Ru(en)Cl] 
Path Legs Dege-
neracy 
i
2, Å2 Length, Å Contribution,  
% 
Ru0-N15 1 1 0.00044 2.10963 100.00% 
Ru0-C7 2 1 0.00101 2.17213 100.00% 
Ru0-N12 1 1 0.00044 2.10976 99.97% 
Ru0-C8 1 1 0.00101 2.1931 75.69% 
Ru0-C4 1 1 0.00101 2.19885 74.44% 
Ru0-C3 1 1 0.00101 2.1989 74.43% 
Ru0-C5 1 1 0.00101 2.19955 74.28% 
Ru0-Cl1 1 1 0.00048 2.40602 53.81% 
N15-Ru0-C4 2 1 0.00145 4.30848 18.58% 
Ru0-N12-Ru0-C6 2 1 0.00145 4.33035 16.51% 
Ru0-C14 1 1 0.00482 2.96428 15.04% 
Ru0-C13 1 1 0.00482 2.96376 15.02% 
Ru0-C2-C3 2 1 0.00163 3.61045 11.82% 
Ru0-C8-Ru0-Cl1 2 1 0.00149 4.59912 11.52% 
Ru0-C10 1 1 0.0005 3.65207 11.37% 
Ru0-C2 1 1 0.00158 3.50214 10.91% 
Ru0-C9 1 1 0.00158 3.3769 10.56% 
Ru0-C5-Ru0-N12 2 1 0.00145 4.30931 10.35% 
Ru0-C9-C6 2 1 0.00166 3.55875 9.00% 
Ru0-C7-C8 2 1 0.00133 2.88872 8.67% 
Ru0-N15-C4 2 1 0.00145 4.2977 8.34% 
Ru0-C8-C3 2 1 0.00133 2.90156 8.32% 
Ru0-C7-C6 2 1 0.00133 2.90226 8.28% 
Ru0-C3-C4 2 1 0.00133 2.90469 8.24% 
Ru0-C5-C4 2 1 0.00133 2.90497 8.23% 
Ru0-C11 1 1 0.0005 3.82942 8.15% 
Ru0-C6-C5 2 1 0.00133 2.91518 8.02% 
Ru0-C14-N15 2 1 0.0044 3.19183 7.93% 
Ru0-C13-N12 2 1 0.0044 3.19159 7.92% 
Ru0-N12-C6 2 1 0.00144 4.31065 7.92% 
Ru0-C5-N12 2 1 0.00142 4.23213 7.72% 
Ru0-C3-N15 2 1 0.0014 4.15919 6.41% 
Ru0-C5-N15 2 1 0.0014 4.15729 6.36% 
Ru0-C3-Ru0-N15 2 1 0.00145 4.30853 5.02% 
Ru0-C5-Ru0-N15 2 1 0.00145 4.30918 4.88% 
Continued on the next page 
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Path Legs Dege-
neracy 
i
2, Å2 Length, 
Å 
Contribution, 
% 
Ru0-C3-C2-C3 1 1 0.00205 3.71877 4.73% 
Ru0-C8-Cl1 2 1 0.00149 4.59567 4.47% 
Ru0-C7-N12 2 1 0.00137 4.05829 4.23% 
Ru0-Cl1-Ru0-C7 2 1 0.00149 4.57816 3.90% 
Ru0-C13-C14 2 1 0.00604 3.71761 3.76% 
Ru0-Cl1-C7 2 1 0.00145 4.4665 3.30% 
Ru0-C7-Ru0-C7 2 1 0.00403 4.34427 3.14% 
Ru0-C4-N12 2 1 0.00133 3.95398 3.09% 
Ru0-N12-N15 2 1 0.00071 3.37768 2.96% 
Ru0-C13-N15 2 1 0.00436 3.70109 2.83% 
Ru0-C14-N12 2 1 0.00436 3.7014 2.83% 
Ru0-Cl1-C3 2 1 0.00143 4.44202 2.77% 
Ru0-C7-C5 2 1 0.00157 3.39765 2.76% 
Ru0-C7-C3 2 1 0.00157 3.39958 2.73% 
Ru0-C8-N15 2 1 0.0013 3.8385 2.61% 
Ru0-C8-C4 2 1 0.00157 3.41763 2.57% 
Ru0-C6-N15 2 1 0.0013 3.86445 2.52% 
Ru0-C5-C3 2 1 0.00157 3.42576 2.50% 
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Table A.8 Conditions, restraints, and constraints used in MS XAFS fitting for  
  (η6-p-cymene)Ru(acac)Cl a 
 
 
 
 
 
Continued on the next page 
 
Conditions  
K range, Å1 : 0-16 b 
FT range, Å  : 1-4.5b  
Determinancy (Ni/p):
c 1.1 
Maximal effective path length of a photoelectron: 5.0 Å 
Maximum number of legs: 2 
Plane-wave path filter threshold: 0% 
Curved-wave path filter threshold: 0% 
Scale factor: 0.9  0.1 
  
Bond length restraints (Å):d  
Ru0-Cl1  2.41 {0.03} Ru0-C10  Ru0-C11  Ru0-C12 {0.04} 
Ru0-O3  2.06 {0.03} 
Ru0-C10  2.145 {0.04} 
Ru0-C13  Ru0-C14  Ru0-C15 {0.04} 
Ru0-O3  Ru0-O7 {0.03} 
Ru0-C13  2.145 {0.04} 
C10-C9  1.57 {0.03} 
C13-C16  1.52 {0.03} 
C13-C16   C16-C17   C16-C18 {0.03} 
O7-C6   O3-C2 {0.05} 
C5-C6   C2-C5 {0.05} 
O7-C6  1.27 {0.05} 
C5-C6  1.43 {0.05} 
C6-C8  1.45 {0.05} 
C10-C11  1.41 {0.05} 
C13-C14  1.41 {0.05} 
 
C6-C8   C2-C4 {0.05} 
C10-C11  C11-C12  C12-C13 {0.05} 
C13-C14  C14-C15  C15-C10 {0.05} 
C20-C21  C20-C22 {0.02} 
Bond angle restraints (⁰):d  
C10-C11-C12 = 120 {5} C10-C11-C12 = C11-C12-C13 = C14-C13-C12 {5} 
C15-C14-C13 = 120 {5} C15-C14-C13 = C10-C15-C14 = C11-C10-C15 {5} 
O7-C6-C5 = 120 {10} O7-C6-C5 =  O3-C2-C5 =  C6-C5-C2 {10} 
Ru0-O7- C6 = 125 {10} Ru0-O7-C6 =  Ru0-O3-C2  
O3- Ru0- Cl1 = 86 {5}  
O3- Ru0- O7 = 87 {5}  
O7- Ru0- Cl1 = 84 {5}  
  
Debye-Waller factor restraints (Å2):d  
0.001{0.0005} < i
2 < 0.02 {0.001}, i= 18  
i
2 (Cl1) > (i
2 (O3) + 0.001) {0.0005}  
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Debye-Waller factor constraints:d  
i
2 (O3) = i
2 (O7)   
i
2 (C8) = i
2 (C4)   
i
2 (C17) = i
2 (C18)   
i
2 (C10) = i
2 (C11) = i
2 (C12)  
i
2 (C13) = i
2 (C14) = i
2 (C15)  
i
2 (C6) = i
2 (C2)  
  
Atoms restrained to be approximately coplanar  
(C10 – C15) x (C14 – C15)^ . (C12 - C15)  0 {0.05}  
(C13 – C12) x (C11 – C12)^ . (C15 - C12)  0 {0.05}  
  
 
aExperimental and calculated spectra are shown in Figure 3.11 (Chapter 3).. bThe applied 
window functions are shown in Figure 3.11. cThe number of independent observations (Ni) 
and the number of varied parameters (p) were calculated taking into account the applied 
restraints and constraints [ref. 27 in Chapter 3]. d The atom numbering used in the MS XAFS 
calculation are shown in Figure 3.14 (Chapter 3). 
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Table A.9 Results of MS XAFS Analysis Fitting for (η6-p-cymene)Ru(acac)Cl a 
 
Parameterb  
-E0  18.69 
S0
2 0.90 
2 (Cl1), Å2 c 0.0041(1) 
2 (O3), Å2 c 0.0009(1) 
2 (O7), Å2 c 0.0009(1) 
2 (C10), Å2 c 0.0020(1) 
2 (C16), Å2 c 0.0005(1) 
2 (C17), Å2 c 0.0005(9) 
2 (C2), Å2 c 0.0200(1) 
2 (C4), Å2 c 0.0005(1) 
2 (C5), Å2 c 0.0200(1) 
      
aExperimental and calculated spectra are shown in Figure 3.11 (Chapter 3). bDesignations of 
parameters: -E0 is the threshold energy; S0
2 is the scale factor; 2 (Å2) is the Debye-Waller 
factor; and N is the number of scatterers in a shell. The values in the parentheses are the 
errors in the last significant figures, obtained from the Monte-Carlo analysis. cAtom 
numbering corresponds to Figure 3.12 with the resulting fit parameters listed in Table 3.3 
(Chapter 3).
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Most significant Photoelectron Scattering Paths in the Calculated XAFS spectrum of  
(η6-p-cymene)Ru(acac)Cl 
Path Legs Dege-
neracy 
i
2, Å2 Length, 
Å 
Contribution, 
% 
Ru0-O3 1 1 0.00096 2.04723 100.00% 
Ru0-C14 2 1 0.00205 2.1706 100.00% 
Ru0-O7 1 1 0.00096 2.04958 99.32% 
Ru0-C13 1 1 0.00205 2.15423 66.28% 
Ru0-C10 1 1 0.00205 2.15577 65.94% 
Ru0-C15 1 1 0.00205 2.16109 64.79% 
Ru0-Cl1 1 1 0.00408 2.4096 56.40% 
Ru0-C11 1 1 0.00205 2.15994 51.87% 
Ru0-O7-Ru0-C11 2 1 0.003 4.20952 23.18% 
Ru0-C14-C13 4 1 0.00271 2.86543 18.31% 
Ru0-C6-O7 2 1 0.01877 3.18195 16.26% 
Ru0-C2-O3 2 1 0.01877 3.17955 16.25% 
Ru0-C16 1 1 0.0005 3.33677 14.78% 
Ru0-C2 1 1 0.02 3.03731 13.72% 
Ru0-C6 1 1 0.02 3.03983 13.68% 
Ru0-C9 1 1 0.00106 3.29121 13.58% 
Ru0-C8-O7 2 1 0.00051 4.30933 13.50% 
Ru0-C4-O3 2 1 0.00051 4.3095 13.48% 
Ru0-C15-Ru0-O3 2 1 0.003 4.20832 11.26% 
Ru0-C16-C13 2 1 0.00083 3.50501 10.70% 
Ru0-C18 1 1 0.0005 3.70527 10.52% 
Ru0-C14-Ru0-Cl1 2 1 0.00613 4.5802 10.43% 
Ru0-C13-Ru0-Cl1 2 1 0.00613 4.56383 9.75% 
Ru0-C12-Ru0-O7 2 1 0.003 4.19704 9.48% 
Ru0-C11-C12 2 1 0.00271 2.85818 9.19% 
Ru0-C11-C10 2 1 0.00271 2.86148 9.17% 
Ru0-C10-C15 2 1 0.00271 2.86288 9.15% 
Ru0-C14-C15 2 1 0.00271 2.8705 9.13% 
Ru0-C12-C7 2 1 0.00293 4.09889 8.93% 
Ru0-C15-O3 2 1 0.00295 4.1299 8.78% 
Ru0-O7-C11 2 1 0.003 4.20753 8.63% 
Ru0-C10-O3 2 1 0.0029 4.06038 8.38% 
Ru0-C2-C4-O3 2 1 0.00247 4.41008 8.36% 
Ru0-C6-C8-O7 2 1 0.00249 4.41114 8.31% 
Continued on the next page 
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Path Legs Dege-
neracy 
i
2, Å2 Length, 
Å 
Contribution, 
% 
Ru0-C10-O7 2 1 0.0029 4.05893 8.30% 
Ru0-C5 1 1 0.02 3.38479 8.04% 
Ru0-C17 1 1 0.0005 4.13994 7.92% 
Ru0-C9-C10 2 1 0.00143 3.50807 7.79% 
Ru0-C4-C2 2 1 0.00247 4.39651 7.36% 
Ru0-O7-C8-O7 1 1 0.00054 4.32258 7.30% 
Ru0-C8-C6 2 1 0.00249 4.39789 7.29% 
Ru0-O3-C4-O3 1 1 0.00054 4.32307 7.28% 
Ru0-C4 1 1 0.0005 4.29593 6.25% 
Ru0-C8 1 1 0.0005 4.29608 6.25% 
Ru0-C10-Ru0-O3 2 1 0.003 4.20301 5.78% 
Ru0-C10-Ru0-O7 2 1 0.003 4.20535 5.51% 
Ru0-O7-C6-O7 1 1 0.02066 3.32407 5.13% 
Ru0-O3-C2-O3 1 1 0.02066 3.3218 5.12% 
Ru0-C14-Cl1 2 1 0.00608 4.54688 5.01% 
Ru0-C10-O7 2 1 0.0029 4.05893 8.30% 
Ru0-C5 1 1 0.02 3.38479 8.04% 
Ru0-C17 1 1 0.0005 4.13994 7.92% 
Ru0-C9-C10 2 1 0.00143 3.50807 7.79% 
Ru0-C4-C2 2 1 0.00247 4.39651 7.36% 
Ru0-O7-C8-O7 1 1 0.00054 4.32258 7.30% 
Ru0-C8-C6 2 1 0.00249 4.39789 7.29% 
Ru0-O3-C4-O3 1 1 0.00054 4.32307 7.28% 
Ru0-C4 1 1 0.0005 4.29593 6.25% 
Ru0-C8 1 1 0.0005 4.29608 6.25% 
Ru0-C10-Ru0-O3 2 1 0.003 4.20301 5.78% 
Ru0-C10-Ru0-O7 2 1 0.003 4.20535 5.51% 
Ru0-O7-C6-O7 1 1 0.02066 3.32407 5.13% 
Ru0-O3-C2-O3 1 1 0.02066 3.3218 5.12% 
Ru0-C14-Cl1 2 1 0.00608 4.54688 5.01% 
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Table A.11 Conditions, restraints, and constraints used in MS XAFS fitting for 
OxaloRAPTA-C a 
 
Condition  
K range: 0-15 Å-1 b 
FT range : 1-4.5 Åb  
Determinancy (Ni/p):
c 1  
Maximal effective path length of a photoelectron: 5.0 Å 
Maximum number of legs: 2  
Plane-wave path filter threshold: 0%  
Curved-wave path filter threshold: 0%  
Scale factor: 0.9  0.1  
  
Bond length restraints (Å)  
Ru0P1  2.31 {0.02} Ru0O2  Ru0O3 {0.02} 
Ru0O2  2.09 {0.02} Ru0-C9  Ru0-C10  Ru0-C11 {0.02} 
Ru0C9  2.19 {0.02} Ru0C12  Ru0C13 Ru0C14 {0.02} 
Ru0C12  2.19 {0.02} P1C19  P1C20 P1C21 {0.04} 
P1C19  1.84 {0.04} N6C21  N6C22  N6C23 {0.04} 
N6C21  1.47 {0.04}  
N7C19  1.47 {0.04} N7C19  N7C23  N7C24 {0.04} 
N8C20  1.47 {0.04} N8C20  N8C22  N8C24 {0.04} 
C9C10  1.41 {0.03} C9C10  C10C11  C11C12 {0.03} 
C12C13  1.41 {0.03} C12C13  C13C14  C14C9 {0.03} 
C9C15  1.52 {0.05} C9C15 C12C18  C15C16  C15C17 {0.05} 
O3C26  1.25 {0.04} O3C26  O2C25 {0.05} 
C25C26  1.56 {0.05}  
O5C26  1.23 {0.02} O5C26  O4C25 {0.02} 
  
Bond angle restraints (⁰):  
C14C13C12  120 {5} C
14-C13-C12 = C11-C12-C13= C10-C11-C12 {5} 
C9C10C11  120 {10} C9C10C11 = C10C9C14= C9C14C13 {5} 
O3C26C25  108 {10} O3C26C25 = O2C25C26 {10}  
C21P1C19  120{10} C21P1C19  = C20P1C21 = C19P1C20{10} 
P1C19N7  109 {10} P1C19N7 = P1C21N6 = P1C20N8 {10} 
C20N8C24  109 {10} 
C24N8C22  120 {10} 
C20N8C24 = C20N8C22 = C19N7C24 {10} 
C24N8C22 = C24N7C23 {10} 
N8C22N6  120 {10} N8C22N6 = N8C24N7 = N7C23N6 {10} 
C21N6C22  109 {10} C21N6C22 = C21N6C23 = C22N6C23{10} 
O3Ru0O2  78 {5}  
P1Ru0O3  84 {5}  
P1Ru0O2  87 {5}  
 
 
Continued on the next page 
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Debye-Waller factor restraints (Å2):  
0.001{0.0005} < i
2 < 0.02 {0.001}, i= 1-26  
  
Debye-Waller factor constraints:  
i
2 (C2) = i
2 (C3)  
i
2 (C21) = i
2 (C20) = i
2 (C19)  
i
2 (C9) = i
2 (C10) = i
2 (C11) = i
2 (C12) = i
2 (C13) = i
2 (C14)  
i
2 (N6) = i
2 (N7) = i
2 (N8)  
i
2 (C23) = i
2 (C22) = i
2 (C24)  
i
2 (C16) = i
2 (C17)  
i
2 (C25) = i
2 (C26)  
i
2 (O4) = i
2 (O5)  
  
Atoms restrained to be approximately coplanar  
(C10 – C11) x (C12 – C11)^.(C14 – C11)  0 {0.1}  
(C13 – C14) x (C9 – C14)^.(C11 – C14)  0 {0.1}  
  
 
aExperimental and calculated spectra are shown in Figure 3.13 (Chapter 3). bThe applied 
window functions are shown in Figure 3.13. cThe number of independent observations (Ni) 
and the number of varied parameters (p) were calculated taking into account the applied 
restraints and constraints [ref. 27 in Chapter 3]. d The atom numbering used in the MS XAFS 
calculation are shown in Figure 3.14 (Chapter 3). 
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Table A.12 Results of MS XAFS Analysis Fitting for OxaloRAPTA-Ca 
 
Parameterb  
-E0 15.11 
S0
2 0.97 
i
2 (P1), Å2 c 0.0001(1) 
i
2 (O2), Å2 c 0.0004(1) 
i
2 (O4), Å2 c 0.0005(1) 
i
2 (N6), Å2 c 0.0005(1) 
i
2 (C9), Å2 c 0.0005(1) 
i
2 (C15), Å2 c 0.0005(1) 
i
2 (C16), Å2 c 0.0005(1) 
i
2 (C25), Å2 c 0.0005(1) 
      
aExperimental and calculated spectra are shown in Figure 3.13 (Chapter 3). bDesignations of 
parameters: -E0 is the threshold energy; S0
2 is the scale factor; 2 (Å2) is the Debye-Waller 
factor; and N is the number of scatterers in a shell. The values in the parentheses are the 
errors in the last significant figures, obtained from the Monte-Carlo analysis [ref. 27 in 
Chapter 3]. cThe atom numbering correspond to Figure 3.14 and the corresponding 
goodness-of-fit parameters are listed in Table 3.4 (Chapter 3). 
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Most significant Photoelectron Scattering Paths in the Calculated XAFS spectrum of  
OxaloRAPTA-C 
Path Legs Dege-
neracy 
i
2, Å2 Length, Å Contribution, 
% 
Ru0-O2 1 1 0.0015 2.11218 100.00% 
Ru0-O3 1 1 0.0015 2.0966 100.00% 
Ru0-P1 1 1 0.00045 2.32921 100.00% 
Ru0-C14 1 1 0.00821 2.06186 80.64% 
Ru0-C13 1 1 0.00821 2.08738 74.93% 
Ru0-C9 1 1 0.00821 2.10493 70.86% 
Ru0-C26 1 1 0.00047 2.93276 34.08% 
Ru0-C10 1 1 0.02025 2.20864 31.77% 
Ru0-C12 1 1 0.02025 2.20968 31.65% 
Ru0-O4-C25 2 1 0.0015 4.05239 29.22% 
Ru0-C25 1 1 0.00047 2.78688 28.93% 
Ru0-C11 1 1 0.02025 2.24975 27.73% 
Ru0-O-C26 2 1 0.0015 4.14683 22.64% 
Ru0-C15 1 1 0.00049 3.40879 21.00% 
Ru0-C26-O3 2 1 0.0008 3.14923 20.40% 
Ru0-C15-C9 2 1 0.00154 3.52929 20.03% 
Ru0-C18 1 1 0.00048 3.18836 19.34% 
Ru0-O2-Ru0-C13 2 1 0.0097 4.19956 18.38% 
Ru0-C19 1 1 0.00064 3.53617 16.76% 
Ru0-O3-Ru0-C9 2 1 0.0097 4.20153 15.58% 
Ru0-C21 1 1 0.00064 3.60924 14.04% 
Ru0-C25-O4-C25 1 1 0.00151 4.05458 13.84% 
Ru0-N7 2 1 0.00261 4.78301 13.64% 
Ru0-C20 1 1 0.00064 3.63468 13.22% 
Ru0-C16 1 1 0.0005 3.78661 13.18% 
Ru0-C26-N5-O3 2 1 0.00159 4.26026 13.09% 
Ru0-C26-O5-C26 1 1 0.00154 4.16348 13.07% 
Ru0-C17-C9 2 1 0.00084 4.64465 11.19% 
Ru0-O3-Ru0-C14 2 1 0.0097 4.15846 11.10% 
Ru0-O5 1 1 0.0015 4.13018 10.80% 
Ru0-O4 1 1 0.0015 4.0502 10.64% 
Ru0-O5-O3 2 1 0.00162 4.24361 10.15% 
Ru0-C25-O4-O2 2 1 0.00169 4.24924 9.89% 
Ru0-C11-Ru0-P1 2 1 0.0207 4.57896 9.81% 
Ru0-C25-O2 2 1 0.00092 3.09662 9.15% 
Continued on the next page 
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Path Legs Dege-
neracy 
i
2, Å2 Length, 
Å 
Contribution, 
% 
Ru0-C14-C13 2 1 0.01097 2.77398 9.10% 
Ru0-C9-C14 2 1 0.01096 2.78334 8.71% 
Ru0-O3-C14 2 1 0.00952 4.08284 8.24% 
Ru0-N6-P1 2 1 0.00261 4.92715 7.96% 
Ru0-C14-O2 2 1 0.00933 4.01561 7.68% 
Ru0-N8-C20 2 1 0.00256 5.03565 7.62% 
Ru0-N8-P1 2 1 0.00261 5.04675 7.44% 
Ru0-O2-C13 2 1 0.0097 4.19599 7.28% 
Ru0-C10-Ru0-P1 2 1 0.0207 4.53784 7.22% 
Ru0-O3-C9 2 1 0.00965 4.17907 7.14% 
Ru0-C19-P1 2 1 0.00071 3.86467 6.96% 
Ru0-C21-P1 2 1 0.00071 3.90249 6.89% 
Ru0-N7-C19 2 1 0.00254 4.89023 6.87% 
Ru0-N6-C21 2 1 0.00253 4.95675 6.83% 
Ru0-C20-P1 2 1 0.0007 3.915 6.72% 
Ru0-O4-O2 2 1 0.0017 4.24706 6.63% 
Ru0-O5-C26-O3 2 1 0.00196 4.36329 6.40% 
Ru0-N6 1 1 0.00261 4.84044 6.34% 
Ru0-N7-P1 2 1 0.0026 4.88979 6.27% 
Ru0-C26-O5-C26-O3 2 1 0.00203 4.37994 6.15% 
Ru0-C17 1 1 0.0005 4.59515 6.10% 
Ru0-C10-C11 2 1 0.02665 2.93435 5.94% 
Ru0-C10-C9 2 1 0.01925 2.8619 5.79% 
Ru0-C12-C13 2 1 0.01933 2.85348 5.59% 
Ru0-C17-C15 2 1 0.00054 4.75953 5.41% 
Ru0-O4-C25-O2 2 1 0.00211 4.36213 5.35% 
Ru0-C18-C12 2 1 0.00614 3.46319 5.33% 
Ru0-C26-C25 2 1 0.0006 3.636 5.01% 
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Table A.14 Conditions, restraints, and constraints used in MS XAFS fitting for  
[Ru(η6-p-cymene)Cl2(mimid)]
 a 
 
 
 
 
 
   Continued on the next page 
 
 
Conditions  
K range, Å1 : 0-15 b 
FT range, Å  : 1-4.5b  
Determinancy (Ni/p):
c 1.1 
Maximal effective path length of a photoelectron: 5.0 Å 
Maximum number of legs: 2 
Plane-wave path filter threshold: 0% 
Curved-wave path filter threshold: 0% 
Scale factor: 0.9  0.1 
  
Bond length restraints (Ǻ):d  
Ru0-Cl1  2.42 {0.05}  
Ru0-Cl2  2.42 {0.05} 
Ru0-C5  2.19 {0.04} 
Ru0-C8  2.19 {0.04} 
Ru0-N3  2.13 {0.05} 
 
Ru0-C5  Ru0-C6  Ru0-C7 {0.04} 
Ru0-C8  Ru0-C9  Ru0-C10 {0.02} 
 
C5-C11  1.5 {0.05} 
C12-C13  1.45 {0.05} 
N3-C15  1.35 {0.04} 
C5-C11  C8-C12 {0.05} 
C12-C13   C12-C14 {0.05} 
N3-C15  N3-C16 {0.02} 
N4-C15  1.35 {0.03} 
C5-C6  1.41 {0.03} 
C8-C9  1.41 {0.03} 
 
N4-C15   N4-C17   N4-C18 {0.02} 
C5-C6 C6-C7  C7-C8 {0.03} 
C8-C9  C9-C10  C10-C5{0.03} 
 
Bond angle restraints (°):d  
C6-C5-C10 = 120 {10} C6-C5-C10 = C5-C10-C9 = C10-C9-C8  {10} 
C9-C8-C7 = 120 {10} C9-C8-C7 = C8-C7-C6 = C5-C6-C7 {10} 
C15-N3-C16 = 108 {10} C15-N3-C16 =  N3-C16-C17 =  N4-C17-C16 
C15-N4-C17 = 108 {10} C15-N4-C17 =  N3-C15-N4 
Cl1-N3-Cl2 = 88 {10}  
Cl2-Ru0-N3 = 85 {3}  
N3-Ru0-Cl1 = 85 {3}  
  
Debye-Waller factor restraints (Å2):d  
0.001{0.0005} < i
2 < 0.02 {0.001}, i= 1-18  
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Debye-Waller factor constraints:d  
i
2 (Cl1) = i
2 (Cl2)   
i
2 (N4) = i
2 (N3)   
i
2 (C5) = i
2 (C6) = i
2 (C7)  
i
2 (C8) = i
2 (C9) = i
2 (C10)  
i
2 (C13) = i
2 (C14)  
  
Atoms restrained to be approximately coplanar  
(C5 – C10) x (C9 – C10)^ . (C7 - C10)  0 {0.1}  
(C6 – C7) x (C8 – C7)^ . (C10 – C7)  0 {0.1}  
  
 
aExperimental and calculated spectra are shown in Figure 3.15 (Chapter 3). bThe applied 
window functions are shown in Figure 3.15. cThe number of independent observations (Ni) 
and the number of varied parameters (p) were calculated taking into account the applied 
restraints and constraints [ref. 27 in Chapter 3]. d The atom numbering used in the MS XAFS 
calculation are shown in Figure 3.16 (Chapter 3). 
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Table A.15 Results of MS XAFS Analysis Fitting for [Ru(η6-p-cymene)Cl2(mimid)]
 a 
 
Parameterb  
-E0 15.09 
S0
2 0.97 
2 (Cl1), Å2 c 0.0022(6) 
2 (Cl2), Å2 c 0.0022(6) 
2 (N3), Å2 c 0.0005(1) 
2 (C5), Å2 c 0.0032(1) 
2 (C11), Å2 c 0.0005(1) 
2 (C12), Å2 c 0.0200(1) 
2 (C13), Å2 c 0.0005(1) 
2 (C15), Å2 c 0.0005(1) 
2 (C16), Å2 c 
2 (C17), Å2 c 
0.0112(5) 
0.0005(1) 
      
aExperimental and calculated spectra are shown in Figure 3.15 (Chapter 3). 
bDesignations of parameters: E0 is the threshold energy; S0
2 is the scale factor; 2 (Å2) 
is the Debye-Waller factor; and N is the number of scatterers in a shell. The values in 
the parentheses are the errors in the last significant figures, obtained from the 
Monte-Carlo analysis. cThe atom numbering correspond to Figure 3.16 and the 
corresponding goodness-of-fit parameters are listed in Table 3.5 (Chapter 3). 
 193 
Appendix A.16  
 
Most significant Photoelectron Scattering Paths in the Calculated XAFS spectrum of  
[Ru(η6-p-cymene)Cl2(mimid)]
    
Path Legs Dege-
neracy 
i
2, Å2 Length, 
Å 
Contribution, 
% 
  Ru0-N3                     1 1 0.0005 2.08738 100.00% 
  Ru0-C5                     1 1 0.00324 2.18977 68.65% 
  Ru0-Cl2                     1 1 0.00215 2.43541 68.27% 
  Ru0-Cl1                     1 1 0.00215 2.43626 68.19% 
  Ru0-C10                     1 1 0.00324 2.19433 67.79% 
  Ru0-C8                     1 1 0.00324 2.19475 67.70% 
  Ru0-C7                     1 1 0.00324 2.19488 67.68% 
  Ru0-C6                     1 1 0.00324 2.195 67.65% 
  Ru0-C9                     1 1 0.00324 2.19567 67.52% 
  Ru0-N3-Ru0-C6               2 1 0.00374 4.28237 31.32% 
  Ru0-C15                     1 1 0.0005 3.06561 29.83% 
  Ru0-C11                     1 1 0.0005 3.2586 23.40% 
  Ru0-C15-N3                  2 1 0.00057 3.26645 19.89% 
  Ru0-C16                     1 1 0.01121 3.02149 19.80% 
  Ru0-C14-C8                  2 1 0.0005 4.46432 18.13% 
  Ru0-N4-N3                  2 1 0.00053 4.20549 17.30% 
  Ru0-C11-C5                  2 1 0.00119 3.47166 15.78% 
  Ru0-C17-N3                  2 1 0.00052 4.19735 14.48% 
  Ru0-N3-C6                  2 1 0.00374 4.28187 13.43% 
  Ru0-N4                     1 1 0.0005 4.12937 12.85% 
  Ru0-C16-N3                  2 1 0.01025 3.2302 12.64% 
  Ru0-C10-C5                  2 1 0.00428 2.89668 12.35% 
  Ru0-C6-C5                  2 1 0.00428 2.89696 12.34% 
  Ru0-C8-C7                  2 1 0.00428 2.89947 12.24% 
  Ru0-N4-C15                  2 1 0.00053 4.27217 12.24% 
  Ru0-C6-C7                  2 1 0.00428 2.89956 12.23% 
  Ru0-C10-C9                  2 1 0.00428 2.89962 12.23% 
  Ru0-C9-C8                  2 1 0.00428 2.89987 12.22% 
  Ru0-C17-C16                  2 1 0.00172 4.23886 11.90% 
  Ru0-C17                     1 1 0.0005 4.13395 11.75% 
  Ru0-C13                     1 1 0.0005 4.09106 11.42% 
  Ru0-C12-C8                  2 1 0.01959 3.656 10.65% 
  Ru0-C5-Ru0-N3               2 1 0.00374 4.27715 10.31% 
  Ru0-C7-Ru0-N3               2 1 0.00374 4.28225 10.23% 
Continued on the next page 
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Path Legs Dege-
neracy 
i
2, Å2 Length, 
Å 
Contribution, 
% 
  Ru0-C7-N3                  2 1 0.00364 4.1622 10.10% 
  Ru0-C5-N3                  2 1 0.00364 4.15761 10.09% 
  Ru0-C12                     1 1 0.02 3.5566 9.84% 
  Ru0-C16-C17-N3               2 1 0.00173 4.30226 9.57% 
  Ru0-C8-Ru0-Cl2               2 1 0.00539 4.63016 9.54% 
  Ru0-C8-C14-C8               1 1 0.0005 4.46445 8.09% 
  Ru0-C15-N4-N3               2 1 0.00056 4.3483 6.97% 
  Ru0-C14                     1 1 0.0005 4.46418 6.88% 
  Ru0-C10-Ru0-Cl1               2 1 0.00539 4.63059 6.58% 
  Ru0-N3-C17-N3               1 1 0.00062 4.26075 6.41% 
  Ru0-N3-N4-N3               1 1 0.00064 4.28161 5.57% 
  Ru0-C10-N3                  2 1 0.00342 3.89907 4.86% 
  Ru0-C8-N3                  2 1 0.00342 3.89931 4.86% 
  Ru0-C8-Cl2                  2 1 0.00534 4.58158 4.83% 
  Ru0-C8-C12-C8               1 1 0.02138 3.75539 4.62% 
  Ru0-C11-Cl2                  2 1 0.00174 4.23632 4.54% 
  Ru0-N3-C15-N3               1 1 0.00095 3.4673 4.51% 
  Ru0-N3-C17-C16-N3            2 1 0.00451 4.51097 4.44% 
  Ru0-C10-Cl1                  2 1 0.00529 4.54514 4.36% 
  Ru0-C15-N3-C15-N3            2 1 0.0027 4.64637 4.26% 
  Ru0-N3-Ru0-N3               1 1 0.002 4.17476 4.14% 
  Ru0-C17-C16-N3               2 1 0.0044 4.44758 4.01% 
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       Table A.17  Conditions, restraints, and constraints used in MS XAFS fitting for Ru2(OH)3
a 
 
Condition  
K range: 0-16 Å-1 b 
FT range : 1-4.5 Å b  
Determinancy (Ni/p):
c 1  
Maximal effective path length of a photoelectron: 5.0 Å 
Maximum number of legs: 8  
Plane-wave path filter threshold: 0%  
Curved-wave path filter threshold: 0%  
Scale factor: 0.9  0.1  
  
Bond length restraints (Å)  
Ru0 Ru1  2.95 {0.05}  
Ru0O2  2.09 {0.05} Ru0- O2  Ru0- O3  Ru0- O4 {0.05} 
Ru1O2  2.09 {0.03} Ru1 O2  Ru1O3 Ru1O4 {0.05} 
Ru0C5  2.18 {0.03} Ru0C5  Ru0C6  Ru0C7 {0.03} 
Ru0C8  2.18 {0.03} Ru0C8  Ru0C9  Ru0C10 {0.03} 
Ru1C15  2.18 {0.03} Ru1C15  Ru1C16 Ru1C17 {0.03} 
Ru1C18  2.18 {0.03} Ru1C18  Ru1C19 Ru1C20 {0.03} 
C7C11  1.52 {0.05} C7C11  C10C14  C14C12 C14C13 {0.05} 
C17C21  1.52 {0.05} C17C21  C20C24  C24C23 C24C22 {0.05} 
C5C6  1.41 {0.02} C5C6  C6C7  C7C8 {0.01} 
C8C9  1.41 {0.02} C8C9  C9C10  C10C5 {0.01} 
C15C16  1.41 {0.02} C15C16  C16C17  C17C18 {0.01} 
C18C19  1.41 {0.02} C18C19  C19C20  C20C15 {0.01} 
x6  0 {0.2} 
x9  0 {0.2} 
 
  
Bond angle restraints (°):  
C16C15C20  120 {5} C
16-C15-C20 = C17-C16-C15= C18-C17-C16 {5} 
C19C18C17  120 {5} C19C18C17 = C20C19C18= C15C20C19 {5} 
C6C5C10  120 {5} C
6-C5-C10 = C7-C6-C5= C8-C7-C6 {5}  
C9C8C7  120 {5} C9C8C7 = C10C9C8= C5C10C9 {5} 
C8C7C11  120 {10} C8C7C11 = C6C7C11= C5C10C14 {10} 
C14C10C9  120 {10} 
C15C20C24  120 {10} 
C14C10C9 = C18C17C21= C16C17C21 {10} 
C15C20C24 = C24C20C19{10} 
C12C14C13  110 {10} C10C14C12 = C10C14C13{10} 
C22C24C23  110 {10} C22C24C23= C20C24C22= C20C24C23{10} 
O3Ru0O2  78 {3} O3Ru0O2 = O2Ru0O4 = O4Ru0O3 {3} 
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O3Ru1O2  78 {3} 
Ru1O4Ru0  90 {6} 
O3Ru1O2 = O2Ru1O4 = O4Ru1O3 {3} 
Ru1O4Ru0 = Ru1O3Ru0 =Ru1O2Ru0 {6} 
 
 Debye-Waller factor restraints (Å2):  
 0.001{0.0005} < i
2 < 0.02 {0.001}, i= 1-24  
  
Debye-Waller factor constraints:  
i
2 (C15) = i
2 (C16) = i
2 (C17)   
i
2 (C18) = i
2 (C19) = i
2 (C20)   
i
2 (C5) = i
2 (C6) = i
2 (C7) = i
2 (C8) = i
2 (C9) = i
2 (C10)  
 
Atoms restrained to be approximately coplanar  
(C17 – C16) x (C15 – C16)^.(C19 – C16)  0 {0.1}  
(C18 – C19) x (C20 – C19)^.(C16 – C19)  0 {0.1}  
(C5 – C6) x (C7 – C6)^.(C9 – C6)  0 {0.1}  
(C10 – C9) x (C8 – C9)^.(C6 – C9)  0 {0.1}  
(C7 – C8) x (C9 – C8)^.(C11 – C8)  0 {0.1}  
(C17 – C18) x (C19 – C18)^.(C21 – C18)  0 {0.1}  
  
 
aExperimental and calculated spectra are shown in Figure 3.17 (Chapter 3). bThe applied 
window functions are shown in Figure 3.17. cThe number of independent observations (Ni) 
and the number of varied parameters (p) were calculated taking into account the applied 
restraints and constraints [ref. 27 in Chapter 3]. d The atom numbering used in the MS XAFS 
calculation are shown in Figure 3.18 (Chapter 3). 
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Table A.18 Results of MS XAFS Analysis Fitting for Ru2(OH)3
 a 
 
Parameterb  
-E0 18.44 
S0
2 0.97 
i
2 (Ru1), Å2 c 0.0105(2)  
i
2 (O2), Å2 c 0.0029(3) 
i
2 (O3), Å2 c 0.0015(1) 
i
2 (O4), Å2 c 0.0073(8) 
i
2 (C5), Å2 c 0.0053(2) 
i
2 (C11), Å2 c 0.0200(1) 
i
2 (C15), Å2 c 0.0200(4) 
i
2 (C14), Å2 c 0.0005(1) 
      
aExperimental and calculated spectra are shown in Figure 3.17 (Chapter 3). bDesignations of 
parameters:  E0 is the threshold energy; S0
2 is the scale factor; 2 (Å2) is the Debye-Waller 
factor; and N is the number of scatterers in a shell. The values in the parentheses are the 
errors in the last significant figures, obtained from the Monte-Carlo analysis. cThe atom 
numbering corresponds to Figure 3.18 and the corresponding goodness-of-fit parameters 
are listed in Table 3.6 (Chapter 3). 
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Most significant Photoelectron Scattering Paths in the Calculated XAFS spectrum of  
Ru2(OH)3 
 
Path Legs Dege-
neracy 
i
2, Å2 Length, 
Å 
Contribution,  
% 
Ru0-C5 4 1 0.0005 2.09429 100.00% 
Ru0-O3 2 1 0.00051 2.15933 44.57% 
Ru0-C9 2 1 0.0005 2.1764 39.38% 
Ru0-O2 1 1 0.00049 2.03193 32.25% 
Ru0-C6-C5 8 1 0.00066 2.84099 15.28% 
Ru0-Ru1 1 1 0.0016 2.98443 11.92% 
Ru0-O2-Ru0-C8 4 1 0.00099 4.19198 11.03% 
Ru0-C17-Ru1 8 1 0.00104 5.03202 10.77% 
Ru0-C5-Ru0-O4 4 1 0.0205 4.21857 10.09% 
Ru0-C11 2 1 0.00049 3.34406 9.79% 
Ru0-O2-Ru0-C9 2 1 0.00099 4.20833 8.90% 
Ru0-C6-Ru0-O3 4 1 0.00101 4.33574 7.69% 
Ru0-C14-C10 4 1 0.00056 3.48712 7.59% 
Ru0-O2-C8 4 1 0.00097 4.12573 7.49% 
Ru0-C8-C7 4 1 0.00066 2.87923 7.22% 
Ru0-C15 4 1 0.00091 4.88647 6.78% 
Ru0-C6-C8 8 1 0.00078 3.39504 4.39% 
Ru0-C5-O4 4 1 0.02044 4.20463 4.23% 
Ru0-C12 1 1 0.00511 3.59909 4.20% 
Ru0-O2-C9 2 1 0.00099 4.19533 3.69% 
Ru0-O3-O2 4 1 0.00081 3.40304 3.60% 
Ru0-Ru1-C8 8 1 0.00205 4.98994 3.53% 
Ru0-O4-C10 4 1 0.02018 4.22385 3.47% 
Ru0-C5-Ru0-C5 4 1 0.002 4.18859 3.42% 
Ru0-C16 2 1 0.00091 4.92418 3.40% 
Ru0-C13-C10 2 1 0.0005 4.52519 3.37% 
Ru0-C19-Ru1 4 1 0.0011 4.97512 3.25% 
Ru0-C6-O4 4 1 0.01947 4.08848 2.98% 
Ru0-O2-C7 4 1 0.00092 3.89956 2.73% 
Ru0-C13 1 1 0.0005 4.50229 2.42% 
Ru0-C10-C5-C10 4 1 0.00187 3.5788 2.32% 
Ru0-C9-C10-C9-C10 8 1 0.00299 4.2905 2.27% 
Continued on the next page 
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Path Legs Dege-
neracy 
i
2, Å2 Length, 
Å 
Contribution, 
% 
Ru0-C7-C8-C6 8 1 0.00119 4.11422 2.21% 
Ru0-C7-C5 4 1 0.00078 3.35098 2.14% 
Ru0-C9-C8-C9 4 1 0.00183 3.58872 2.09% 
Ru0-C13-C14 2 1 0.00053 4.65536 2.00% 
Ru0-C8-C5 4 1 0.00083 3.52658 1.99% 
Ru0-C9-C8-C10 8 1 0.00119 4.08938 1.99% 
Ru0-C10-C9-C10 4 1 0.00182 3.57903 1.96% 
Ru0-C7-C5-C8 8 1 0.00128 4.78326 1.96% 
Ru0-C10-C9-C5 8 1 0.00118 4.06318 1.90% 
Ru0-C6-C5-C10 8 1 0.00081 3.58324 1.87% 
Ru0-C5-C9-C6 8 1 0.00127 4.79234 1.83% 
Ru0-C6-C7-Ru0-O3 4 1 0.00117 5.0468 1.80% 
Ru0-C9-C7-C10 8 1 0.00126 4.80107 1.78% 
Ru0-C6-Ru0-C8 8 1 0.001 4.33645 1.77% 
Ru0-O3-Ru0-C8 4 1 0.00101 4.31938 1.70% 
Ru0-Ru1-C9 4 1 0.00205 5.00085 1.70% 
Ru0-C9-Ru0-C9 2 1 0.002 4.3528 1.67% 
Ru0-C14-C9 4 1 0.0007 4.01522 1.66% 
Ru0-C14-C13-C10 2 1 0.00052 4.67827 1.63% 
Ru0-Ru1-C4 4 1 0.01149 3.61618 1.40% 
Ru0-C10-C14-C10 2 1 0.0009 3.6773 1.34% 
Ru0-C10-C9-Ru0-O2 4 1 0.00115 4.90965 1.29% 
Ru0-O3-O4 2 1 0.01643 3.44922 1.15% 
Ru0-C8-C7-C8-C7 4 1 0.00298 4.28938 1.13% 
Ru0-C7-C6-C8-C7 8 1 0.00189 4.82528 1.13% 
Ru0-O4-C7 4 1 0.01812 3.82733 1.11% 
Ru0-C5-C7-C5 4 1 0.00204 4.5137 1.10% 
Ru0-C6-C10-C6 4 1 0.00207 4.63329 1.05% 
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Table A.20 Conditions, restrains, and constrains used in MS XAFS fitting for  
[Ru(η6-p-cymene)(tsal)]2 
a 
 
Condition  
K range: 0-16 Å-1 b 
FT range : 1-4.5 Åb  
Determinancy (Ni/p):
c 1.2  
Maximal effective path length of a photoelectron: 5.0 Å 
Maximum number of legs: 6  
Plane-wave path filter threshold: 0%  
Curved-wave path filter threshold: 0%  
Scale factor: 0.9  0.1  
  
Bond length restraints (Å)  
Ru0 S1  2.39 {0.02} Ru0 S1 Ru21- S22 {0.02} 
Ru0O2  2.09 {0.02} Ru0O2  Ru21O23{0.02} 
Ru0S22  2.42 {0.02} Ru0S22  Ru1S21 {0.02} 
O3C4  1.25 {0.02} O3- C4  O2- C4 {0.02} 
S1C6  1.78 {0.04} S1C6  S22C27 {0.02} 
C4C5  1.51 {0.04} C4C5  C25C26 {0.04} 
Ru0C12  2.18 {0.02} Ru0 C12  Ru0C13 Ru0C14 Ru0C16  Ru0C17 {0.02} 
C5C6  1.41 {0.02} C5C6  C6C7  C7C8 C8C9 {0.01} 
C9C10  1.41 {0.02} C9C10  C10C5 {0.01} 
C12C13  1.41 {0.02} C12C13  C13C14  C14C15 {0.01} 
C15C18  1.52 {0.02} C15C18  C18C19  C18C20 C12C11 {0.02} 
C18C19  1.41 {0.02} C18C19  C19C20  C20C15 {0.01} 
Ru21C33  2.18 {0.02} Ru21 C33  Ru21C34 Ru21C35 {0.02} 
Ru21C36  2.18 {0.02} Ru21 C36  Ru21C37 Ru21C38 {0.02} 
C26C27  1.41 {0.02} C26C27  C27C28  C28C29 C29C30 {0.01} 
C30C31  1.41 {0.02} C30C31  C31C26 {0.01} 
C33C34  1.41 {0.02} C33C34  C34C35  C35C36 C36C37 {0.01} 
C37C38  1.41 {0.02} C37C38  C38C23 {0.01} 
C32C33  1.52 {0.05} C32C33  C36C39  C39C40 C39C41 {0.05} 
  
Bond angle restraints (°):  
C12C13C14  120 {2} C
12-C13-C14 = C17-C12-C13= C12-C17-C16 {2} 
C17C16C15  120 {2} C17C16C15 = C16C15C14= C13C14C15 {2} 
C18C15C14  120 {3} C
18-C15-C14 = C18-C15-C16 {3}  
O2Ru0S1  88 {5} O2Ru0S1 = O22Ru21S1 {5} 
O2Ru0S22  78 {5} O2Ru0S22 = O23Ru21S1 {5} 
S1Ru0S22  81 {5} S1Ru0S22 = S1Ru21S22 {5} 
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C6S1Ru0  105 {5} C6S1Ru0 = C27S22Ru21 {5} 
C6S1Ru21  112 {5} C6S1Ru21 = C27S22Ru0{5} 
Ru0S1Ru21  99 {5} Ru0S1Ru21= Ru0S22Ru21{5} 
C4C5C6  124 {5} C4C5C6 = C25C26C27 {5} 
C4O2Ru0  134 {5} C4O2Ru0 = C25O23Ru21 {5} 
C10C5C4  117 {5} C10C5C4 = C26C25C24 {5} 
O3C4O2  122 {5} O3C4O2 = O24C25O23 {5} 
C5C6S1  124 {5} C5C6S1 = C25C26S27 {5} 
O3C4C5  118 {5} O3C4C5 = O24C25C26 {5} 
C7C6S1  116 {5} C7C6S1 = C28C27S22{5} 
C10C5C6  120 {2} C10C5C6 = C7C6C5= C8C7C6= C9C8C7 {2} 
C37C36C35  120 {2} C37C36C35= C34C35C36= C33C34C35 
= C38C33C34{2} 
C37C36C35  120 {3} C37C36C35= C35C36C39 {3} 
C26C27C28  120 {2} C26C27C28= C27C28C29= C30C29C28= C30C29C28 
= C31C30C29= C26C31C30= C27C26C31{2} 
C40C39C41  110 {5}  
  
Debye-Waller factor restraints (Å2):  
 0.001{0.0005} < i
2 < 0.02 {0.001}, i= 1-41  
  
Debye-Waller factor constraints:  
i
2 (C19) = i
2 (C20)   
i
2 (C40) = i
2 (C41)   
i
2 (C5) = i
2 (C6) = i
2 (C10) = i
2 (C9) = i
2 (C8)   
i
2 (C15) = i
2 (C16) = i
2 (C14) = i
2 (C12) = i
2 (C13) 
i
2 (C38) = i
2 (C37) = i
2 (C33) = i
2 (C34) = i
2 (C35) 
i
2 (C26) = i
2 (C27) = i
2 (C28) 
i
2 (C30) = i
2 (C31) = i
2 (C29) 
i
2 (O3) = i
2 (O24)  
 
Atoms restrained to be approximately coplanar  
(C16 – C15) x (C14 – C15)^.(C12 – C15)  0 {0.1} (C27 – C26) x (C31 – C26)^.(C29 – C26)  0 {0.1} 
(C13 – C12) x (C17 – C12)^.(C15 – C12)  0 {0.1} (C28 – C29) x (C30 – C29)^.(C26 – C29)  0 {0.1} 
(C38 – C33) x (C34 – C33)^.(C36 – C33)  0 {0.1} (C5 – C6) x (C7 – C6)^.(C9 – C6)  0 {0.1} 
(C35 – C36) x (C37 – C36)^.(C33 – C36)  0 {0.1} (C10 – C9) x (C8 – C9)^.(C6 – C9)  0 {0.1} 
  
 
aExperimental and calculated spectra are shown in Figure 3.19 (Chapter 3). bThe applied 
window functions are shown in Figure 3.19. cThe number of independent observations (Ni) 
and the number of varied parameters (p) were calculated taking into account the applied 
restraints and constraints [ref. 27 in Chapter 3]. d The atom numbering used in the MS XAFS 
calculation are shown in Figure 3.20 (Chapter 3). 
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Appendix A.21 
 
Table A.21 Results of MS XAFS Analysis Fitting for [Ru(η6-p-cymene)(tsal)]2
a 
 
Parameterb  
-E0 17.10 
S0
2 0.97 
i
2 (S1), Å2 c 0.0011(2) 
i
2 (O2), Å2 c 0.0051(3) 
i
2 (O3), Å2 c 0.0005(1) 
i
2 (C4), Å2 c 0.0200(1) 
i
2 (C5), Å2 c 0.0005(4) 
i
2 (C12), Å2 c 0.0083(3) 
i
2 (C14), Å2 c 0.0017(4) 
i
2 (C17), Å2 c 0.0083(3) 
i
2 (Ru21), Å2 c 0.0037(4) 
i
2 (S22), Å2 c 0.0019(3) 
i
2 (O23), Å2 c 0.0033(10) 
i
2 (O24), Å2 c 0.0005(1) 
i
2 (C25), Å2 c 0.0005(5) 
      
aExperimental and calculated spectra are shown in Figure 3.19 (Chapter 3). bDesignations of 
parameters: E0 is the threshold energy; S0
2 is the scale factor; 2 (Å2) is the Debye-Waller 
factor; and N is the number of scatterers in a shell. The values in the parentheses are the 
errors in the last significant figures, obtained from the Monte-Carlo analysis. cThe atom 
numbering correspond to Figure 3.20 and the corresponding goodness-of-fit parameters are 
listed in Table 3.7 (Chapter 3). 
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Appendix A.22 
 
 
 
 
Most significant Photoelectron Scattering Paths in the Calculated XAFS spectrum of  
[Ru(η6-p-cymene)(tsal)]2 
 
Path Legs Dege-
neracy 
i
2, Å2 Length, Å Contribution, % 
Ru0-O2 1 1 0.0051 2.09454 100.00% 
Ru0-C13 3 1 0.00828 2.18353 100.00% 
Ru0-C16 3 1 0.00174 2.18727 100.00% 
Ru0-S1 1 1 0.00114 2.37646 44.32% 
Ru0-S22 1 1 0.00193 2.41089 40.79% 
Ru0-C4-O2 2 1 0.01952 3.22682 10.66% 
Ru0-C27 1 1 0.0005 3.48983 10.36% 
Ru0-C5 1 1 0.0005 3.55062 9.85% 
Ru0-C11 1 1 0.0005 3.41044 9.40% 
Ru0-C6 1 1 0.0005 3.30233 9.18% 
Ru0-C18 1 1 0.00104 3.30126 9.07% 
Ru0-Ru21 1 1 0.00374 3.63717 9.01% 
Ru0-O3-O2 2 1 0.00082 4.21889 8.89% 
Ru0-C17-C12 4 1 0.01095 2.88526 8.32% 
Ru0-C15-Ru0-S22 2 1 0.00366 4.59305 8.30% 
Ru0-C4 1 1 0.02 3.10166 8.06% 
Ru0-O2-Ru0-C14 2 1 0.00684 4.27509 7.92% 
Ru0-O23 1 1 0.0033 3.87207 7.52% 
Ru0-C11-C12 2 1 0.00176 3.55608 7.30% 
Ru0-O3-C4 2 1 0.00269 4.2508 7.04% 
Ru0-C26 1 1 0.0005 3.96622 6.80% 
Ru0-O2-Ru0-C13 2 1 0.01338 4.27807 6.57% 
Ru0-C19 1 1 0.0005 3.95957 6.53% 
Ru0-C20-C15 2 1 0.00053 4.49197 6.33% 
Ru0-C18-C15 2 1 0.00132 3.50156 6.26% 
Ru0-C17-Ru0-S1 2 1 0.00942 4.55763 6.06% 
Ru0-C16-Ru-S22 2 1 0.00366 4.59816 6.04% 
Ru0-C25 1 1 0.0005 3.81965 6.03% 
Ru0-C15-C14 2 1 0.0023 2.88512 5.65% 
Ru0-C16-C15 2 1 0.0023 2.88849 5.62% 
Ru0-O3 1 1 0.0005 4.14979 5.62% 
Ru0-C6-S1 2 1 0.00086 3.72996 5.58% 
Ru0-C4-O3-O2 2 1 0.00301 4.3199 5.51% 
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Path Legs Dege-
neracy 
i
2, Å2 Length, 
Å 
Contribution, 
% 
Ru0-O24 1 1 0.0005 4.49107 5.07% 
Ru0-C12-Ru0-S1 2 1 0.00942 4.55832 5.06% 
Ru0-C7-C6 2 1 0.00052 4.6164 5.04% 
Ru0-C14-C13 2 1 0.00663 2.88578 4.82% 
Ru0-C16-C17 2 1 0.00661 2.88797 4.80% 
Ru0-C10-C5 2 1 0.00051 4.92431 4.79% 
Ru0-O2-C14 2 1 0.00675 4.22377 4.72% 
Ru0-C20 1 1 0.0005 4.47337 4.46% 
Ru0-C7 1 1 0.0005 4.52167 4.43% 
Ru0-C28 1 1 0.0005 4.54894 4.29% 
Ru0-C15-S22 2 1 0.00365 4.57161 4.03% 
Ru0-O2-C13 2 1 0.01322 4.2266 3.91% 
Ru0-C15-C20-C15 1 1 0.00061 4.51057 3.67% 
Ru0-C16-S22 2 1 0.00362 4.54183 3.63% 
Ru0-O2-O3-O2 1 1 0.00179 4.28799 3.61% 
Ru0-O2-C4-O2 1 1 0.02313 3.35198 3.59% 
Ru0-C27-S22 2 1 0.00105 3.84141 3.59% 
Ru0-C28-C27 2 1 0.00054 4.72414 3.44% 
Ru0-C16-Ru0-C16 3 1 0.00695 4.37455 3.32% 
Ru0-O3-C4-O2 2 1 0.00595 4.37596 3.32% 
Ru0-C17-S1 2 1 0.00933 4.51859 3.24% 
Ru0-C34 1 1 0.0005 4.93414 3.23% 
Ru0-C35 1 1 0.0005 4.93441 3.23% 
Ru0-C10 1 1 0.0005 4.8895 3.12% 
Ru0-C15-C13 4 1 0.0078 3.40162 3.02% 
Ru0-C12-S1 2 1 0.00929 4.49945 3.02% 
Ru0-C20-C18 2 1 0.00063 4.6475 2.98% 
Ru0-C18-C20-C15 2 1 0.00064 4.66611 2.71% 
Ru0-C5-C10-C5 1 1 0.00057 4.95912 2.68% 
Ru0-C18-C14 4 1 0.0018 4.0079 2.66% 
Ru0-C15-O2 2 1 0.00633 3.96402 2.31% 
Ru0-C4-O3-C4 1 1 0.00936 4.3518 2.29% 
Ru0-O2-O3-C4-O2 2 1 0.00706 4.44506 2.17% 
Ru0-C12-O2 2 1 0.01241 3.96363 1.90% 
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Appendix A.23  
 
Table A.23 Conditions, restrains, and constrains used in MS XAFS fitting for  
[(η6-p-cymene)Ru(en)SPh] a 
 
Condition  
K range: 0-15 Å-1 b 
FT range : 1-4.5 Å b  
Determinancy (Ni/p):
c 1.1  
Maximal effective path length of a photoelectron: 5.0 Å 
Maximum number of legs: 2  
Plane-wave path filter threshold: 0%  
Curved-wave path filter threshold: 
0% 
 
Scale factor: 0.9  0.1  
  
Bond length restraints (Å)  
Ru0 N1  2.13 {0.03} Ru0 N1 Ru0- N2 {0.03} 
Ru0S3  2.39 {0.05}  
N1C4  1.45 {0.05} N1C4  N2C5 {0.05} 
C4C5  1.41 {0.05}  
C12C13  1.50 {0.04} C12C13  C12C14 {0.04} 
C9C12  1.51 {0.05} C9C12  C6C15 {0.05} 
Ru0C6  2.10 {0.03} Ru0 C6  Ru0C7 Ru0C8 {0.03} 
Ru0C9  2.10 {0.03} Ru0C9  Ru0C10 Ru0C11 {0.03} 
S3C21  1.77 {0.05}  
C6C7  1.41 {0.02} C6C7  C7C8  C8C9 C9C10 C10C11  
  C11C6 {0.01} 
C21C16  1.41 {0.02} C21C16  C16C17  C17C18 C18C19 } 
  C19C20  C20C21 {0.01} 
  
  
Bond angle restraints (°):  
C7C6C11  120 {2} C
7-C6-C11 = C6-C7-C8= C7-C8-C9  
 = C8C9C10 = C9C10C11= C10C11C6 {2} 
C8C9C12  120 {5} C
8-C9-C12 = C10-C9-C12 = C7-C6-C15 = C11-C6-C15 {5}  
C13C12C9  110 {5} C13C12C9 = C14C12C9 {5} 
C16C21C20  120 {2} C
16-C21-C20 = C21-C16-C17= C18-C17-C16  
 = C19C18C17 = C20C19C18= C19C20C21 {2} 
N1Ru0N2  79 {8}  
S3Ru0N2  83 {6}  
S3Ru0N1  84 {6}  
Ru0N1C4  123 {10} Ru0N1C4 = Ru0N2C5 {10} 
N1C4C5  110 {10} N1C4C5 = C4C5N2 {10} 
  
  Continued on the next page 
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Debye-Waller factor restraints (Å2):  
 0.001{0.0005} < i
2 < 0.02 {0.001}, i= 1-21  
  
Debye-Waller factor constraints:  
i
2 (C13) = i
2 (C14)   
i
2 (C10) = i
2 (C11) = i
2 (C6)  
i
2 (C6) = i
2 (C7) = i
2 (C8) = i
2 (C9) = i
2 (C10)   
i
2 (C21) = i
2 (C16) = i
2 (C17) = i
2 (C18) = i
2 (C19) 
i
2 (C19) = i
2 (C20) = i
2 (C21)  
 
Atoms restrained to be approximately 
coplanar 
 
(C9 – C10) x (C11 – C10)^.(C7 – C10)  0 {0.1}  
(C8 – C7) x (C6 – C7)^.(C10 – C7)  0 {0.1}  
(C16 – C21) x (C20 – C21)^.(C18 – C21)  0 {0.1}  
(C17 – C18) x (C19 – C18)^.(C21 – C18)  0 {0.1}  
  
 
aExperimental and calculated spectra are shown in Figure 3.21 (Chapter 3). bThe applied 
window functions are shown in Figure 3.21. cThe number of independent observations (Ni) 
and the number of varied parameters (p) were calculated taking into account the applied 
restraints and constraints [ref. 27 in Chapter 3]. d The atom numbering used in the MS XAFS 
calculation are shown in Figure 3.22 (Chapter 3). 
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Appendix A.24 
 
 
Table A.24   Results of MS XAFS Analysis Fitting for [(η6-p-cymene)Ru(en)SPh] a 
 
Parameterb  
-E0 15.72 
S0
2 0.94 
i
2 (N1), Å2 c 0.0001(4) 
i
2 (N2), Å2 c 0.0001(4) 
i
2 (S3), Å2 c 0.0002(1) 
i
2 (C6), Å2 c 0.0035(2) 
i
2 (C12), Å2 c 0.0005(1) 
i
2 (C13), Å2 c 0.0005(1) 
i
2 (C15), Å2 c 0.0005(1) 
i
2 (C21), Å2 c 0.0005(1) 
     
aExperimental and calculated spectra are shown in Figure 3.21 (Chapter 3). bDesignations of 
parameters: E0 is the threshold energy; S0
2 is the scale factor; 2 (Å2) is the Debye-Waller 
factor; and N is the number of scatterers in a shell. The values in the parentheses are the 
errors in the last significant figures, obtained from the Monte-Carlo analysis. cThe atom 
numbering correspond to Figure 3.22 and the corresponding goodness-of-fit parameters are 
listed in Table 3.8 (Chapter 3). 
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Appendix A.25 
 
 
 
 
 
Most significant Photoelectron Scattering Paths in the Calculated XAFS spectrum of  
[(η6-p-cymene)Ru(en)SPh] 
 
Path Legs Dege-
neracy 
i
2, Å2 Length, Å Contribution, 
% 
Ru0-C11 2 1 0.0047 2.10564 100.00% 
Ru0-S3 1 1 0.00063 2.33274 100.00% 
Ru0-C9 2 1 0.0047 2.10804 99.69% 
Ru0-N2 1 1 0.0005 2.14351 89.70% 
Ru0-N1 1 1 0.00313 2.1227 73.77% 
Ru0-C8 1 1 0.0047 2.10557 50.00% 
Ru0-C7 1 1 0.0047 2.10678 49.92% 
Ru0-C21 1 1 0.0005 2.58807 33.09% 
Ru0-C5 1 1 0.0005 3.21741 22.54% 
Ru0-C20 1 1 0.0005 3.01409 20.43% 
Ru0-C12-C9 2 1 0.00103 3.50434 19.84% 
Ru0-C15-C6 2 1 0.00105 3.50612 19.28% 
Ru0-C6-Ru0-N1 2 1 0.00783 4.23014 19.07% 
Ru0-C16 1 1 0.0005 3.52852 15.79% 
Ru0-C10-Ru0-S3 2 1 0.00532 4.43732 15.23% 
Ru0-C15 1 1 0.0005 3.3952 14.47% 
Ru0-C5-N2 2 1 0.00056 3.41192 14.41% 
Ru0-C12 1 1 0.0005 3.39857 14.24% 
Ru0-C8-Ru0-N2 2 1 0.00519 4.24908 13.62% 
Ru0-C7-Ru0-N2 2 1 0.00519 4.25029 13.11% 
Ru0-C14 1 1 0.0005 3.7311 12.78% 
Ru0-C11-C10 2 1 0.00628 2.81377 12.19% 
Ru0-C7-C8 2 1 0.00628 2.81481 12.19% 
Ru0-C9-C10 2 1 0.00628 2.81495 12.18% 
Ru0-C6-C11 2 1 0.00627 2.81519 12.18% 
Ru0-C9-C8 2 1 0.00627 2.81543 12.18% 
Ru0-C6-C7 2 1 0.00627 2.81561 12.18% 
Ru0-C13-C9 2 1 0.0005 4.53688 11.02% 
Ru0-C4 1 1 0.02001 3.16709 10.96% 
Ru0-C21-S3 2 1 0.00075 3.34167 10.24% 
Ru0-C19 1 1 0.0005 4.11114 9.87% 
Ru0-C9-Ru0-S3 2 1 0.00532 4.44078 9.47% 
Ru0-C19-C20 2 1 0.00054 4.26664 8.43% 
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Path Legs Dege-
neracy 
i
2, Å2 Length, 
Å 
Contribution, 
% 
Ru0-C8-N2 2 1 0.00513 4.1992 7.91% 
Ru0-C7-N2 2 1 0.00513 4.19684 7.87% 
Ru0-C10-S3 2 1 0.0053 4.42266 7.63% 
Ru0-C6-N1 2 1 0.00781 4.22052 7.61% 
Ru0-C4-N1 2 1 0.01899 3.37438 7.08% 
Ru0-C16-C21 2 1 0.00056 3.76235 7.05% 
Ru0-C13 1 1 0.0005 4.53531 7.04% 
Ru0-C9-C13-C9 1 1 0.00052 4.53846 6.73% 
Ru0-C9-C12-C9 1 1 0.0027 3.61011 6.64% 
Ru0-C17 1 1 0.0005 4.57393 6.52% 
Ru0-C6-C15-C6 1 1 0.0028 3.61705 6.14% 
Ru0-C9-S3 2 1 0.00524 4.38232 6.05% 
Ru0-N1-C7 2 1 0.00754 4.07251 5.66% 
Ru0-N1-C11 2 1 0.00753 4.06966 5.60% 
Ru0-C18 1 1 0.0005 4.79633 5.25% 
Ru0-C13-C12 2 1 0.00054 4.71465 5.01% 
Ru0-S3-C11 2 1 0.00507 4.24874 4.91% 
Ru0-C17-C16 2 1 0.00054 4.75529 4.81% 
Ru0-C20-S3 2 1 0.00079 3.90608 4.64% 
Ru0-C21-C10 2 1 0.00503 4.56687 4.09% 
Ru0-S3-C8 2 1 0.00495 4.1522 3.93% 
Ru0-C12-C13-C9 2 1 0.00054 4.71623 3.61% 
Ru0-C21-Ru0-C10 2 1 0.00519 4.69265 3.56% 
Ru0-N1-Ru0-C7 2 1 0.00783 4.22947 3.53% 
Ru0-N1-Ru0-C11 2 1 0.00783 4.22834 3.45% 
Ru0-N2-C6 2 1 0.00478 3.91855 3.42% 
Ru0-C20-C21 2 1 0.00061 3.50513 3.40% 
Ru0-N2-C9 2 1 0.00479 3.92721 3.40% 
Ru0-C17-C21 2 1 0.00056 4.79902 3.37% 
Ru0-N2-Ru0-N2 1 1 0.00199 4.28702 3.26% 
Ru0-C20-N2 2 1 0.00096 4.96157 2.96% 
Ru0-N2-N1 2 1 0.00285 3.35636 2.86% 
Ru0-C8-C10 2 1 0.00743 3.33217 2.76% 
Ru0-C6-C10 2 1 0.00743 3.33315 2.76% 
Ru0-C7-C11 2 1 0.00743 3.33344 2.75% 
Ru0-C6-C8 2 1 0.00743 3.33407 2.75% 
Ru0-C9-C7 2 1 0.00743 3.33471 2.75% 
Ru0-C9-C11 2 1 0.00743 3.33469 2.74% 
Ru0-C11-C6-C11 2 1 0.01723 3.52294 2.63% 
